NRC P	DAM	3%	3	
(1-84) 10 CF8 35 and		32.	33,	34.

APPLICATION FOR MATERIAL LICENSE

STRUCTIONS: SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION. SEND TWO COPIES

U.S. NUCLEAR REGULATORY COMMISSION APPROVED BY OMB 3150-0120 Expine: 5-51-87

OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED E	BELOW.
FEDERAL AGENCIES FILE APPLICATIONS WITH:	IF YOU ARE LOCATED IN:
U.S. NUCLEAR REGULATORY COMMISSION DIVISION OF FUEL CYCLE AND MATERIAL SAFETY, NMSS WASHINGTON, DC 20555	ILLINDIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN, SEND APPLICATIONS TO:
ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS, IF YOU ARE LOCATED IN:	U.S. NUCLEAR REGULATORY COMMISSION, REGION III MATERIALS LICENSING SECTION 799 ROOSEVELT ROAD GLEN ELLYN, IL 60137
CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, MAINE, MARYLAND, MARSACHUSETTS, NEW JERSEY, NEW YORK, PENNSYLVANIA, RHODE ISLAND, OR VERMONT, SEND APPLICATIONS TO:	ARKANSAS, COLORADO, IDAHO, KANSAS, LOUISIANA, MONTANA, NEBRASKA, NEW MEXICO, NORTH DAKOTA, OKLAHOMA; SOUTH DAKOTA, TUXAS, UTAH, OR WYOMING, SEND APPLICATIONS TO:
U.S. NUCLEAR REGULATORY COMMISSION, REGION I NUCLEAR MATERIAL SECTION B 531 PARK AVENUE KING OF PRUSSIA, PA 19406	U.S. NUCLEAR REGULATORY COMMISSION, REGION IV MATERIAL RADIATION PROTECTION SECTION 611 RYAN PLAZA DF 'F, SUITE 1000 ARLINGTON, TX 766
ALABAMA, FLORIDA, GEORGIA, KENTUCKY, MISSISSIPPI, NORTH CAROLINA, PUERTO RICO, BOUTH CAROLINA, TENNESSEE, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA, SEND APPLICATIONS TO:	ALASKA, ARIZONA, CAL. ORNIA, HAWAII, NEVADA, OREGON, WASHINGTON, AND U.S. TERRITORIES AND POSSESSIONS IN THE PACIFIC, SEND APPLICATIONS TO:
U.S. NUCLEAR REGULATORY COMMISSION, REGION II MATERIAL RAGIATION PROTECTION SECTION 101 MARIETTA STREET, SUITE 2900 ATLANTA, GA 30323	U.S. NUCLEAR REGULATORY COMMISSION, REGION V MATERIAL RADIATION PROTECTION SECTION 1450 MARIA LANE, SUITE 210 WALNUT CREEK, CA 94596
PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAS IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTION.	I
1. THIS IS AN APPLICATION FOR (Check appropriate item)	2. NAME AND MAILING ADDRESS OF APPLICANT (Include Zip Cade)
A. NEW LICENSE	Department of the Army
8. AMENDMENT TO LICENSE NUMBER	Letterman Army Medical Center
X C. RENEWAL OF LICENSE NUMBER 04-01496-01	ATTN: HSHH-PM-HP (Health Physics) Presidio of San Francisco, CA 94129-6700
3. ADDRESS(ES) WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED.	
A NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION Carl E. Bergsagel, MAJ, MS, Chief, Health Ph	
SUBMIT ITEMS & THROUGH 11 ON 8% x 11" PAPER. THE TYPE AND SCOPE OF INFORMAT	ION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GUIDE.
B. RADIOACTIVE MATERIAL a. Element and mass number, b. chemical and/or physical form, and c. maximum amaging which will be possessed at any one time.	6. PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED. TAB B
7. INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING AND EXPERIENCE.	8. TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED TABS. D
9. FACILITIES AND EQUIPMENT. TAB E	TAB F
11. WASTE MANAGEMENT. TAB	12. LICENSEE FEES (See 19 CFR 170 and Section 170.31) FEE CATEGORY EXCEPTED AMOUNT ENCLOSED \$ 0
 CERTIFICATION. (Muct be completed by applicant) THE APPLICANT UNDERSTANDS TH BINDING UPON THE APPLICANT. 	AT ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE
THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS, PAR IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF.	ITS 30, 32, 33, 34, 35, AND 40 AND THAT ALL INFORMATION CONTAINED HEREIN
WARNING: 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948, 62 STAT. 749 MAKES IT A TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WI	CRIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION THIN ITS JURISDICTION.
SIGNATURE-CIRTIFYING OFFICER	Commander 20 DEC 198
Taul / K heller PAUL L. SHETLER, (
ANNUAL RECEIPTS D. NUMBER OF EMPLOYEES (Total for	d VOULD YOU BE WILLING TO FURNISH COST INFORMATION (Dollar and/or staff hours)
<pre><\$230K \$1M-3.5M entire fecility excluding outside contractors/ \$250K-590K \$3.5M-7M</pre>	UN THE ECONOMIC IMPACT OF CURRENT NRC REGULATIONS OR ANY FUTURE PROPOSED NRC REGULATIONS THAT MAY AFFECT YOU? (NRC regulations permit it to protect confidencial commercial or financial—proprietery—information furnished to the ensure in confidences.)
\$500K-750K \$7M-10M C NUMBER OF BEDS	the egency in confidence)
\$750K-1M >\$10M	YES
	CUSEONLY
TYPE OF FEE FEE LOG FEE CATEGORY COMMENTS	APPROVED BY
REG5 LI	D111 890505
PRIVACY ACT STATEMENT ON THE REVERSE	96-01 PDR

Radioactive Materials

.

	Isotope		Chemical Form		Quantity		Purpose
1.	Byproduct materials Atomic Nos. 3-83 with a half life of less than 120 days	1.	Any	1.	500 millicuries each with a maximum possession limit of 10000 millicuries	1.	See Item 6
2.	Byproduct materials Atomic Nos. 3-83	2.	Sealed	2.	500 millicuries each	2.	See Item 6
З.	Americium 241	3.	Sealed	з.	2 millicuries	3.	See Item 6
4.	Cadmium 109	4.	Any	4.	10 millicuries	4.	See Item 6
5.	Calcium 45	5.	Any	5.	15 millicuries	5.	See Item 6
6.	Carbon 14	6.	Any	6.	1000 millicuries	6.	See Item 6
7.	Cesium 137	7.	J.L Shepard Model 28-6A with Amersham X. Cs-137 Source	7.	1000 millicuries $\frac{2}{3} \times \frac{9}{3}$	7.	Calibration Range
8.	Cesium 137	8.	Any	8.	20 millicuries	8.	See Item 6
9.	Hydrogen 3	9.	Any	9.	1000 millicuries	9.	See Item 6
10.	lodine 131	10.	Any	10.	1000 millicuries	10.	See Item 6
11.	Manganese 54	11.	Any	11.	10 millicuries	11.	See Item 6
12.	Molybdenum 99	12.	Any	12.	5000 millicuries	12.	See Item 6
13.	Technetium 99m	13.	Any	13.	5000 millicuries	13.	See Item 6
	Any byproduct material in 10 CFR 35.400		IAW 10CFR 30.32	14.	3500 millicuries		Medical use CFR 35.400
15.	Any byproduct material in 10 CFR 35.500	15.	IAW 10CFR 30.32	15.	8000 millicuries		Medical use CFR 35.500
16.	Uranium depleted in U-235	16.	Plated metal	16.	136.4 kilograms	16.	Linear accelerator shield

6

ŗ

the second

Authorized Uses

Authorized Uses.

6

;

- a. Medical uses as defined in 10 CFR 35.2.
- b. Research in humans as approved either:
 - 1) by the FDA, or
 - 2) by an RDRC approved by the FDA.
- c. Research in animals.
- d. Research as defined in 10 CFR 30.4(q).

e. In vitro testing.

- f. Instrument calibration.
- g. Training.

Individuals Responsible for Radiation Safety Program Their Training and Experience

1. Criteria for Authorization of Radioisotope Users.

a. The following excerpt of our local regulation LAMC 40-34, details the criteria used for the authorization of radioisotope users. The forms included below are examples and should not be misinterpreted otherwise. If the need arises, these forms are subject to change. Any changes would be initiated to more closely comply with the regulations and would be approved by the Radiation Control Committee before being used.

POLICY ON USE OF RADIOACTIVE MATERIALS

Radioactive materials are to be used only by, or under the direct supervision of, individuals approved by the Radiation Control Committee and in accordance with procedures approved by the Radiation Control Committee.

PROCEDURES FOR OBTAINING AUTHORIZATION TO USE RADIOACTIVE MATERIALS

 GENERAL. This Annex outlines the procedures for individuals to obtain authorization to use radioactive materials under the Letterman Army Medical Center's Nuclear Regulatory Commission Byproduct Materials License and Department of the Army Authorization.

2. DEFINITIONS.

- a. PRINCIPAL AUTHORIZED USER: The "principal authorized user" is the individual who bears the ultimate responsibility for possession, inventory, and implementation of the safety procedures necessary to assure the safe use of the materials specified in the application. The principal authorized user is directly responsible to the Radiation Control Committee and to the Radiation Protection Officer for matters relevant to radiation safety.
- b. AUTHORIZED USER: An "authorized user" is an individual who possesses adequate training and experience with radioactive material to qualify him as a principal authorized user for those materials specified in the application. The authorized user works under the direction of and is directly responsible to the principal authorized user for the safe and proper use of the material specified in the application. He must demonstrate training and experience in radiation safety procedures and submit documentation of previous training and experience for all materials specified in the application.
- c. TECHNOLOGIST: A "technologist" is an individual who by virtue of training and experience is capable of making routine decisions commensurate with his duties involving the use of radioactive materials. This individual should require minimal supervision and should be capable of supervising subordinate technologists and trainees. The technologist is responsible to the principal authorized user for the safe and proper handling of radioactive material. Professional certification is desirable but not a prerequisite for classification as a technologist; however, documentation of training and experience equivalent to requirements for certification must be submitted in lieu of the certification.
- d. RESIDENT USER: A "resident user" is an individual who works under the direct supervision of a principal authorized user, or authorized user for the purpose of performing certain routine duties associated with use of materials specified in the application. He may not possess the necessary training or experience to be classified as a principal authorized user or authorized user. He must demonstrate previous training and experience comparable with use of radioactive material specified in the application. The principal authorized user must assure that resident users have been trained in the safe use of radioactive materials.

Individuals Responsible for Radiation Safety Program Their Training and Experience

- e. TRAINEE: A "trainee" is an individual who does not possess adequate training and experience to be designated in any of the above categories. He is assigned to this category so that he may obtain the necessary training and experience under immediate supervision. It is the goal of the trainee to obtain suitable training and experience to become qualified for a higher classification.
- RADIATION PROTECTION OFFICER: The "Radiation Protection Officer" is the individual identified by the Nuclear Regulatory Commission as the person responsible for ensuring compliance with the applicable regulations associated with the radioisotope license. This person is named on the NRC license and on orders by the Radiation Control Committee.
- g. RADIATION CONTROL COMMITTEE: This group of individuals are persons who have demonstrated the training and experience with radioisotopes required to implement and oversee a broad scope radioisotope program. This group convenes at least quarterly or more frequently as needed. They address all questions regarding radicactive materials used at LAMC and LAIR.
- h. DIRECT SUPERVISION: Direct supervision means being either physically present or immediately available by phone and within one hour of the facility.
- IMMEDIATE SUPERVISION: Immediate supervision means being physically present or in the immediate area where isotopes are being used.
- 3. PROCEDURE.

51

- a. To obtain authorization to use radioactive materials, to renew, or modify an existing authorization, individuals will submit an "Application for Authorization to Use Radioactive Materials" (Human Use/Non-Human Use) to the Radiation Protection Officer. This form will be reviewed by the Radiation Control Committee to assure compliance with established procedures and regulations.
- b. In addition to the above form, each individual listed on the authorization is required to submit a completed "Summary of Radiological Qualifications" and an NRC Form 313M, Supplement A, "Training and Experience Authorized User or Radiation Safety Officer," and a current *curriculum vitae*. Physicians requesting a Human Use Authorization are also required to submit a completed NRC 313M, Supplement B, "Preceptor Statement", or applicable board certification. Training and experience documentation submitted by the principal authorized user, authorized users, and technologists will be reviewed by the Radiation Control Committee for the purpose of making recommendations to the Commander, LAMC, regarding the granting of privileges to receive, store, use, and dispose of radioactive materials under the LAMC radioactive material license and the pertinent LAMC regulations.
- c. individuals who want to perform research with radioisotopes will complete a "Research Protocol for Radioisotope Use." This form addresses procedures that will be utilized to insure proper and safe use of the authorized materials.

Individuals Responsible for Radiation Safety Program Their Training and Experience

- 4. EVALUATION.
 - a. "Application for Authorization to Use Radioactive Materials" will be individually reviewed by the Radiation Protection Officer and by the Radiation Control Committee to assure adequate training and experience of users for the use of radioactive material requested in the authorization. The applicant is expected to demonstrate in the application that, based upon education, experience, and the equipment and the facilities available, the radioactive materials requested will be used in a safe manner and in accordance with existing directives.
 - b. The applicant may be required to obtain additional education, experience, or equipment, if it is deemed necessary.
 - c. The Radiation Protection Officer will review each application to ensure that:
 - Individuals listed on the application have sufficient training and experience to safely conduct the proposed procedures;
 - 2) Proposed procedures do not violate applicable regulations; and
 - 3) Facilities and equipment at the proposed work site provide an adequate margin of safety for individuals performing the procedure and for public safety. Unacceptable applications will be returned to the applicant for correction or modification. Applications recommended for approval are signed by the Radiation Protection Officer and transmitted to the Chairman, Radiation Control Committee with a recommended list of conditions that should apply to the authorization on a "Conditions For Authorized Use of Radioactive Materials at LAMC."
 - d. The Radiation Control Committee will review the training and experience of all principal authorized users, authorized users, and technologists to assure that the documented training and experience of all users of radioactive material is adequate for the material being authorized or requested and for the individual's level of responsibility. Criteria to be utilized in this determination will be those specified in 10 CFR Part 35, Subpart J, 10 CFR 33.15, and this Annex as appropriate. Principal authorized users, and authorized users listed on an authorization must be credentialed by the Committee or receive interim approval prior to their initiating or participating in any work under the authorization. Technologists and trainees may receive interim approval to use radioisotopes by the Radiation Protection Officer. These approvals must be received before beginning work with any radioisotopes.
 - e. The Chairman of the Radiation Control Committee reviews applications to assure compliance with established procedures, precedents, and regulations. Unacceptable applications are returned to the applicant via the Radiation Protection Officer. Approved applications are signed by the Chairman and transmitted to the applicant via the Radiation Protection Officer.
 - Notification of the granting of interim approval to utilize radioactive material as specified in the application will be mansmitted in writing to the principal authorized user by the Radiation Protection Officer following required approvals in paragraph c, and e above.
 - g. Final approval/disapproval action will be accomplished for each authorization presented to the Radiation Control Committee during quarterly meetings.
 - h. The Radiation Control Committee is the final approving authority for radioactive material authorizations and will adjudicate any conflicts with regard to approval of authorizations.

Individuals Responsible for Radiation Safety Program Their Training and Experience

5. TERMINATION OF AN AUTHORIZATION.

- a. An authorization may be terminated by the principal user at any time. When such termination occurs, it is the responsibility of the principal user to notify the Radiation Protection Officer in a timely manner so that a close-out survey of the area involved may be completed prior to the time the area is to be used for other purposes and/or the principal authorized user leaves the present assignment.
- b. An authorization may be terminated by the Radiation Control Committee if it is determined that the principal user has not complied with his/her authorization provisions. The Radiation Protection Officer has the authority to suspend the use of radioactive material by a principal user if in his/her opinion a condition exists necessitating such action. However, in such a case, the principal authorized user will be permitted to make on-the-spot corrections, if possible, to preciude such action. If such conditions are not corrected the Radiation Control Committee may, after review of the situation, terminate the authorization, continue the suspension pending correction of the condition, or rescind the suspension.

6. APPLICATION PROCEDURES.

Application packets are available from the Health Physics Office located in Bldg. 1007, phone # 561-2794. A supply of these application packets will also be available in the LAIR Radioisotope Branch Office, phone # 561-3318.

TRAINING AND E: PERIENCE REQUIREMENTS FOR PRINCIPAL AUTHORIZED USER; AUTHORIZED USER; TECHNOLOGIST

- To qualify as adequately trained to use or directly supervise the use of radioactive materials listed on the "Application For Authorization to Use Radioactive Materials", individuals should have sufficient training and experience with all types and quantities of radioactive materials requested to assure safe receipt, transport, use, transfer and disposal procedures as permitted by the LAMC authorization.
- Each individual authorized to directly supervise the use of radioactive materials (Principal Authorized User, Authorized User, Technologist) should have:
 - a. Training in basic radioisotope handling techniques applicable to the use of sealed/unsealed sources. This training should consist of lectures, laboratory sessions, discussion groups or supervised experience in the following areas as appropriate.
 - 1) Radiation Physics and Instrumentation
 - 2) Radiation Protection
 - 3) Mathematics Pertaining to the Use and Measurement of Radioactivity
 - 4) Radiation Biology
 - 5) Radiopharmaceutical Chemistry (Human Use)
 - t. Experience with the types and quantities of radioactive materials listed on the authorization.
 - c. Supervised clinical training in an institutional Nuclear Medicine program, Radiation Oncology program, or equivalent. (For Human Use Authorizations)
- USNRC BML APPLICATION

Individuals Responsible for Radiation Safety Program Their Training and Experience

- 3. The minimum number of hours necessary to satisfy the training and experience requirements is dependent on the type and quantities of all radioactive materials listed on an authorization. Designation as a principal authorized user, authorized user or technologist is based on the particular authorization. Such designation is not necessarily transferable to another authorization. For example, an individual designated as an authorized user on an authorized user or technologist on the necessarily have the training and experience to be designated as an authorized user or technologist on an authorized or training and experience to be designated as an authorized user or technologist on an authorized or utilization of volatile iodine. Training and experience must be evaluated relative to the particular radioactive material to be utilized and the potential hazards associated with the use of that material.
- 4. Examples of minimum acceptable training and experience are listed below for various broad categories of radioactive materials. Each LAMC authorization must be reviewed individually to assure that the individual authorized has adequate training and experience to supervise the safe use of these radioactive materials.
- This training and experience must be documented, reviewed and approved by the Radiation Control Committee and maintained by the Radiation Protection Officer, LAMC, as a part of the documentation for each authorization.

		HUM	NON-HUMAN	USE		
	Prin		Tech-	Prin		Tech
	Auth	Auth	nolo	Auth	Auth	nolo-
TRAINING	User	User	gist	User	User	gist
TOTAL HOURS (Didactic)	200	200	200	40	40	20
1) Radiation Physics & nstrumentation	100	100	100	14	14	7
2) Radiation Protection	30	30	30	10	10	5
3) Mathematics Pertaining the Use and Measurement of Radioactivity	20	20	20	8	8	4
(4) Radiation Biology	20	20	20	8	8	4
5) Radiopharmaceutical Chemistry	30	30	30	NA	NA	NA

Individuals Responsible for Radiation Safety Program Their Training and Experience

		HUMAN U	SE	N	ON-HUMAN	USE
Experience Felevant to Radioisotope Usage Supervised Clinical Training	Prin Auth User	Auth User	Tech- nolo gist	Prin Auth User	Auth User	Tech nolo- gist
Supervised Training & Experience Felevant to Radioisotope Usage	500	500	500	500	500	500
Supervised Clinical Training in an Institutional Nuclear Medicine Program or Radiation (Program Relevant to Diagnostic/ Procedu () Authorized		500	NA	NA	NA	NA
Supervised Training as a Nuclear Medicine Tech- nician or Equivalent	NA	NA	500	NA	NA	NA

REGULATORY BASIS

- 1. The Regulatory basis for required training is as follows:
 - a. Title 10 ("Energy" Nuclear Regulatory Commission), Code of Federal Regulations, Part 30 ("Rules of General Applicability to Domestic Licensing of By-Product Material") states in:

Section 30.3:

"No person shall manufacture, produce, transfer, receive, acquire, own, possess or use byproduct material except as authorized in this chapter."

and in Section 30.33:

"(a) An application for a specific license will be approved if...(3) The applicant is qualified by training and experience to use the material requested in such manner as to protect health and minimize danger to life or property; (4) The applicant satisfied any special requirements contained in Parts 32-35."

- b. The criteria utilized to determine the acceptability of training and experience for a Principal Authorized User, or Authorized User, for human use of radioactive material will, at a minimum, be as follows:
 - The licensee's Radiation Control Committee may permit any physician to use byproduct material for medical use, research, and development. The physician must meet the appropriate training and experience criteria in 10 CFR Part 35, Subpart J.
 - The use of licensed material in or on humans shall be by a physician as defined in 10 CFR 35.2.

Individuals Responsible for Radiation Safety Program Their Training and Experience

- c. The criteria utilized to determine the acceptability of training and experience for a Principal Authorized User, or Authorized User, for non-human use of byproduct material in greater than exempt quantities will, at a minimum, be that specified in 10 CFR 33.15 in that radioactive materials will be used only by, or under the direct supervision of, individuals who have received:
 - 1) A colk of the segree at the bachelor level, or equivalent training and experience in the physical or biolog and beinges or in engineering
 - 2) At least 40 hours of training and experience in the safe use and handling of radioactive materials, and in the characteristics of ionizing radiation, units of radiation dose and quantities, radiation detection and instrumentation and biological hazards of exposure to radiation appropriate to the type and forms of byproduct material to be used

INSTRUCTIONS FOR PREPARATION OF "APPLICATION FOR AUTHORIZATION TO USE RADIOACTIVE MATERIAL" (HUMAN USE/NON-HUMAN USE)

- An individual desiring authorization to use radioactive material shall complete an "Application For Authorization To Use Radioactive Material" (Human Use/Non-Human Use), and submit in duplicate to the LAMC Health Physics Office.
- 2. All proposed locations where the applicant desires to use, store, or dispose of radioactive material should be coordinated with the Health Physics Office prior to submission of the application in order to assure expeditious processing of the application. Submission of an incomplete application will often result in a delay in the issuance of an authorization because of the correspondence necessary to obtain information requested on the application.

EXPLANATION OF APPLICATION FOR AUTHORIZATION.

- 1. The form "Application For Authorization to Use Radioactive Material" (Human Use/ Non-Human Use) is designed to supply information on radioactive material programs of varying complexity. The applicant should provide complete information on the proposed program for the possession and use of radioactive material. For those items that do not apply, indicate with N/A (not applicable).
- Application for new authorizations should be completed in their entirety. Applications for amendment to existing authorizations may be completed as follows:
 - a. Complete items 1, 2, and 6

67

- b. For those items that do not require amendment, indicate as N/C (no change)
- For those items that require amendment, indicate the proposed changes to the current authorization
- 3. All authorizations will be granted for an indefinite period of time but must be reviewed by the RCC on a biennial basis. The principal user must submit an "Application for Authorization to Use Radioactive Materials" completing items 2. (a, b, and c) above as appropriate. Failure to submit a request for review will result in the termination of the authorization.

Individuals Responsible for Radiation Safety Program Their Training and Experience

EXPLANATION OF NUMBERED ITEMS

1. Self-explanatory.

 The "Principal Authorized User" is the individual who bears ultimate responsibility for possession, inventory, and implementation of the safety procedures necessary to assure the safe use of the materials specified in the application. He is directly responsible to Radiation Control Committee. Attach a completed training packet pages, B-13 - B-17, if a current copy is not on file with the Health Physics Office. The applicant's address shou'd include organization, activity, building, room number, and reference or office symbol.

3. Users.

- a. An "authorized user" is an individual who possesses adequate training and experience with radioactive material to qualify as a "principal user". He works under the direction of and is directly responsible to the "principal authorized user" for the safe and proper use of the materials specified in the application. List all authorized users alphabetically by last name. Each authorized user should be identified as follows: Last name, first name, middle initial, and grade. Attach a completed training packet, pages B-13 -B-17, for each authorized user if a current copy is not on file with the Health Physics Office.
- b. A "technologist" is an individual who by virtue of training and experience is capable of making routine decisions commensurate with his duties involving the use of radioactive materials. This individual should require minimal supervision and should be capable of supervising subordinates (technologists, and trainees). List all technologists alphabetically by last name. Each technologist should be identified as follows: Last name, first name, middle initial, and rank/grade. Attach a completed training packet, pages B-13 B-17, for each technologist or documentation of training and experience equivalent to certification requirements is necessary to be designated as a technologist.
- c. A "resident user" is an individual who works under the direct supervision of a principal authorized user, or authorized user, for the purpose of performing certain duties associated with the use of materials specified in the application. He may not possess adequate training or experience to be classified as a principal authorized user. List all resident users alphabetically by last name. Each resident user should be identified as follows: Last name, first name, middle initial, and rank/grade. Attach a completed training packet, pages B-13 -B-17, for each resident user if a current copy is not on file with the Health Physics Office.
- d. A "trainee" is an individual who does not possess adequate training and experience to be designated as an authorized user or a technologist. He is assigned to this category to obtain the necessary experience under the immediate supervision of authorized users/technologists. List all trainees alphabetically by last name. Each trainee should be identified as follows: Last name, first name, middle initial, and rank/grade.

4. RADIOISOTOPES.

- a. List radioisotopes by ascending mass number, i.e., the isotope with the smallest mass number is placed at the top of the column and the isotope with the greatest mass number is placed at the bottom of the column.
- b. List the chemical form of the radioisotope.

Individuals Responsible for Radiation Safety Program Their Training and Experience

- c. Indicate whether the physical form is solid, liquid, or gaseous form. Additionally, state whether it is a sealed or unsealed source. In order for radioactive material to gualify as a "sealed source," the radioactive source must be sealed in an impervious container which has sufficient mechanical strength to prevent contact with and dispersion of the radioactive material under the conditions of use and wear for which it was designed.
- d. State the maximum activity (in units of millicuries) for each chemical form of the radioisotope authorized or requested that must be kept in the inventory, in order to satisfy the mission requirements.
- e. State in column e., the intended use of each chemical form of the radioisotopes listed in column a.
- f. Items 5-8 self-explanatory.

EXPLANATION OF TRAINING FORMS

All persons listed on an authorization will complete the worksheet "Summary of Radiological Qualification." From the information contained on that form, complete NRC 313M, Supplement A, "Training and Experience of an Authorized User or Radiation Safety Officer." Persons desiring a "Human Use Authorization" must complete an NRC 313M, Supplement B, "Preceptor Statement" or supply applicable Board Certification Certificates.

EXPLANATION OF RESEARCH PROTOCOL FOR RADIOISOTOPE USE

Persons requesting authorization to use radioisotopes for research must complete the "Research Protocol For Radioisotope Use" form. Insure that a complete description of the "Life Cycle of Radioisotopes" is given. This description should detail the intended use in full and should include all procedures to be implemented to insure compliance with the regulations and maximum safety of personnel.

DEC 2 0 1988

Individuals Responsible for Radiation Safety Program Their Training and Experience

APPLICATION FOR AUTHORIZATION TO USE RADIOACTIVE MATERIAL*

1.	New Authorization			Human Use
	Renewal of Authorization	n#		Non' luman Use
	Amendmers of Authorit	zation #		
2. Principa	I Authorized User (Applicant)			
NAME:	(Last, First, MI)	SSAN	PHC	NE:
OFFICE:_				
	(Dept/Activity/Service)		(Organiz	ation/Station)
a. A	Authorized Users		 Technologist 	
с. Т	rainee		d. Resident User	
4. RADIO	ISOTOPES:			
Radioisoto	Chemical Form	Physical Form	Possession Limit	Use

*If more space is needed to complete any item, use additional pages properly identified by a consecutive numbering sequence.

6

Individuals Responsible for Radiation Safety Program Their Training and Experience

5. Management of Radioactive Materiais:

USE	LOCATION		
RECEIPT STORAGE			
MATERIAL USE	RESERVICE DE LA DESERVICE DESERVICE DE LA DESERVICIÓN DE LA DESERVICIÓN DE LA DESERVICIÓN DESERVICIÓN DE LA DESERVICIÓN DE LA DESERVICIÓN DESERVICIÓN DESERVICIÓN DESERVICIÓN DE LA DESERVICIÓN DE LA DESERVICIÓN DESERVICIÓN DESERVICIÓN DE LA DESERVICIÓN DE LA DESERVICIÓN DESERVICIÓN DE LA DESERVICIÓN DE LA DESERVICIÓN DESERVICIÓN DESERVICIÓN DE LA DESERVICIÓN DE LA DESERVICIÓN DESERVIC		
FUME HOOD	Minister in the second second second second second		
RAD WASTE DISPOSAL SINK	*		
INTERIM WASTE STORAGE			
	solid	liquid	gas

Other Associated Hazards:

6. CERTIFICATION: (This item must be completed by Principal Authorized User)

I certify compliance with relevant provisions of AR 40-7 (Clinical Use of Investigational Drugs), TB Med 525 (Control of Hazards to Health from Ionizing Radiation Used by the Army Medical Department), AR 70-25 (Use of Volunteers as Subjects of Research), LAMC Reg 40-34 and that all information contained herein, including any supplements attached hereto are true and correct to the best of my knowledge and belief.

Typed Name/Grade	mangalent, anagalenter	Date	Signature
	ADMINISTRAT	TIVE APPROVAL	
Approve/Disapprove	Typed Name/Grade	/Position	Date
	Signature		
	Radiation Control	Committee Approval	
	Interim	Approval	
Radiation Protection Officer	Date	Chairman, Radiation Control Committee	Date
	Final /	Approval	
Radiation Protection Officer	Date	Chairman, Radiation Control Committee	Date
Authorization Review Date			
Authorization Review Date			

Individuals Responsible for Radiation Safety Program Their Training and Experience

RESEARCH PROTOCOL FOR RADIOISOTOPE USE

Beginning Date:	_ Ending Date:_	Repetitive S	tudy? YES_
Principal Authorized User for I	Protocol		
Principal Investigator for Protoc	loo	Tel	ephone No
Other Personnel Involved with	Protocol:		
AUTHORIZED USERS TE	CHNOLOGISTS	RESIDENT USERS	TRAINE
RADIOISOTOPE SOURCE		CAL/CHEMICAL FORM & TITY PER EXP(mCi)	
UTILIZATION OF RADIOISOT	OPE:	LOCATIONS	
STORAGE OF RADIOISOTOF MAXIMUM mCi	PE:	LOCATIONS	
RADIOACTIVE WASTE STOR MAXIMUM mCi	AGE:	LOCATIONS	

All radioactive waste will be transferred to the Health Physics Office, LAMC or the Radioisotope Branch, LAIR, IAW pertinent sections of LAMC Reg 40-34, Annex M, RADIOACTIVE WASTE.

LIFE CYCLE OF RADIOISOTOPES UTILIZED FOR RESEARCH PROCEDURES. Describe the intended use of radioisotopes in full. Use the back of the form if required.

67:

;

Individuals Responsible for Radiation Safety Program Their Training and Experience

LABELING AND TRANSPORT OF RADIOACTIVE MATERIAL.

All radioactive solutions, tissues, animals and waste will be identified by proper label. Transport of radioactive material between authorized work areas will be conducted in a manner that precludes the spread of contamination and inadvertent exposure of non-participating personnel.

LABORATORY ANIMAL USAGE	:NO	YES	SPECIES:
Location of Animal Usage:			
AnimalsWILL be sad WILL NOT	rificed at the concl	usion of the experiment	L
ROOM SURVEY: All room surve	ys will be conc	ducted IAW LAMC	Reg 40-34, Annex O.
PERSONNEL DOSIMETRY:	WHO	LE BODY BADGE	S
	WRIS	T BADGES	will be requested.
	RING	BADGES	
Assigned designets, monitors will	ho war hu all	noticipating perm	annal

Assigned dosimetry monitors will be worn by all participating personnel

The research protocol enumerated above is designed to insure that occupational radiation exposures and release of radioactive effluents to the environment will be "as low as reasonably achievable," ALARA, during all phases of the research procedures.

Administrative Approval:

Applicant:

Signature

ş

_____ Signature _

Radiation Protection Officer

(Print Name)

Date

Date

Individuals Responsible for Radiation Safety Program Their Training and Experience

CONDITIONS FOR AUTHORIZED USE OF RADIOACTIVE MATERIALS AT LETTERMAN ARMY MEDICAL CENTER

Authorization Number

Principal Authorized User

Date _____

Department/Service

THE PRINCIPAL AUTHORIZED USER FOR LAMC RADIOACTIVE MATERIAL AUTHORIZATIONS IS RESPONSIBLE FOR COMPLIANCE WITH THE FOLLOWING PROVISIONS:

- a. Maintaining occupational, occasional and environmental ionizing radiation exposures as iow as reasonably achievable (ALARA). Current dose limitations are detailed in LAMC Reg 40-34, Annex E. In addition to these limits, pregnant radiation workers shall be required to consult with their immediate supervisor and the Radiation Protection Officer with respect to an evaluation of their work environment. The names of all pregnant radiation workers will be reported to the Radiation Protection Officer at the earliest possible time to assure appropriate review and continued monitoring of the worker's radiation environment during the gestation period. Exposures to pregnant occupational workers should be kept as far below 0.5 rem as possible in keeping with the ALARA principle.
- Obtaining and using the proper personnel dosimetry devices as determined by the Radiation Protection Officer and Annex E, LAMC Reg 40-34.
- c. Having available and using appropriate radiation detection/monitoring devices.
- d. Performing Surveys of Working Areas required by Annex O, LAMC Reg 40-34, to insure that external radiation levels for occupational workers do not exceed the limits specified by the Radiation Control Committee and that contamination in lab areas does not exist in excess of limits specified in Annex S, LAMC Reg 40-34. Surveys for contamination should include any protective clothing used, the bottoms of shoes and all potentially exposed areas of the body. The Radiation Protection Officer will be notified of areas of contamination in excess of 100 dpm/100cm² and any contamination on clothing or personnel.
- e. Notifying the Radiation Protection Officer when radiation levels in unrestricted areas exceed 2 inillirems in any one hour or 100 millirems in any seven days.
- Complying with the provisions of LAMC Reg 40-34, Annex C, RESPONSIBILITIES OF PRINCIPAL USERS OF RADIOACTIVE MATERIALS.
- g. Maintaining an inventory of radioactive materials as specified in LAMC Reg 40-34, Annex K, ACCOUNTABILITY AND INVENTORY OF RADIOACTIVE MATERIAL AND MACHINES WHICH PRODUCE IONIZING RADIATION.
- h. Utilization of appropriate radiation warning signs and labels.

Individuals Responsible for Radiation Safety Program Their Training and Experience

- i. Instructing authorized users, technologists, trainees, and resident users concerning the safe handling and usage of the radioactive materials listed in the authorization and concerning their responsibilities and rights as occupational radiation workers. Ensuring that each authorized user, technologist, trainee and resident user attends annual radiation protection training.
- j. Ensuring the proper disposal of radioactive materials in accordance with LAMC Reg 40-34 Annex M, RADIOACTIVE WASTE and any other provisions specified in the authorization.
- k. Notifying the Radiation Protection Officer promptly of any changes in personnel, use, location, or possession of radioisotopes from the terms of this authorization.
- Radioactive materials shall be stored such that they are secured from unauthorized removal. Radioactive materials in an area not designated for use, storage, or disposal, must be kept under constant surveillance and the immediate control of the principal user, authorized user, resident user, or technologist.
- m. Compliance with applicable provisions of LAMC Reg 40-34, Annex J, RECEIPT, TRANSFER, AND SHIPMENT OF RADIOACTIVE MATERIAL and in particular, ensuring that all NRC licensed or DA authorized radioactive materials entering Letterman Army Medical Center, Letterman Army Institute of Research, or supported activities have either been processed through the Health Physics Office, LAMC, Radioisotope Branch, LAIR, or have been documented by the Health Physics Office as having been received.
- n. Ensuring that NRC licensed or DA authorized radioactive materials are not transferred between users, facilities, or outside of LAMC/LAIR, without prior approval of either the Radiation Protection Officer or Alternate Radiation Protection Officer.
- In the event of an emergency situation, accomplishing the emergency procedures outlined in LAMC Reg 40-34, RADIOLOGICAL EMERGENCIES.
- p. The form "Research Protocol for Radioisotope Use" will be submitted for each new usage of radioactive material.

End of Excerpt

USNRC BML APPLICATION

DEC 2 0 1988

Individuals Responsible for Radiation Safety Program Their Training and Experience

- b. Radiation Control Committee.
 - 1) Composition: The Radiation Control Committee will be composed of certain members who, by virtue of their training and experience, will make up the "core" of the Committee. They will be specifically named and submit *Curricula vitae* indicating their qualifications. Other members of the Committee will be named only by title and/or position and will be approved by the "core" membership. To establish a quorum and to conduct business, at least one-half of the Committee's members' must be present, including the Radiation Protection Officer and the management representative. The Radiation Control Committee will be comprised of the following personnel:
 - Deputy Commander for Clinical Services, Chairman, Member
 - Radiation Protection Officer, Recorder, Core Member
 - Nuclear Medical Science Officer, Core Member
 - Chief, Department of Radiology, Core Member
 - Chief, Nuclear Medicine Service, Core Member
 - Chief, Radiation Therapy Service, Co.) Member
 - Chief, Nuclear Pharmacy Service, Core Member
 - Chief, Radioisotopes Services Branch, LAIR, Core Member
 - Hospital Safety Manager, Member
 - Chief, Department of Pathology, Member
 - Chief, Department of Clinical Investigation, Member
 - Chief, Department of Nursing, Member
 - Medical Physicist, Nuclear Medicine Service, Member
 - Commanding Officer, LAIR, Member
 - Research Scientist, LAIR, Member
 - Research Scientist, WHNRC, Member
 - Chief, Logistics Division, Non-voting Member

USNRC BML APPLICATION

Individuals Responsible for Radiation Safety Program Their Training and Experience

- Core Members: The Core members of the Radiation Control Committee at the time of this submission are identified below. Their Curriculum vitae are clached.
 - Daniel L. Glaubiger, COL, MC, Chief, Radiation Therapy Service
 - Robert J. Lull, COL, MC, Chief, Nuclear Medicine Service
 - Raoul O. Hagen, COL, MC, Chief, Department of Radiology
 - Richard Stotler, LTC, MS, Chief, Nuclear Pharmacy Service
 - Carl E. Bergsagel, MAJ, MS, Chief, Health Physics Office
 - Louie L. Tonry, 1LT, MS, Nuclear Medical Science Officer
 - Donald K. Green, SFC, USA, Chief, Radioisotope Services Branch

2. Authorized Users for Non-Medical Use.

Individuals approved by the RCC in accordance with paragraph 1, this item.

3. Radiation Protection Officer.

The Radiation Protection Officer is MAJ Carl E. Bergsagel. Alternate Radiation Protection Officers are 1LT Louie L. Tonry and SFC Donald K. Dreen. Their credentials have been reviewed and approved by the Radiation Control Committee, LAMC. The credentials reviewed included a NRC Form 313M, Supplement A, and a *Curriculum vitae*. Their training and experience meet the requirements for Radiation Protection Officers defined in 10 CFR Part 35.900.

CURRICULUM VITAE

NAME: Daniel Leo Glaubiger

CITIZENSHIP: U.S.

EDUCATION:

1961 - B.A., Harvard University

1966 - Ph.D., (Chemistry), University of California at Berkeley

1969 - M.D., University of California School of Medicine (S.F.)

MEDICAL LICENSURE:

California Maryland North Carolina

SPECIALTY BOARD CERTIFICATION:

Pediatrics Pediatric Hematology-Oncology Radiation Therapy

POSITIONS HELD:

- 1969-70 Intern (Pediatrics), Stanford University Medical Center, Palo Alto, California
- 1970-72 Staff Associate, Molecular Pharmacology Section, Laboratory of Chemical Pharmacology, National Cancer Institute, Bethesda, Maryland
- 1972-73 Resident (Pediatrics), Stanford University Medical Center, Palo Alto California
- 1973-75 Fellow, Hematology-Oncology, Stanford University Medical Center, Palo Alto, California
- 1975-76 Staff Oncologist, Childrens' Hospital at Stanford, Assistant Professor of Clinical Pediatrics, Stanford University Medical Center, Palo Alto, California

NEC 20 1988

POSITIONS HELD (continued) :

- 1976-1982 Senior Investigator, Attending Physician, Pediatrics Branch, National Cancer Institute, Bethesda, Maryland
- 1982-1985 Fellow, Kadiation Therapy, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- 1985- Chief, Radiation Therapy Service, Letterman Army Medical Center, San Francisco, California
- 1986- Associate Clinical Professor, Department of Radiation Oncology, University of California School of Medicine, San Francisco, California

COMMITTEES AND OTHER OFFICES:

National Cancer Institute Clinical Research Committee 1976-1978 National Cancer Institute Decision Network Committee 1977-1983 National Institutes of Health Pharmacy and Therapeutics Committee 1978-1983

MILITARY SERVICE:

USPHS, U.S. Army

PROFESSIONAL SOCIETIES:

American Association for Cancer Research American Society of Clinical Oncology American Society for Radiation Therapy and Oncology

RESEARCH INTERESTS :

Radiation-Chemotherapy interactions Mechanisms of human tumor cell resistance to anticancer therapy

BIBLIOGRAPHY

Daniel L. Glaubiger, M.D., Ph.D.

- Glaubiger, D.: Optical properties and structures of polynucleotides (Ph.D. Thesis), 1966.
- Glaubiger, D., and Hearst, J.E.: Effect of superhelical structure on the secondary structure of DNA rings. Biopolymers 5: 691, 1967.
- 3. Glaubiger, D., Lloyd, D.A., and Tincco, I., Jr.: Temperaturedependent optical properties of torsional oscillator model for dinucleoside phosphates. Biopolymers 6: 409, 1968.
 - Kohn, K.W., Glaubiger, D., and Spears, C.: The reaction of anthramycin with DNA II studies of kinetics and mechanism. Biochem. et Biophys. Acta 361: 288, 1974.

and a state of a sea should be

-

- Glaubiger, D., Kohn, K.W., and Charney, E.: The reaction of anthramycin with DNA III properties of the complex. Biochem. et Biophys. Acta 361: 303-311, 1974.
- Kohn, K.W., Waring, M.J., Glaubiger, D., and Friedman, C.A.: Intercalative binding of ellipticine to DNA. Cancer Res. 35: 71, 1975.
- 7. RDBS, W.E., Glaubiger, D., and Kohn, K.W.: Protein associated DNA breaks in cells treated with adriamycin and ellipticine. Biochem. et Biophys. Acta. 519: 23-30, 1978.
- Levine, A.S., and Glaubiger, D.L.: Rational pharmacology in pediatric malignancies: A new perspective on old drugs. In Merkin, B., (Ed.): <u>Clinical Pharmacology and Therapeutics: A Pediatric</u> Approach. Yearbook Medical Publishers, Chicago, 1978, pp. 123-152.
- Ramu, A., Fusner, J.E., Blaschke, T., and Glaubiger, D.L.: Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. Cancer Treat. Rep. 62: 1465-1470, 1978.
- Ramu, A., Glaubiger, D., Ramu, N.P., Eldridge, N., and Blaschke, T.F.: Probenecid inhibition of methotrexate excretion from cerebrospinal fluid in dogs. J. Pharmacokinetics and Biopharmaceutics 6: 389-397, 1978.
- 11. Von Hoff, D.D., Howser, D., Gormley, P., Bender, R.A., Glaubiger, D., Levine, A.S., and Young, E.C.: Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule. Cancer Treat. Rep. 62: 1421-1426, 1978.

NEC 20 1983

Page 2 - Bibliography - Daniel L. Glaubiger, M.D., Ph.D.

- Wakelin, L.P., Ramonas, M., Glaubiger, D., Canellakis, E.S., and Waring, M.J.: Structural limitations on the biofunctional intercalation of diacridines into DNA. Biochem. 17: 5057-5063, 1978.
- Ziegler, J.L., Magrath, I.T., Deisseroth, A.B., Glaubiger, D., Kent, H.C., Pizzo, P.A., Poplack, D.G., and Levine, A.S.: Combined modality treatment of Burkitt's lymphoma. Cancer Treat. Rep. 62: 2031-2034, 1978.
- 14. Ross, W.E., Glaubiger, D.L., and Kohn, K.W.: Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochem. Biophys. Acta 562: 41-50, 1979.
- 15. Glaubiger, D., Makuch, R., Wackenhut, J., and Glatstein, E.: Early results of current combined modality therapy trials in Ewing's sarcoma at NCI. In Jones, S.E., and Salmon, S.E. (Eds.): Adjuvant <u>Therapy of Cancer II</u>, New York, Grune & Stratton, Inc., 1979, pp. 409-418.
- Pizzo, P.A., Robichaud, K.J., Gill, F.A., Witebsky, F.G., Levine, A.S., Deisseroth, A.B., Glaubiger, D.L., MacLowry, J.D., Magrath, I.T.,
 Poplack, D.G., and Simon, R.M.: Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Amer. J. Med. <u>67</u>: 194-200, 1979.
- Catane, R., Von Hoff, D.D., Glaubiger, D.L., and Huggia, F.M.: Azaserine, DON, and Azotomycin: Three Diazo analogs of L-glutamine with clinical antitumor activity. Cancer Treat. Rep. 63: 1033-1038, 1979.
- Kohn, K.W., Ross, W.E., and Glauliger, D.: Ellipticine. In Hann, F.E., (Ed.): Antibiotics V/2. Mechanism of Action of Antieukaryotic and Antiviral Compounds. Heidelberg, Springer-Verlag, 1979, pp. 195-213.
- Glaubiger, D.: Studies on Complexes of Antineoplastic Agents with DNA. In Selegny, E. (Ed.): Charged and Reactive Polymers V.5. Optically Active Polymers. Boston, D. Reidel, 1979, pp. 351-356.
- Greene, M.H., Glaubiger, D.L., Mead, G.E., and Fraumeni, Jr., J.F.: Subsequent cancer in patients with Ewing's sarcoma. Cancer Treat. Rep. 63: 2043-2046, 1979.

21. Gangji, D., Cohen, L., Bleyer, W.A., Vigersky, R., Glaubiger, D., and Poplack, D.G.: Methotrexate CNS Pharmacokinetics in Combination Chemotherapy. In Whitehouse, J. and Kay, E. (Eds.): <u>CNS Complications</u> of Malignant Disease. London, MacMillan Press, Ltd., 1979, pp. 407-412. Page 3 - Bibliography - Daniel L. Glaubiger, M.D., Ph.D.

- Bode, U., Oliff, A., Bercu, B.B., DiChiro, G., Glaubiger, D.L., and Poplack, D.G.: Absence of CT brain scan and endocrine abnormalities with less intensive CNS prophylaxis. Am. J. Pediatr. Hematol.-Oncol. 2: 21-24, 1980.
- 23. Glaubiger, D., Makuch, R., Schwartz, J., Levine, A.S., and Johnson, R.E.: Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 45: 2213-2219, 1980.
- Alabaster, O., Glaubiger, D.L., Hamilton, V.T., Bentley, S.A., Shackney, S.E., Sknamstad, K.S., and Chen, R.F.: Electrolytic degradation of DNA fluorochromes during flow cytometric measurement of electronic cell volume. J. Histochem. Cytochem. 28: 330-334, 1980.
- 25. Abrams, R.A., Claubiger, D., Simon, R., Lichter, A., Deisseroth, A.B.: Hsemopoietic recovery in Eving's sarcoms after intensive combination therapy and autologous marrow infusion. Lancet 11: 385-389, 1980.
- 26. Alrams, R.A., Glaubiger, D., Appelbaum, F.R., and Deisseroth, A.B.: Result of attempted hematopoietic reconstitution using isologous, peripheral blood mononuclear cells: A case report. Blood 56: 516-520, 1980.
- 27. Von Hoff, D.D., Johnson, G., and Glaubiger, D.: Initial Experience with the Human Tumor Stem Cell Assay System: Potential and Problems. In Salmon, S. (Ed.): <u>Cloning of Human Tumor Stem Cells</u>. New York, Alan Liss & Co., 1980, pp. 113-124.
- 2. Bode, U., Magrath, I.T., Bleyer, W.A., Poplack, D.G., Glaubiger, D.L.: Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res. 40: 2184-2187, 1980.

1

- Tepper, J., Glaubiger, D., Lichter, A., Wackenhut, J., and Glatstein, E.: Local control of Ewing's sarcoms of bone with radiotherapy and combination chemotherapy. Cancer 46: 1969-1973, 1980.
- 30. Cohen, L.F., Ewig, R.A.G., Kohn, K.W., and Glaubiger, D.: Interstrand DNA crosslinking by 4,5°,8-trimethylpsoralen plus monochromatic ultraviolet light: Studies by alkaline elution in mouse L1210 leukemis cells. Biochem. Biophys. Acta 610: 56-63, 1980.
- 31. Jentzsch, K., Binder, H., Cramer, H., Glaubiger, D.L., Kessler, R.M., Bull, C., Pomeroy, T.C., and Gerber, N.L.: Leg function after radiotherapy for Ewing's sarcoma. Cancer 47: 1267-1278, 1981.

Page 4 - Bibliography - Daniel L. Glaubiger, M.D., Ph.D.

- 32. Cohen, L.F., Kraemer, E., Waters, B.L., Kohn, K.W., and Glaubiger, D.L.: DNA crosslinking and cell survival in human lymphoid cells treated with 8-methoxypsoralen and long wavelength ultraviolet radiation. Hutation Res. 80: 347-355, 1981.
- 33. Kraemer, K.H., Waters, H.L., Cohen, L.F., Popescu, N.C., Amsbaugh, S.C., DiPaolo, J.A., Glaubiger, D., Ellingson, O.L., and Tarone, R.E. Effects of 8-methoxypsoralen and ultraviolet radiation on human lymphoid cells in vitro. J. Invest. Dermatol. 76: 80-87, 1981.
- 34. Blatt, J., Trigg, M.E., Pizzo, P.A., and Glaubiger, D.: Tolerance to single dose Dactinomycin in combination chemotherapy for solid tumors. Cancer Treat. Rep. 65: 145-147, 1981.
- 35. Hamel, E., Johnson, G., and Glaubiger, D.: Pharmacokinetics of leucovorin rescue using a new methotrexate independent biochemical assay for leucovorin and N⁵-methyltetrahydrofolate. Cancer Treat. Rep. 65: 545-553, 1981.
- 36. Poplack, D.C., Sallan, S.E., Rivera, G., Holcenberg, J., Murphy, S.B., Blatt, J., Lipton, J.M., Venner, P., Glaubiger, D.L., Ungerleider, R., and Johns, D.: Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res. 41: 3343-3346, 1981.
- 37. Glaubiger, D., Makuch, R., and Schwartz, J.: Influence of prognostic factors on survival in Ewing's sarcoma. Proceedings of the Symposium on Sarcomas of Soft Tissue and Bone in Childhood. Natl. Cancer Inst. Honogr 56: 285-288, 1981.
- 38. Riccardi, R., Holcenberg, J.S., Glaubiger, D.L., Wood, J.H., and Poplack, D.G.: L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid. Cancer Res. 41: 4554-4558, 1981.
- 39. Glaubiger, D.L., Von Hoff, D.D., Holcenberg, J.S., Kamen, B., Pratt, C., and Ungerleider, R.S.: The relative tolerance of children and adults to anticancer drugs. Front. Radiat. Ther. Onc. 16: 42-49, 1982.
- 40. Levine, A.S., Brennan, M.F., Ramu, A., Fisher, R.I., Pizzo, P.A., and Glaubiger, D.L.: Controlled clinical trials of nutritional intervention as an adjunct to chemotherapy, with a comment on nutrition and drug relistance. Cančer Res. 42 (Suppl.): 7748-7818, 1982.
- 41. Glaubiger, D.L.: Chemotherapy: Biologic basis, molecular mechanisms and clinical considerations. In Levine, A.S. (Ed.): Cancer in the Young. New York, Masson Publishing USA, Inc., 1982, pp. 213-236.
- 42. Riccardi, R., Chabner, B., Glaubiger, D.L., Wood, J.H., and Poplack, D.G.: Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-B-D-arabinofuranosylcytosine. Cancer Res. 42: 1736-1739, 1982.

1

J' - 18

Page 5 - Bibliography - Daniel L. Glaubiger, M.D., Ph.D.

- Glaubiger, D., Tepper, J., and Mackuch, R.: Eving's Sarcoma. In Levine, A.S. (Ed.): <u>Cancer in the Young</u>. New York, Masson Publishing USA, Inc., 1982, pp. 603-614.
- Srinivasan, U., Reaman, G.H., Poplack, D.G., Glaubiger, D.L., and Levine, A.S.: Phase II study of 5-Azacyticine in sercomes of bone. Cancer Clinical Trials. Am. J. Clin. Oncol. (CCT) <u>5</u>: 411-415, 1982.
- Trigg, M.E., Glaubiger, D., and Nesbit, M.E.: The Frequency of Isolated CNS Involvement in Ewing's Sarcoma. Cancer 49: 2404-2409, 1982.
- ...46. Dwyer, A., Glaubiger, D.L., Ecker, J.G., Doppman, J.L., Prewitt, J.M., and Plunkett, J.: The Radiographic Pollow-up of Patients with Ewing's Sarcoma: A Demonstration of a General Method. Radiology <u>145</u>: 327-331, 1982.
 - 47. Friedman, H.M. and Glaubiger, D.L.: Assessment of In Vitro Drug Sensitivity of Human Tumor Cells Using [³H] Thymidine Incorporation in a Modified Human Tumor Stem Cell Assay. Cancer Res. 42: 4683-4689, 1982.
 - 48. Glaubiger, D. and Ramu, A.: Antitumor Antibiotics. In Pharmacologic Principles of Cancer Treatment. Ed. Chabner, B.A., W. B. Saunders and Company, Philadelphia, Pennsylvania, 1982, pp. 402-415.
 - 49. Johnson, G.E. and Glaubiger, D.L.: Correlation of Cellular Tritiated Thymidine. Incorporation with soft agar clonogenicity in Chemosensitivity Testing of Human Neuroblastoma Cells. Cancer Treatment Deports 67: 163-168, 1983.
 - Kiasella, T.J., Triche, T.J., Dickman, P.S., Costa, J., Tepper, J.E., and Glaubiger, D.: Extraskeletal Ewing's Sarcoma: Results of Combined Hodality Treatment. J. Clin. Oncol. 1: 489-495, 1983.
 - 51. Kinsella, T., Glaubiger, D., Deisseroth, A., Makuch, E., Waller, B., Pizzo, P. and Glatstein, E.: Intensive Combined Modality Therapy including Low Dose TBI in High Risk Ewing's Sarcoma Patients. Int. J. Rad. Oncol. Biol. and Physics 9: 1955-1960, 1983.
 - 52. Ramu, A., Glaubiger, D., Magrath, I.T., and Joshi, A.: Plasma Mombrane Lipid Structural Order in Adriamycin Sensitive and Resistant P388 Cells. Cancer Res. 43: 5533-5537, 1983.
 - 53. Ramu, A., Shan, T., and Glaubiger, D.: Enhancement of Doxorubicin and Vinblastine sensitivity in Anthracycline resistant P388 Cells. Cancer Treatment Reports 67: 895-899, 1983.

Page 6 - Bibliography - Daniel L. Glaubiger, M.D., Ph.D.

- 54. Gangji, D., Ross, W.E., Bleyer, W.A., Poplack, D.G., and Glaubiger, D.L.: Probenecid inhibition of methotrexate cytotoxicity in mouse L1210 leukemia cells. Cancer Treatment Reports 68: 521-529, 1984.
- 55. Ramu, A., Glaubiger, D., Soprey, P., Reaman, G.H., and Feuerstein, N.: 5'- Nucleotidase activity and arachidonate metabolism in Doxorubicin sensitive and resistant P388 cells. Brit. J. Cancer <u>49</u>: 447-451, 1984.
- 56. Ramu, A., Fuks, Z., Gatt, S., and Glaubiger, D.: Reversal of acquired resistance to Doxorubicin in P388 murine leukemia cells by perhexiline maleate. Cancer Res. 44: 144-148, 1984.
- 57. Ramu, A., Cohen, L., and Glaubiger, D.: Oxygen radical detoxification enzymes in Doxcrubicin sensitive and resistant P388 murine leukemia cells. Cancer Res. 44: 1976-1980, 1984.
- Ramu, A., Glaubiger, D., and Weintraub, H.: Differences in lipid composition of Doxorubicin sensitive and resistant cells. Cancer Treatment Reports. 68: 637-641, 1984.
- 59. Ramu, A., Glaubiger, D., and Fuks, Z.: Reversal of acquired resistance to Doxorubicin in P388 murine leukemia cells by Tamoxifen and other Triparancl analogues. Cancer Res. 44: 4392-4395, 1984.
- 60. Ungerleider, R.S., Pratt, C.B., Vietti, T.J., Holcenberg, J.S., Kamen, B.A., Glaubiger, D.L., and Cohen, L.F.: Phase I trial of Mitoxantrone in children. Cancer Treatment Reports. 69: 403-407, 1985.
- 61. Trigg, M.E., Makuch, R., and Glaubiger, D.: Actuarial Risk of isolated CNS involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate. Int. J. Rad. Oncol. Biol. and Physics. 11: 699-702, 1985.

Page 7 - Bibliography - Daniel L. Glaubiger, M.D., Ph.D.

· · ·

.

IN PPESS

- Fierquin, B., Mazeron, J.J., and Glaubiger, D.: Conservative treatment of breast cancer in Europe - Two reports of the European brachytherapy group. Radiotherapy and Oncology
- 2. Holcenberg, J.S., Tutsch, K.D., Earhart, R.H., Ungerleider, R.S., Kamen, B.A., Pratt, C.B., Gribble, T.J., and Glaubiger, D.L.: Phase I study of ICRF 187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treatment Reports.

DICAL SPECIALTIE 89188198 alle Durveiran Board of Activity the American Radium Pociety, the Radiological Pociety of North America. American College of Radiology, the Inverticen Roontgen Ray Soriety. and clinical work, has met certain standurds and qualifications and Jam H. R. Jeallin Brythe D the Section on Radiology of the American Medical Association has passed the examinations conducted under the authority of Thereby demonstrating to the satisfaction of the Board and the American Pociety of Therapeutic Radiologists Has pursued an accepted course of gradicate study that he is qualified to practice the specially of Daniel A: Glaubiger, M.D. The American Board of Radiology Therapeutic Radiology On this sixtly day of June, 1986 Hereby cortifier that Queron we Breeder, min ACON ORATED DISTRICT 18 MATO BUARD IN THE

REM PORTE

Page 5 of 9 pag SUPERVISE LABORATOR EXPERIENC TYPE AND LENGTH OF TRAININ BOWTH AND YEAR CERTIFIE (Haurd) U.S. NUCLEAR REGULATORY COMMI 2 TYPE OF LEE 2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE Callf., MG. clinical clinical Clinical Clinica! B. EXPERIENCE WITH RADIATION. (Acrus' use of RadioInstance or Equiprimum Experience) LECTURE/ LABORATORY COURSES INSUND ... 081 4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIGUES DURATION OF EXPERIENCE 20 09 180 AUTHORIZED USER OR RADIATION SAFETY OFFICER 982-1985 982-1985 982-1935 942-1985 LOCATION AND DATER! OF TRAINING TRAINING AND EXPERIENCE - 1982-1985 1982-1985 USUNS - 1982-1985 - 1982-1985 CATEGORY WHERE EXPERIENCE WAS CAINED. CERTIFICATION . . NAME OF AUTHORIZED USER OF RADIATION SAFETY OFFICER 1 BRUNE USCHS SHOSO -Daniel L. Glaubiger, M.D. MATHEMATICS PERTAINING TO THE USE AND MEASUREIAENT OF RADIOACTIVITY FORM NRC31364 SUPPLEMENT A SPECIALTY BOARD FIELD OF TRAINING RADIATION PHYSICS AND INSTRUMENTATION HADIOPHARMACEUTICAL CHEMISTEY MAXISHING AND UNIT RADIATION PROTECTION 90 mg.Ra.eq/ RADIATION BIOLOGY Tomc1./use 60mc1/use 60mc1/use 1501071 37 Cs 192Tr 19891 251

American Board of Pediatrics

end spoke with

of Pediatric

the

contacted

at 919-929-0461 and verified bampis.

unde.

the 85.

8 Jul Vick

S N

19983

No.

Valid

-Board certificate

y Can C

hereby certifies that

Daniel Teo Glaubiger, M.D.

has successfully fulfilled the requirements of this board . as to competency to practice Pediatrics as a specialty und is declared a Diplomate of The American Board of Pediatrics

. Becember 5, 1976

AMERICAN BOARD 864 Wid 5 da Dresident Secretar The ngunal pre enled a true copy 8 pro fort fig , admin addi Dest of Rad 18 NOV 85 Exando

			a a to man	1	CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN ROMMMAN		purbinuireed in duplica	£	·	•		••				• • •		• • •		* •	•••		 •••	•	RADIOISUTOPE TRAINING			s. Freceptors signature	() gate		3. PRECEPTOR'S MANUE BRANN NOP OF DRIVING	ELI J. GLATSTEIN, H.D.	21.100	1.11.C
				PRECEPTOR STATEMENT (Continued)	ERIENCE OF ABC	CASES INVOLVING	PARTICIPACION	2						35	20	150		7			T				ED IN CLINICAL			1	12	3	7. PRECEPT	113	8. 6475	Т
	•	•		PRECEPTO	2. CLINICAL TRAINING AND EXP	CONDITIONS DIAGNOSTD AR TREAVEN		TREATMENT OF POLVCYTHEMIA VERA	INTRACAVITARY TREATMENT	TREATMENT OF THYROID CARCINOMA	TREATMENT OF HYPERTHYROIDISM	INTRACAVITARY TREATMENT	IN TERSTITIAL TREATMENT	INTRACAVITARY TREATMENT	INTERSTITIAL, TREATMENT	teletherapy treatment	TREATMENT OF EVE DISEASE	RADIOPHARMACEUTICAL PREPARATION	GENERATOR	GENERATOR	REAGENT KITS				3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISUTOPE TRAINING		July 1982-June 1985. 4500 hrs	THE TRAINING AND EXPERIENCE INDICATED ABOVE	A NAME OF SUPERVISION OF	Fil. J. Glatstein, M.D.	Mat'l. Cancer Institute	Rm. B3B69, B1dg, 10, NIH	ands thus land	6. МАТЕЛИСТИСКИЕ ИЛАЛЕНИЕ 1 7 - СО 296-10
		•••				ISOTOPE	*	P-32 (Statutate)	-	1:131		Au-198		Cs137		Co 50 or Co 137	06-15			Ser134		Other	•		3. DATES A			4. THE TRAI	A NAME O	F11.	Nat *	R. MAILING	& CITY BAFNU	E. WATERVALL
		:			•	i,	•						•	** #**					-		•					•	•							, ,
•		Page 6 of 9 pages	L & NUCLEAR REGULATORT LUMMISSION	· · · · · · · · · · · · · · · · · · ·		in's preceptor. If more than one preceptor is necessary to occument were to coll UMN C	PERSONAL PARTICIPATION SHOULD CONSIST OF:	4.8 upprovised exercises on persons to occurrence to an exercised exercised for the provision of the prov	2.Cetta-bocarton in diose cett/bration and actual administration of direa to the patient including catedotection of the redistion does, related	A corousts period of treining to anable physicilan to manage red boctive partness and follow partness through diagno. Is and/or course of		BC	CONNENTS	process on one service of a superior of several several of the superior of the several several of the several of the several several of the several of the several several of the several s									 	 				•			•			
				OR STATEMENT		an's preceptor. If	1134	1.Supervised redicisate prescribed	2.Cellaborat te the part	S.A.dequete	trestruter	XPERIENCE OF	NUMBER OF	PARTICIPATION				-																

Page 7 of 9 p.

·· PRECEP

. 5.

.

FORM NRC-313M-SUPPLEMENT B

•

*

Supplement 8 must be completed by the applicant physepticant providence, obtain a system statement from each. A special physician system s NAME AND ADDRESS

2. CLINICAL TRAINING AND

San Francisco, CA 94123

CONDITIONS DIAGNOSED ON TREATED

1201078

*

.

DIAGNOSIS OF THYROID FUNCTION

DE TERMINATION OF BLOOD MND BLOOD FLASMA VOLUME

T STATE 1 21

2290 Francisco

Daniel Leo Glaubiger. N.D. Braser Aconesa

FULL NAME

4

PORM NRC-3134-SUPPLEMENT B 18-751 1.111C 675

*

DEC 2 0 1988

UVER AND SPLEEN INAGING

LUNG INIGING BONE IMAGING

PLACENTA LOCALIZATION

SLOOD FOOL IMAGING

Tc.BBm

SALIVARY GLAVD IMAGING

THYRORD IMAGING CARDIAC IMAGINO

BRAIN IMAGING

CISTE RHOGRAPHY BLOOD FLOW STUDIES AND FULMON ARY FUNCTION STUDIES

Xe-133

OTHER

Y5-169

DETECTION OF THROMBOSIS

EVE TUMOR LOCALIZATION

27.4 12-32

THYROID IMACING

PANCREAS IMAGING

KIDNEY FUNCTION STUDIES

IN VITRO STUDIES

OTHER 1.125 151-1

FAT ABSORPTION STUDIES LIVER FUNCTION STUDIES

1131

OTHER

TO WHOM IT MAY CONCERN:

This is to certify that, in my opinion, Daniel L. Glaubiger, M.D., is fully gualified to independently perform Group VI therapy procedures (involving sealed sources).

2 platste

Eli Glatstein, M.D. Chief, Radiation Oncology Branch



GRADUATE AND

INTINUING EDUCATION

UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES F. EDWARD HÉBERT SCHOOL OF MEDICINE 4301 JONES BRIDGE ROAD BETHESDA, MARYLAND 20814-4799

31 January 1986



TEACHING HOSPITALS WALTER REED ARMY MEDICAL CENTER NAVAL HOSPITAL, BETHESDA MALCOLM GROW AIR FORCE MEDICAL CENTER WILFORD HALL AIR FORCE MEDICAL CENTER

To Whom It May Concern:

This is to certify that the training program in Radiation Therapy at the Uniformed Services University of the Health Sciences is approved by the Residency Review Committee for Radiology of the Accreditation Council for Graduate Medical Education.

ulland

John W. Bullard, Ph.D. Associate Dean for Continuing Education and Assistant Dean for Graduate Education

She Jub- Moard of Wediatric Mematology- Onrology of the American Poard of Pediatrics hereby certifies that Baniel I. Glaubiger, M.D. has satisfied the requirements of this Sub-Board as to competency in the specialty of . Pediatric Hematology-Oncology No.341 October 5, 1978 Eurenofiler alvin m. mauer 341 spoke That is blowing -50 steps that this is a true copy of the documented pre-LS Department of Health and Human Services Public Health Service National Institutes of Health In recognition that Daniel Laubiger M.D. Feo; has faithfully and satisfactorily completed the duties and responsibilities of . Medical Staff Fellow in Elinical Oncology Program National Cancer Institute June 28, 1982 to June 23, 1985 this certificate awarded On 9 5457. So till ILT Enarte, admin apat, Dest & had 18 Nov 55 DFC 2 0 1988

The Board of Medical F. TO ALL WHOM IT MAY CONCERN, GREETING: This Certifies that Naniel Lea Blaubiaer having presented due evidence of Authority to Practice Me and Surgery in the State of California is hereby livense in accordance with the provisions of the State of Maryland to practi MEDICINE AND SURGERY in the STATE OF MARYLAND. And in testimony where of have caused the names of the President and Secretary of our board to be subscribed, and the sec of our Sciety to be affixed hereto. Witness our hand and the seal of our Societ this wet day of november true copy of doce ment pra 18 INDV 50 men anot Deat of lad Stanford University Medical Center 050505 THIS IS TO CERTIFY THAT Daniel L. Glaubiger, M.D. HAS SERVED AS Fellow in Pediatrics-Pediatric Hematology: February 1, 1973 to June 30, 1975 is a true copy of ogenial presented r that th 1988 Grade, admin apot, Dept & Rad. 18 No/85

Jun 65, the undersigned conterned (Mod Eaminners in Calif.) and varified the License is valid and current. (940-920-6411). ROSE S. YOUNG DEPARTMENT OF PROFESSIONAL AND VOCATIONAL STA The Board of Medical Examiners of the State of California This is to Certify, that MANTEL LEO GLAUBIGER, M.D. a graduate of UNIVERSITY OF CALIFORNIA, SCHOOL OF MEDICINE on the 14th day of ____ JUNE 1959 having shown to the satisfaction of this Board that the is possessed of the qualifications required by law, and having successfully passed a personal Examination by this Board as to $h \frac{15}{10}$ qualifications, is hereby granted a Physician and Surgeon Certificate Do Brartice Medirine and Burgerp in this State BE WESTIMONY MATTERS, THE FOARD OF MEDICAL EXAMINERS of the STATE OF CALIFORNIA has issued this CERTIFICATE and caused the same to be signed by its PRESIDENT and SECRETARY-TREASURER, and its SEAL to be hereto affixed this 17th day of___ TULY A. D. 19.70 The Koard of Redical Examiners OF THE STATE OF CALIFORNIA No. A - 23848 "Certific that this is a true copy of document presented. "Example admin apot, Dept of Rad. 18 Nov 85 On 28 Jun 85, the undersigned connected (Stanford Univ Med Ctr) and spoke with Beverly at 415-497-6154 this certificate is valid . se' D. ynis Iniversity Medical Center STANFORD UNIVERSITY HOSPITAL/STANFORD UNIVERSITY SCHOOL OF MEDICINE 125,25,25 THIS IS TO CERTIFY THAT Daniel Leo Glaubiger, M.D. HAS SERVED AS ... Resident in Pediatrics: July 1, 1972-June 30, 1973

1. Int this is a frue cover of the opinial oreigented.

DEC 2 C 1988

ROSE S. YOUNG Stanford University Medical Center

STANFORD UNIVERSITY HOSPITAL/STANFORD UNIVERSITY SCHOOL OF MEDICINE

05.05.05

THIS IS TO CERTIFY THAT

Daniel Leo Glaubiger, M.D.

HAS SERVED AS.

Resident in Pediatrics: July 1, 1972-June 30, 1973

Associate Dran of the School of Mediciae

I callify that this is a true copy of the aginial presented. 1 hT Graves, admin agat, Dept & Rad 18 Norts

On 28 Jun 85, the undersigned contactor (Nor Landruck M) Collect the License is valid and current. (965920-6411). ROSE 5. YOUNG

The Board of Medical Examiners

DEPARTMENT OF PEOPERSIONAL AND VOCATIONAL STANDARD

of the State of California

Whis is to Certify, that _____ ENTEL LED CLAUBICER, M.D. _____ o graduale of

UNIVERSITY OF CALIFORNIA, SCHOOL OF MEDICINE on the 14th day of JUNE 1969. having shown to the satisfaction of this Board that _he is passessed of the qualifications required by law, and having successfully passed a personal Examination by this Board as to h 10 qualifications, is hereby granted a

> Physician and Surgeon Certificate To Practice Mediciae and Surgery

in this State

The Westimony Whereos, THE BOARD OF MEDICAL EXAMINERS of the STATE OF CALIFORNIA has issued this CERTIFICATE and caused the some to be signed by its PRESIDENT and SECRETARY-TREASURER, and its SEAL to be hereto affixed this _______ Applied of the some to be signed by the STATE of the STATE o

The Kourd of Bediral Examiners OF THE STATE OF CALIFORNIA No. A - 23848 C CHARLEND

DEC 2 0 1988

Stanford University Medical Center

STANFORD UNIVERSITY HOSPITAL / STANFORD UNIVERSITY SCHOOL OF MEDICINE

050505

THIS IS TO CERTIFY THAT

Daniel L. Glaubiger, M.D.

HAS SERVED AS

Intern in Pediatrics: June 24, 1969-June 23, 1970

Enumas A. Contas, M.D., Director of Haspital Robert J. Charge, M.D., Vien-President for Herds a Associate Draw al the "chool of Me On 28 Jun 85, the undersigned contacted (Stanford Univ Med Ctr) and spoke with Beverly at 415-497-6154. terpy piletted to callet

Devot & Rad 18 Nov 85

a true con

and D. Gouve

ROSE S

- ant.

Grand admen

the de la de

ON THE NOMINATION OF THE FACULTY OF THE SCHOOL HAVE CONFERRED UPON

TOTOTIATO AT TITE ATATA PRODIT T AL

DANIEL LEO GLAUBIGER

THE DEGREE OF DOCTOR OF MEDICINE WITH ALL THE RIGHTS AND PRIVILEGES THERETO PH

GIVEN AT SAN FRANCISCO THIS FOURTEENTH DAY OF JUN NINETEEN HUNDRED AND SIXTY-NINE

On 28 Jun 85, the undersigned contacted Univ of Calif and verified the certificate is valid per Registrar office 415-666-1742.

PRESIDENT OF CALIFORNIA AND

I certify that the to



FORM NRC-3 (8-78)	AUTHORIZE	TRAININ D USER OR	IG AND EXPERIEN	VCE	EAR REGULAT	DRY COMMISSI
	AUTHORIZED USER OR RAD		Y OFFICER		2. STATE OR TE WHICH LICEN PRACTICE ME	DICINE
Daniel	L D. OIGUDIGEI, M.D		CERTIFICATION		Calif.,	Md,
	SPECIALTY BOARD		CATEGORY			EAR CERTIFIED
The Americ	can Board of Radiol	.ogy :	Therapeutic Rad:	iology	June 1986	•
	4. TRAINING R	ECEIVED IN E	BASIC RADIOISOTOP	E HANDLING T	ECHNIQUES	en a partentaren (provedi yr tro-manif
A CONTRACTOR OF	*	T		an investment of the second state of the secon	TYPE AND LEN	STH OF TRAINING
	FILLD OF TRAINING A	LC	DCATI IN AND DATE S	OF TRAINING	LECTURE/ LABORATORY COURSES [Hours] C	SUPERVISE L/ 208 101 EXPERIENC (Hears) D
a. RADI INST	ATION PHYSICS AND RUMENTATION					
b. RADI	ATION PROTECTION					
THE	MEMATICS PERTAINING TO USE AND MEASUREMENT RADIOACTIVITY					
d. RAD	IATION BIOLOGY					
	NOPHARMACEUTICAL MISTRY					-
	5. EXPERIENCE W	TH RADIAT	ION. (Actual use of Ra			
ISOTOPE	MAXIMUM AMOUNT	WHERE EXPER	HENCE WAS GAINED	DURATION OF	EXPERIENCE	TYPE OF USE
		•				

ROBERT J. LULL, M.D.

Address:

16.3

Office: Letterman Army Medical Center Presidio of San Francisco, CA 94129 Phone: (415) 561-3088

0

Education:

Canisius College (A.B.), Buffalo, N.Y., 1958-1962.

Albany Medical College of Union University (M.D.), Albany, N.Y., 1962-1966.

Internship (Rotating), Brooke General Hospital, San Antonio, TX; 1967-1970.

Residency (Internal Medicine), Brooke General Hospital, San Antonio, TX; 1967-1970.

Residency (Nuclear Medicine), William Beaumont General Hospital, El Paso, TX: 1970-1972.

Scholarships and Honors:

New York Regent's Scholarship (1958-1962)

Canisius College Scholarship (1958-1962)

Albany Medical College Alumni Scholarship (1962-1966)

American Business Women's Association Northern California Chapter Boss of the Year Award (1979)

"A" Professional Designator Award in Nuclear Medicine from U.S. Army Surgeon General (1983)

Who's Who in California (1984-1986)

Robert J. Lull, M.D.

Current Positions & Appointments:

Chief, Nuclear Medicine Service, Letterman Army Medical Center Presidio of San Francisco, CA (1976-Present)

Director, ACGME Approved Nuclear Medicine Residency Program (1976 - Present)

Medical. Director, ASHP Approved Residency in Nuclear Pharmacy (1983 - Present)

Medical Director, AMA Approved Training Program for Nuclear Medicine Technologists U.S. Army portion of Tri-Service Program (1976 - Present)

Nuclear Medicine Consultant to U.S. Army Surgeon General (1977 - Present)

Executive Committee Member, Nuclear Medicine Technology Training Program at University of California San Francisco (1978 - Present)

Clinical Associate Professor of Radiology, George Washington University School of Medicine, Washington, D.C. (1978 - Present)

Clinical Assistant Professor of Radiology, University of California School of Medicine, San Francisco, CA (1978 - Present)

Consulting Staff, Roseville Community Hospital, Roseville CA (1980 - Present)

Member, Letterman Army Medical Center Speaker's Bureau (1985 - Present)

Previous Positions and Appointments

Chief, Nuclear Medicine Service Brooke Army Medical Center San Antonio, TX (1972 - 1976)

Nuclear Medicine Consultant to U.S. Army Health Services Command, San Antonio, TX (1972 - 1978)

Medical Consultant and Guest Lecturer at Nuclear Hazards Training Course and Flag Officers' Nuclear Accident Course, Interservice Nuclear Weapons School, Kirtland AFB, New Mexico (1976 - 1986)

Clinical Assistant Professor of Radiology, George Washington University School of Medicine, Washington, D.C. (1973 - 1978)

Clinical Associate Professor of Radiology, University of Texas Health Science Center, San Antonio, TX (1973 - 1976)

Chief Resident in Internal Medicine, Brooke General Hospital, San Antonio, TX (1970)

Robert J. Lull, M.D.

Clinical Instructor in Internal Medicine, University of Texas Medical School, San Antonio, TX (1970)

Visiting Resident in Internal Medicine at Harvard Medical Service, Peter Bent Brigham Hospital, Boston, MA (1970)

Certification

Diplomate National Board of Medical Examiners (1967)

Diplomate American Board of Internal Medicine (1972) 19 Jun 72; #36031

Diplomate American Board of Nuclear Medicine (1972) 5 May 72; #1492

Professional Societies:

American College of Physicians: Fellowship - 1983

American College of Nuclear Physicians: Charter Member Fellowship, 1983 Member, California Chapter Delegate for U.S. Army 1977 - 1985 Chairman Fellowship Committee, 1980 - 1982 Member, Executive Committee, 1982 - 1985 Member, Instrument Standardization and Performance Committee, 1984-Present Member, Speaker's Bureau, 1980 - Present House of Delegates Council, 1978 - 1982 Vice-Speaker, House of Delegates, 1983 - 1984 Regent, Western United States, 1985 - Present

Society of Nuclear Medicine - Chapter Level:

Southwest Chapter: Member, 1970 - Present Member, Program Committee, 1976 Trustee, 1975 - 1978; 1979 - 1981 Northern California Chapter: Member, 1976 - Present Councillor (Trustee), 1982 - 1984 Chairman, Scientific Program Committee, 1983 - 1986 Member, Executive Committee, 1983 - Present Chairman, Membership Committee, 1985 - 1986 President-Elect 1985 - 1986 President 1986 - Present

. . .

Robert J. Lull, M.D.

Western Regional Chapters: Member, Program Committee, 1983 - 1986 Member, Hawaii Spring Conference Program Committee, 1984 - Present Member, Winter Brainstorm Conference Program Committee, 1986 Member, Steering Committee, 1984 - Present Chairman, Scientific Program Committee, 1986

Society of Nuclear Medicine - National Level:

Member, 1970 - Present Member, Scientific Exhibits Committee 1974, 1978 Co-Director, Annual S.N.M. Meeting Review Course, 1983 - Fresent Academic Council: Member, 1976 - Present Executive Committee, 1980 - 1984 Chairman Issues Committee, 1980 - 1984 Computer Council: Member, 1976 - Present Radioassay Council: Member, 1976 - Present Cardiovascular Imaging Council: Member, 1986 - Present Chapter Presidents Committee, 1986 - Present Trustee, 1985 - 1989

Council on Cardiovascular Radiology of the American Heart Association, 1976 - 1984

Radiological Society of North America: Member, 1984 - Present

Texas Association of Physicians in Nuclear Medicine, 1972 - Present

Texas Medical Association, 1972 - Present

Bexar County Medical Association, 1972 - Present

California Medical Association Nuclear Medicine Advisory Board, 1986 - 1989

Cal-Rad Forum, 1985 - Present

Journal Peer Review:

Chest, 1983

Non-Invasive Imaging, 1983 - 1985

Journal of Nuclear Medicine, 1985 - 1986

Arthritis and Rheumatism, 1986

Medical Licenses:

New York State (#78216) Texas (D9841) California (G23180) NRC Institutional Broad Medical License (04-1496-01; Region VI)

Scientific Exhibits:

"A Clinician's Guide to the Modulation Transfer Function." <u>Silver Medal Award</u> for Teaching Scientific Exhibit at 19th Annual Meeting of Society of Nuclear Medicine, Boston, MA (1972). <u>Certificate of Merit</u> at 60th Annual Meeting of Radiological Society of North America, Chicago, IL (1974).

"Radionuclide Evaluation of Inhalation Injury." <u>Honorable Mention</u> for Clinical Scientific Exhibit at 21st Annual Meeting of The Society of Nuclear Medicine, San Diego, CA (1974). <u>Invited Historical Exhibit at 22nd Annual Meeting of Society of</u> Nuclear Medicine, Philadelphia, PA (1975).

"Natural History of Technetium-99m MDP Bone Scan in Asymptomatic Total Hip Protheses." <u>Silver Medal Award at 30th Annual Society of</u> Nuclear Medicine Meeting, St. Louis, MO (1983). American Academy of Orthopaedic Surgeons 51st Annual Meeting, Atlanta, GA (1984)

. .

. .

Robert J. Lull, M.D.

Mi	1	1	ta	r-w	Se	rvi	ce
	-	-	-	- 4			100.000

June 1966-June 1967 Internship Brooke General Hospital San Antonio, TX

July 1967-Aug 1967 Medical Field Service School Fort Sam Houston, TX

Sept 1967-Aug 1970 Internal Medicine Residency Brooke General Hospital San Antonio, TX

Sept 1970-Aug 1972 Nuclear Medicine Fellowship William Beaumont Army Medical Center El Paso, TX

Sept 1972-May 1976 Chief, Nuclear Medicine Service Brooke Army Medical Center Fort Sam Houston, TX

Aug 1973-May 1976 Nuclear Medicine Consultant to Health Services Command

May 1976-Present Chief, Nuclear Medicine Service (Director, Nuclear Medicine Residency Program) Letterman Army Medical Center Presidio of San Francisco, CA

> Nuclear Medicine Consultant to The Surgeon General, U.S. Army

Aug 1977-Present

June, 1980

July, 1980

Awarded "A" Professional Designator, Nuclear Medicine

U.S. Army Representative on U.S. Radiation Policy Council Public Hearing, San Francisco, CA

1978 - 1984 U.S. Army Delegate to American College of Nuclear Physicians

December 1985

and the second statements and the second statements

U.S. Army Medical Department Representative to F.E.M.A. Relocation Tabletop Exercise at National Emergency Training Institute, Emmittsburg, PA

, and a strate star in the state of the grade is the

• .

. .

Military Training Courses:

- 1967 Bisic Officer's Course, Medical Field Service School Fort Sam Houston, TX
- 1975 Nuclear Hazards Training Course, Interservice Nuclear Weapons School, Kirtland AFB, NM
- 1975 Nuclear Emergency Team Exercise, Interservice Nuclear Weapons School Kirtland AFB, NM, Training Course
- 1979 Medical Effects of Nuclear Weapons Course at Armed Forces Radiobiological Research Institute, Bethesda, MD
- 1981 Flag Officer Nuclear Accident Course, Interservice Nuclear Weapons School, Kirtland AFB, NM
- 1981 O.P.M. Executive Training Workshop on Sexual Harassment at Letterman Army Medical Center, San Francisco, CA

- -+

Lectures and Honoraria

- "The Diagnosis of Pulmonary Emboli and Other Pulmonary Perfusion-Ventilation Disorders", at 2nd Annual Symposium in Clinical Nuclear Medicine. El Paso, TX (1971).
- "The Liver Scan in Patients with Cancer", at 1st Scientific Assembly of the World Federation of Nuclear Medicine and Biology. Los Angeles, CA (June, 1971).
- "Recent Diagnostic Advances in the Evaluation of Neurological Disorders and how They Can Help the Busy Clinician", at 3rd Annual Symposium in Clinical Nuclear Medicine. El Paso, TX (1972).
- "Lung Imaging Techniques", at Southwestern Chapter of Society of Nuclear Medicine Technologist Symposium. San Antonio, TX (October, 1973).
- "Cisternography", at New Concept in Nuclear Medicine Symposium for Technologists. San Antonio, TX (August, 1974).
- "Inhalation Injuries". at Annual Scientific Session of Texas Association of Physicians in Nuclear Medicine, Lakeway, TX (November, 1974).
- "Radioisotope Imaging of Trauma", at Continuing Education Course: Radiology for Trauma and Acute Care, by University of Texas Health Science Center at San Antonio, TX (January, 1975).
- B. "Hyperthyroidism A Choice of Treatments", at Therapeutics Seminars Series, at University of Texas Health Science Center at San Antonio, TX (March, 1975).
- "Nuclear Medicine in Pulmonary Disease", at 28th KOPPA Memorial Pulmonary Disease Conference, Hunt, TX (August, 1975).
- "Role of the Computer in Clinical Nuclear Medicine", at 3rd Annual Fall Meeting of Texas Association of Physicians in Nuclear Medicine, Salado, TX (November, 1975).
- "Radionuclide Evaluation of Burn Patients", at Texas Medical Association Annual Meeting, San Antonio, TX (May, 1975).
- "Radionuclide Evaluation of Inhalation Injury", at 22nd Annual Meeting of Society of Nuclear Medicine, Philadelphia, PA (June, 1975).

* #

ŗ

Lectures and Honoraria (continued)

- "Iodocholesterol Imaging of Adrenal Gland", at Meeting of San Antonio Endocrine Club, San Antonio, TX (February, 1976).
- "Thyroid Imaging Pitfalls", at North Texas Technologist Symposium on Thyroid Disease, Dallas, TX (March, 1976).
- "Clinical Role of Computerized Whole Body Scanning Camera", at International Modumed Users Group Symposium, Lausanne, Switzerland (May, 1976).
- "Medical Aspects of Nuclear Accidents", at Interservice Nuclear Weapons School, Kirtland A.F.B., New Mexico (3 times per year: 1976-Present).
- "Medical Principles of Dealing with Patients Contaminated by Radioactivity", at Monthly Meeting of San Luis Obispo County Medical Society, San Luis Obispo, CA (September, 1976).
- "Clinical Role of a Computerized Whole Body Scanning Camera", at 22nd Annual Meeting of Southwestern Chapter Society of Nuclear Medicine. El Paso, TX (March, 1977).
- 19. "Quantitative Analysis of 133-Xenon Washout in Acute Inhalation Injuries: An Animal Model", at 22nd Annual Meeting of Southwestern Chapter Society of Nuclear Medicine, El Paso, TX (March 1977), and 25th Annual Meeting of Society of Nuclear Medicine, Anaheim, CA (June, 1978).
- "Current and Future Role of Nuclear Medicine Computers," at Texas Association of Physicians in Nuclear Medicine Annual Meeting, Austin, TX (November, 1978).
- "Radionuclide Evaluation of Inhalation Injury: Implications For Diagnosis and Therapy in Burn Patients", at 4th Annual Western Regional Meeting of Society of Nuclear Medicine, Monterey, CA (October, 1979).
- 22. "Time Sequence of Bone and Gallium Scan Changes in Acute Osteomyelitis: An Animal Model", at 26th Annual Meeting of Society of Nuclear Medicine, Atlanta, GA (June, 1979) and 26th Annual Meeting of Southwest Chapter of Society of Nuclear Medicine, New Orleans, LA (March, 1981).
- 23. "Multiple Imaging Modalities: How to Select the Best Tests for Your Patient", at Faculty of ACP Course: Advances in Internal Medicine, San Francisco, CA, (October, 1981).
- 24. "The Use of Radionuclides to Diagnose Gastrointestinal Hemorrhage", at University of California San Francisco (March, 1982).

Lectures and Honoraria (continued)

- "Radionuclide Evaluation of Gastrointestinal Hemorrhage and Biliary Imaging Studies", at Present Concepts in Diagnostic Radiology, San Francisco, CA (May, 1982).
- "Nuclear Medicine Resident Job Market Experience Survey Results", at Academic Council Meeting at 29th Annual Meeting of Society of Nuclear Medicine, Minne, FLA (June, 1982).
- 27. "G.I. Bleeding Problems in Detection and Localization", at 7th Annual Western Regional Meeting of Society of Nuclear Medicine, San Diego, CA (October, 1982).
- 28. "Scintigraphic Evaluation of G.I. Bleeding," at Stanford University Nuclear Medicine Grand Rounds, Stanford, CA (March, 1983).
- "G.I. Bleeding Studies", at Society of Nuclear Medicine Hawaii Spring Conference, Kauai, HI (April, 1983).
- 30. "Nuclear Medicine Resident Job Market Experience Survey II Results", et Academic Council Meeting at 30th Annual Meeting of Society of Nuclear Medicine, St. Louis, MO (June, 1983).
- 31. "New Advances in Nuclear Medicine-Gastrointestinal Function Studies", at Roseville Community Hospital, Roseville, CA (September, 1983).
- 32. "G.I. Bleeding An Update on Problems in Detection and Localization", at 8th Annual Western Regional Meeting of the Society of Nuclear Medicine, Seattle, WA (October, 1983).
- 33. "Radionuclide evaluation of joint disease" at Annual Midwinter Meeting of Northern California Chapter of the Society of Nuclear Medicine, San Francisco, CA (January, 1984).
- 34. "Radionuclide Evaluation of Lung Trauma" at Nuclear Medicine Grand Rounds at Stanford University School of Medicine, Stanford, CA (April 1984).
- 35. "Controversies in scintigraphic detection of lower G.I. bleeding" at Present Concepts in Diagnostic Radiology Course at Letterman Army Medical Center, San Francisco, CA (May, 1984).
- 36. "Radionuclide evaluation of joint disease" at Clinical Nuclear Medicine Course at Baptist Memorial Hospital, Memphis, TN, (November, 1984).
- 37. "Radionuclide Evaluation of gastrointestinal bleeding," at XV Annual Meeting of Mid-Eastern Chapter of Society of Nuclear Medicine, Charlottesville, VA (March, 1985).

TEC 2 0 1989

and a state of the second of the second of the second of the

1 4

. .

Lectures and Honoraria (continued)

- 38. "nadiation Risk in Perspective" at Quad-Service Public Health Meeting at Travis AFB, CA (April, 1985).
- 33. "Panel: Management of Pulmonary Embolism," at Present Concepts in Internal Medicine Post Graduate Course and 2nd Annual ACP Army Regional Meeting, San Francisco, CA (October, 1985)
- 40. "Risks and Benefits of Nuclear Medicine" at Annual Meeting of the Hawaii Medical Association, Kona, HI (October, 1985).
- "Nuclear Scintigraphy in the evaluation of G.I. Hemorrhage" at University of Hawaii Medical Grand Rounds, Honolulu, HI (October, 1985).
- 42. "G.I. Bleeding Pitfalls" at Refresher Course Symposium at 10th Annual Western Regional Society of Nuclear Medicine Meeting, Palm Springs, CA (October, 1985).
- 43. "Acute Radiation Syndromes" at University of California San Francisco Nuclear Medicine Seminar, San Francisco, CA (November, 1985).
- 44. "Radiation Medicine" at meeting of Kiwanis Club, San Francisco, CA (November, 1985).
- 45. "Detection of Acute G.I. Bleeding" at 12th Annual meeting of the American College of Nuclear Physicians, West Palm Beach, FL (February, 1986).
- 46. "Imaging of Infection and Inflammation: Joints and Prothesis" at 12th Annual meeting of the American College of Nuclear Physicians, West Palm Beach, FL (February, 1986).
- 47. "Evaluation of Infection and loosening of Joint Prostheses," Nuclear Medicine Grand Rounds, Straub Clinic and Hospital, Honolulu, HI (April, 1986).
- 48. "Can the benefits of Nuclear Medicine be used to justify low-level waste management risks?" at the American Nuclear Society Annual meeting, Reno, NV (June, 1986).
- 49. "Introduction to Nuclear Medicine" and "Low level radiation exposure in perspective" at Annual Radioisotope Safe Use and Handling Course, Letterman Army Medical Center, San Francisco, CA (1978 - 1986).
- 50. "Nuclear Medicine Overview" and "Biological effects of ionizing radiation" at Annual Introduction to Nuclear Pharmacy Course, LAMC, SF, CA (1976 - 1986).
- 51. "Nuclear Medicine Instrument Safety Assurance Testing at 11th Annual Meeting of NEMA Diagnostic Imaging and Therapy Systems Division, Monterey, CA (September, 1986).

. .

Robert J. Lull, M.D.

Lectures and Honorarium (continued)

- 52. "Evaluation of G.I. Bleeding via Scintigraphy" at Annual Clinical Nuclear Medicine course Bethesda Naval Medical Center, Bethesda, MD (October 1986).
- 53. "Radionuclide evaluation of Joints" at Annual Clinical Nuclear Medicine course Bethesda Naval Medical Center, Bethesda, MD (October 1986).
- 54. "Nuclear Medicine Role in Evaluating Gastrointestinal Hemorrhage" Johns Hopkins University School of Medicine, Baltimore, MD (October 1986).
- 55. "Nuclear Medicine's Role in Biliary and Gastrointestinal Bleeding Disorders" at Internal Medicine Update Course at California Medical Associations Annual Session and Western Scientific Assembly, Anaheim, CA 1 March 1987).

AudioVisual Productions

Society of Nuclear Medicine Audiotape SNM 204: "Lung Trauma."

Baptist Memorial Hospital Nuclear Medicine Audiotape #4: "Radionuclide evaluation of joint disease."

University of California Videotape: Current opics in Nuclear Medicine, Series 1: "Scintigraphic identification and localization of gastrointestinal hemorrhage."

American College of Nuclear Physicians Audiotape 8: "Detection of Acute G.I. Blerding."

American College of Nuclear Physicians Audiotape 12B: "Nuclear Medicine Role in evaluating Joints and Protheses."

BIBLIOGRAPHY

- Strader WJ, Lull RJ: Bone Scanning: a very useful and commonly performed procedure in evaluation of patients with carcinoma. <u>Southwestern Medi-</u> cine 51: 252-253, 1970.
- Volpe AJ, Lull RJ, Nusynowitz ML: The liver scan in patients with cancer: histologic correlation. J of Surg Oncology 3: 649-655, 1971.
- Lull, RJ, Strader WJ, Blumhardt R: Tests of vitamin B-12 absorption. Southwestern Med 52:198-200, 1972.
- Lull RJ: Further observations on I-131 rose bengal clearance in Gilbert's disease (Letter to Ed). J of Nucl Med 12:5789, 1971.
- Blumhardt R, Lull RJ, Strader WJ: Thyroid nodules and carcinoma. Southwestern Med 53:61-64, 1972.
- Lull RJ: Stereo cisternography (Letter to Editor). J of Nucl Med 13: 289, 1972.
- Lull RJ, Dunn BE, Gregoratos G, Cox WA, and Fisher GW: Ventricular aneurysm due to cardiac sarcoidosis with surgical cure of refractory ventricular tachycardia. Amer J of Card 30:282-287, 1972.
- Lull RJ (Letter to Editor): "Hot" hepstic lesions on liver scans. J of Nucl Med 13:703, 1972.
- Milstein D, Nusynowitz M, Lull RJ: Radionuclide diagnosis in chest disease resulting from trauma. Semin in Nucl Med IV:339-356, 1974.
- Roy JE, Lull RJ: P-32 Uptake in ocular tumor localization (Abstract). Health Physics 27: 619, 1974.
- . 11. Nusynowitz M, Lull RJ: Modulation transfer function (Book chapter in <u>Textbook of Nuclear Medicine Technology</u>). PJ Early, MA Razzak, BD Sodee, Eds. Pg. 222-229. C.V. Mosby Co, St. Louis, 1975.
 - Lull RJ, Agee RN, Long JK, Petroff PA, and Andrews JA: Radionuclide evaluation of inhalation injury in patients with thermal injury (Abstract). J of Nucl Med 16, 547, 1975.
 - McGuinnis EW, Lull RJ: Bronchial adenoma causing unilateral absence of pulmonary perfusion. Radiol 120:367-368, 1976.
 - Agee RN, Long JM, Hunt SL, Petroff PA, Lull RJ, Mason AD and Pruitt BA Jr: Use of 133Xenon in early diagnosis of inhalation injury. J of Trauma 16: 218-224, 1976.

.....

- Cutter P, Arney GK, Lull RJ, Pestana C, Woeber KA, Becker RA: Your hyperthyroid patients: will drugs be enough? Current Prescribing 1: 20-29, 1977.
- Welch GW, Lull RJ, Petroff PA, Hander EW, McLeod CG Jr, and Clayton WH: The use of steroids in inhalation injury. <u>Surg. Gyn and (bst</u> 145:539-544, 1977.
- Henry WH, Staples D, Lull RJ, Kiser SR, Kehn BD, Yuille D, Telepak RJ, Lambrecht RW, McAuley RJ: Radionuclide marshmallow swallow for evaluation of dysphagia (Abstract). J of Nucl Med 19:738, 1978.
- Kiser SR, Lehman HG, Lull RJ, Yuille DL, Dewey BT, Kehn BD: A general purpose radioassay program for obtaining the best fit in constructing the standard radioassay curve (Abstract). J of Nucl Med 19:748, 1978.
- Nusynowitz M, Lull RJ: Modulation transfer function. Book chapter in <u>Textbook of Nuclear Medicine Technology</u>, 3rd Ed(PS Early, MA Razzak, ... BD Sodee, Eds). Pg 283-291, CV Mosby Co., St. Louis, 1979.
- 20. Dye SF, Lull RJ, McAuley RJ, Van Dam BE, Young W: Time sequence of bone and gallium scan changes in acute osteomyelitis: an animal model (Abstract). J of Nucl Med 20:647, 1979.
- Lull RJ, Anderson JH, Telepak RJ, Brown JM, Utz JA: Radionuclide imaging in the assessment of lung injury. Sem in Nucl Med X:302-310, 1980.
- Utz JA, Lull RJ, Anderson JH, Lambrecht RW, Brown JM, Henry W: Hepatoma visualization with Tc-99m pyridoxylidene glutamate. J of Nucl Med 21: 747-749, 1980.
- 23. Bunker SR, Lull RJ, McAuley RJ, Brown JM, Jackson JH, Hattner RS, Huberty JP: Advantages of in-vitro labelled Tc-99m red blood cells in the detection of gastrointestinal bleeding sites (Abstract). Clin Nucl Med 6:445, 1981.
- 24. Brown JM, White CJ, Sobel SM, Lull RJ: Increased left ventricular ejection fraction after a meal: potential source of error in performance of radionuclide angiography (Abstract). Clin Nucl Med 6:447, 1981.
- Utz JA, Galvin EG, Lull RJ: Tc-99m bone scan in the evaluation of the Wagner "Cup Type" hip prosthesis (Abstract). Clin Nucl Med 6:456, 1981.
- Sobel SM, Brown JM, Bunker SR, Patel J, Lull RJ: Noninvasive diagnosis of cardiac amyloidosis by technetium-99m-pyrophosphate myocardial scintigraphy. Amer Heart J 103:563-6, 1982.

. .

.....

- Brown JM, White CJ, Sobel SM, Lull RJ: Increased left ventricular ejection fraction after a meal: potential source of error in performance of radionuclide angiography (Abstract). Am J Cardiol 49:991, 1982.
- 28. Bunker SR, Brown JM, McAuley RJ, Lull RJ, Jackson JH, Hattner RS, Huberty JP: Detection of gastrointestinal bleeding sites: use of <u>in-vitro</u> Tc-99m-labelled RBCs. JAMA 247:789-792, 1982.
- Bunker SR, Lull RJ, Brown JM, McAuley RJ, Redwine MD, Jackson JH, Hattner RS (Abstract): Clinical comparison of Tc-99m-sulfur colloid and <u>in-invtro</u> labelled Tc-99m-red blood cells in the detection of gastrointestinal hemorrhage. J Nucl Med 23:p52, 1982.
- Utz JA, Galvin EG, Lull RJ: Natural history of tecinetium-99m-MDP bone scan in asymptomatic total hip prostheses (Abstract). J Nucl Med 23:28-29, 1982.
- Bunker SR, Lull RJ, Hattner RS, Brown JM: The ideal tracer in gastrointestinal bleeding detection. Amer J Roentgen 138:982-984, 1982.
- 32. Utz JA, Lull RJ, Anderson JH, Lambrecht RW, Brown JM, Henry HW: Hepatoma visualization with 99m-Tc-pyrodoxylidene glutamate. <u>Yearbook of Nuclear</u> <u>Medicine</u> (Ed. PB Hoffer) 1982:365-366.
- Lull RJ, Anderson JH, Telepak RJ, Brown JM, Utz JA; Radionuclide imaging in assessment of lung injury. <u>Yearbook of Nuclear Medicine</u> (Ed. PB Hoffer) 1982:151-153.
- 34. Kaplan KA, White CJ, Watson TJ, Redwine MD, Jackson JH, Lull RJ: Diastolic filling of the left ventricle as a predictor of coronary artery disease: a simplified approach (Abstract). Clin Nucl Med 7:34, 1982.
- 35. Jackson JH, Utz JA, Lull RJ, Galvin EG, Kolina JS, Boll DA, Kaplan KA, Turnbull GL, Redwine MD: "Hot Shaft Sign": a confusing finding in asymptomatic hip prosthesis patients (Abstract). Clin Nucl Med 7: 43, 1982.
- # 36. Lull RJ: G.I. bleeding -- problems in detection on localization. chapter III in 7th Western Regional Rev. ew Course Syllabus. Pg 10-18. Society of Nuclear Medicine Western Region, San Francisco, CA 1982.
 - Bunker SR, Lull RJ, Jackson H, McAuley RJ, Forster MJ, Warren RW: The nuclear enema: a technique f r scintigraphically demonstrating colonic anatomy. <u>Radiology</u> 145:213, 1982.
 - 38. Bunker SR, Kolina JS, Kaplan KA, McAuley RJ, Lull RJ: Scintigraphic detection of occult hemorrhage using red blood cells labelled <u>in-vitro</u> with Tc-99m. Arch Int Med 143:1027-1026, 1983.

DEC 2 0 1938

- Brown JM, White CJ, Sobol SM, Lull RJ: Increased left ventricular ejection fraction after a meal: Potential Source of Error in performance of Radionuclide angiography. Amer J Cardiol 51:1709-1711, 1983.
- 40. Lull RJ, Utz JA, Jackson JH, Redwine MD, Turnbull GL, Kolina JS, Boll DA, and Kaplan KA: Radionuclide evaluation of joint disease. Book chapter in <u>1983 Nuclear Medicine Annual</u> (LM Freeman and HS Weissman, Eds). Pg 281-328, Raven Press, New York, 1983.
- Lull RJ, Tatum JL, Sugerman HJ, Hartshorne MF, Boll DA, and Kaplan KA: Radionuclide evaluation of lung trauma. Semin Nucl Med X111:223-237, 1983.
- 42. Utz JA, Lull RJ, Galvin EG: The variability of follow-up bone scans after asymptomatic total hip protheses (Abstract): J Nucl Med 24:5, p72, 1983.
- Kilbride HW, Lull RJ, Lehmann HC: Screening for Hypothyroidism (Letter to Editor) Pediatrica 73:263-264, 1983.
- Lull RJ: Radionuclide detection of scute lower gastrointestinal tract bleeding site. West J Med. 139: 697-698, 1983.
- 45. Weber DA, Paras P, Harris CC, Benua RS, Brill AB, Brown ML, Croft EY, Lull RJ, Wiley AL: Initial Testing and Quality Control for radionuclide dose calibrators. ACNP monograph. Washington, D.C., 1984.
- 46. Bunker SR, Lull RJ, Tanasescu DE, Redwine MD, Rigby J, Brown JM, Brachman MB, McAuley RJ, Ramanna L, Landry A, Waxman A: Scintigraphy of gastrointestinal hemorrhage: superiority of 99mgs red blood rells over 99mmc sulfur colloid. AJR 143: 543-548, 1984.
- McAuley RJ, Lull RJ, Ice RD: ⁸²Br Contamination in fission product ^{99m}Tc Generator Eluate. Europ J. Nucl Med 10: 60-62, 1985.
- 48. Nusynowitz M, Lull RJ: Modulation transfer function. Book chapter in Principles and Practice of Nuclear Medicine (PS Early, BD Sodee, Eds) Pg 463-471, CV Mosby Co., St. Louis, 1985.
- Orrecchia PM, Hensley EK. McDonald PT, Lull RJ: Localization of lower gastrointestinal hemorrhage: Experience with red blood cells labeled in vitro with Technetium Tc-99m. Arch Surg 120:621-624, 1985.
- Lull RJ, Morris GL: Scintigraphic detection of gastrointestinal hemorrhage: Current status. J Nucl Med Tech 14: 79-88, 1986.
- 51. Lull RJ: Can the benefits of nuclear medicine be used to justify low level waste management risks? <u>Transactions</u> (L. Palagi, Ed) Pg 38-39, American Nuclear Society, La Grange Park, IL, 1986.

16

*** * * *

(1-1)

ţ

Robert J. Luli, M.D.

- 52. Weber DA, Paras P, Harris CC, Benua RS, Brill AB, Brown ML, Croft BY, Lull RJ, Wiley AL: Initial testing and quality control for radionuclide dose calibrators. ACNP monograph. <u>Nuclear Medicine Communications</u> 7: 555-565, 1985.
- 53. Utz JA, Lull RJ, Galvin EG: Asymptomatic total hip prothesis: natural history determined using Tc-99m MDP bone scans. Radiology 161: 509-512, 1986.
- 54. Lull, RJ, Tatum JL, Hartshorne MF, Algeo JH: * Sessment of lung function following injury to toxic agents. Book chapter in <u>Pulmonary Nuclear Medicine</u> (M Loken, Ed.) pg xxx-xxx, Appleton-Century-Crofts, East Norwalk, CT, 1987. (in Press).

ORM NRC-313M-SUPPLEMENT A	TR/	AINING AND EXPERIENCE R OR RADIATION SAFE	CE	EAR REGULATO	
Robert J. Lull, M.D.	ADIATION	SAFETY OFFICER		2. STATE OR TER WHICH LICENS PRACTICE MED Calif., N.1	ED TO
	and of the second s	3. CERTIFICATIO		MONTH AND YE	AD CERTIFIED
SPECIALTY BOARD		CATEGORY		MONTHANDIC	
The American Board of Nuclear Medicine		Nuclear Medici	lne	May 19	72
	RECEIVI	ED IN BASIC RADIOISOTOPE	HANDLING	ECHNIQUES	
9, TRAINING			ala, brankforge generation in Later of Aleman	TYPE AND LENG	TH OF TRAINING
FIELD OF TRAINING		LOCATION AND DATE (S) (OF TRAINING	LECTURE/ LABORATORY COURSES [Hours] C	SUPERVISED LABORATO.II EXPERIENCE (Hours) D
. RADIATION PHYSICS AND INSTRUMENTATION	-	- *			
b. RADIATION PROTECTION					
C. MATHEMATICS PERTAINING THE USE AND MEASUREMEN OF RADIOACTIVITY	TO T				
d. RADIATION BIOLOGY		1			
. RADIOPHARMACEUTICAL CHEMISTRY					
5. EXPERIENCI	WITHR	ADIATION. (Actual use of Rad	dioisotopes or E	Equivalent Experien	ce)
ISOTOPE MAXIMUM AMOUNT		E EXPERIENCE WAS GAINED	DURATION OF	FEXPERIENCE	TYPE OF USE
		•			
					FC 2 0 1988

ş

4

.

NAME:

Raoul O. Hagen

PREMEDICAL EDUCATION: B.A., University of Iowa, 1955

MEDICAL EDUCATION:

School:	M.D., Univ. of Iowa Medical School, 13 June 1958
Internship:	Rotating, St. Benedict's Hospital, Odgen, Utah 1 July 1958 - 30 June 1959
Residency:	Radiology, Tripler Army Hospital, 1963-1965 Radiology, Walter Peed General Hospital, 1965-1966

MILITARY ASSIGNMENTS:

Clinical Clerk, Letterman General Hospital, July-September 1957.

Army Senior Medical Student Program, Iowa City, Iowa, September 1957-June 1958

General Medical Officer, Prison doctor, Dermatologist, and Flight Surgeon, Fort Leavenworth, Kansas, 1959-1963

Radiologist and Chief, Radiation Therapy Service, Department of Radiology Brooke General Hospital, 1967-1968

- Chief of Radiology, 93rd Evacuation Hospital, Vietnam September 1968 - September 1969
- Chief, Professional Services, 93rd Evaluation Hospital, Vietnam 1 March - 1 September 1969
- Consultant in Radiology, USARV June-August 1969.
- Radiologist, Brooke General Hospital September 1969 - July 1970
- Chief, Department of Radiology, Brooke Army Medical Center July 1970 - June 1979
- Radiology Consultant to Health Services Command 1975 - June 1979
- Radiology Consultant to The Surgeon General January 1978 - July 1982
- Chief, Department of Radiology, Tripler Army Medical Center July 1979 - August 1984

NEC 20 1988

Curriculum Vitae (con't) Raoul O. Hagen, M.D.

> Chief, Department of Radiology, Walter Reed Army Medical Center September 1984 - July 1987

Radiology Consultant to The Surgeon General September 1984 - present

Chief, Department of Radiology, Letterman Army Med Ctr - May 88-present ACADEMIC APPOINTMENTS:

Clinical Instructor, University of Texas Health Science Center, San Antonio 1967

Clinical Assistant Professor, University of Texas Health Science Center, San Antonio, 1968-1970

Clinical Associate Professor, University of Texas Health Science Center, San Antonio, 1970-1974

Clinical Professor, University of Terms Mealth Science Center, San Antonio 1 September 1974 - June 1978

Associate Clinical Professor, University of Hawaii, John A. Burns School of Medicine, Honolulu, HI, 1982 - 1984

PROFESSIONAL ORGANIZATIONS:

American College of Radiology Radiological Society of North America Long Binh Radiological Society

BOARD CERTIFICATION:

American Board of Radiology, December 1967

HONORS:

Prefix "A" in Radiology Who's Who in Texas Who's Who in the South and Southwest Recipient, Magna Cum Laude Award, Radiological Society of North America, 1971, for scientific exhibit Elected a Fellow, American College of Radiology, 1981

LICENSURE:

Texas California Iowa Curriculum Vitae (con't) Raoul O. Hagen, M.D.

a comment of an and a state of the

*

---- - **

PUBLICATIONS:

Gastric bezoars: A frequent complication in the postoperative ulcer patient. Radiology, 197:341-344, May 1973.

Carcinoma of the testis: An analysis of 104 patients with germinal tumors of the testis other than seminoma. Cancer, 31:633-640, March 1973.

Scientific exhibit on "Multisystem radiographic analysis of complications in thermally burned patients", Radiological Society of North America, 1971.

The American Board of Kadiology

: tt*

,4

and .

DEAR DOCTOR:

I am pleased to inform you that at its last meeting The American Board of Radiology voted to granf, you its certificate in RADIOLOGY.

With personal congratulations, I am

....

Sincerely yours, 0

Secretary

Raoul O. Hagen, M.D. Department of Radiology Brooke General Hospital Ft. Sam Houston, Texas 78234

- 51'-54

DEC 2 0 1983

,

September 1986

NAME: STOTLER, RICHARD ELMO

CITIZENSHIP: U.S.A.

PROFESSIONAL LICENSE: PHARMACIST - District of Columbia, Number 1999-C, July 1965

BOARD CERTIFICATION: Board Certified Nuclear Pharmacist, Nuclear Pharmacy Certification Exam, Board of Pharmaceutical Specialities, American Pharmaceutical Association. April 1982.

ACADEMIC AND PROFESSIONAL EDUCATION:

DEGREES:

INSTITUTION		DEGREE		GRAI	KOITAUG
The Upiversity of Ann Arbor, Michiga		M.S. Hospi Pharmacy	tal	Augu	st 1975
The Medical Colleg Richmond, Virginia		B.S. Pharm	nacy	June	1965
The George Washing Washington, D.C.	ton University	A.A.		June	1964
OTHER:					
June 1986	Society of Nuclear Washington, D.C.	Medicine,	33rd	Annual	Meeting,
June 1985	Society of Nuclear Houston, TX.	Medicine,	32nd	Annual	Meeting
June 1984	Society of Nuclear Los Angeles, CA.	Medicine,	31st	Annual	Meeting,

DEC 20 1988

OTHER:

Society of Nuclear Medicine, 30th Annual Meeting, June 1983 St. Louis, MO. Society of Nuclear Medicine, 29th Annual Meeting, June 1982 Miami Beach. FL. Army Pharmaceutical Services Management Course, Academy of May 1982 Health Sciences, U.S. Army, Ft. Sam Houston, TX. Army Pharmaceutical Management Course, Walter Reed Army August 1980 Medical Center, Washington, D.C. Mid-Year Clinical Meeting, ASHP;, San Antonio, TX. December 1978 ADP Orientation, U.S. Civil Service Commission, Honolulu, HA. September 1977 Residency Preceptors Conference, ASHP, Bethesda, MD. August 1977 Postgraduate Short Course, Nuclear Pharmacy Orientation, April 1976 Letterman Army Medical Center, Presidio of S.F., CA. March 1976 Institute on Hospital Pharmacy Management Technique, ASHP, San Francisco, CA. Organization Excellence Through Effective Communication, April 1970 A Seminar for Executives. Augsburg, Germany. Institute on General Practice of Hospital Pharmacy, ASHP, July 1969 New Haven, CT. Army Pharmaceutical Service Management Course, WRAIR, May 1969 Washington, D.C. Institute on the Law of Drugs and Hospital Pharmacy Practice, September 1967 ASHP, Miami, FL. Army Pharmaceutical Service Management Course, WRAIR, May 1967 Washington, D.C. AMEDD Pharmacy Officers Orientation Course, Brooke General November 1966 Hospital, BAMC, Ft. Sam Houston, TX. Adjunct Professor in the University of the Pacific School of ACADEMIC APPOINTMENT: Pharmacy, Clinical Pharmacy Clerkship Program, December 1976. American Society of Hospital Pharmacists PROFESSIONAL SOCIETIES: American Pharmaceutical Association Society of Nuclear Medicine Technology Section, Society of Nuclear Medicine

NEC 20 1988

MILITARY SERVICE:

LTC, United States	Army, Medical Service Corps, active duty Sept 1966 to present.	
December 1982	U.S. Army Command and General Staff College graduate.	
February 1982	Received Regular Army Commission, Medical Service Corps.	
November 1980	Promoted to LTC, U.S. Army, Medical Service Corps.	
June 1974	AMEDD Officer Advanced Course graduate.	
November 1966	AMEDD Officer Basic Course graduate.	

LECTURES:

"Radiopharmaceutical Quality Assurance," Nuclear Medicine Review Course conducted at the 33rd Annual Meeting of the Society of Nuclear Medicine, Washington, D.C. June 86.

"Functions of A Radiopharmacist in Nuclear Medicine" and "Misadministrations", Nuclear Medicine Course, National Naval Medical Center, Bethesda, MD.

PUBLICATIONS:

Van Nostrand, Douglas; Corley, James H.; Kyle, Ralph W.; and Stotler, Richard E., "Value of Selective Spleen Scintigraphy When Liver/Spleen Image Shows Equivocal Spleen Defects: Concise Communication." <u>The Journal of Nuclear Medicine</u> (vol.24, No7) pp.559-562, 1983.

Lucket, Larry W. and Stotler, Richard E. "Radioiodine Volatization from Reformulated Sodium Iodine I-131 Oral Solution." <u>The Journal of Nuclear Medicine</u> (Vol. 21) pp.477-479, 1980.

CURRENT RESEARCH PARTICIPATION:

Intravenous Administration of 131 I-6-B Iodomethylnorcholestrol (NP-59) for Adrenal Evaluation and Imaging.

Evaluation of Indium Oxine In-111 Labeled Cellular Blood Components in Detection of Inflammation.

PROFESSIONAL EXPERIENCE:

1985 - Present

Assigned as Chief, Nuclear Pharmacy Service and Director, Nuclear Pharmacy Residency Program, Letterman Army Medical Center, Presidio of S.F. CA.

1980 - 1985	Ch, Nuclear Pharmacy, Nuclear Medicine Service, Dept of Radiology, Walter Reed Army Medical Center, Washington, D.C. Responsible for the direction of the largest and busiest Nuclear Pharmacy Service in the Army. This service prepared over 10,000 radiopharmaceutical doses per year. This assignment involved participation in and support of clinical research involving diagnostic radiopharmaceuticals. In addi- tion to these duties, there was active involvement in the education and training of nuclear medicine "fellows", radiol- ogy residents, hospital pharmacy residents, and nuclear medicine technology students.
1976 - 1980	Nuclear Pharmacist and Assistant Chief, Pharmacy Service, Tripler Army Medical Center, Honolulu, HA. Was responsible for establishment of Nuclear Pharmacy support for the Nuclear Medicine Service at Tripler. Duties included the procurement, receipt;, preparation (to include the compounding of radio- labeling kits), quality control, dispensing, disposition and and pharmacology of radioactive drugs. Assisted in the train- ing of nuclear medicine technologists and radiology residents. Provided the medical staff with information as to dose, avail- ability and pharmacology of related therapeutic agents avail- able from the Pharmacy Service. Assisted in the management of the Medical Center Pharmacy Service with a staff of 45 and budgetary expenditures of over two million dollars.
1975 - 1976	Completed an American Society of Hospital Pharmacist's approved Hospital Pharmacy Residency at Letterman Army Medical Center, San Francisco, CA. This residency included rotations through all phases of the Pharmacy Service with added emphasis in the Nuclear Pharmacy operations. Nuclear Pharmacy training was taken under LTC George Dunson, MSC, and included completing and instructing in the AMEDD Nuclear Pharmacy Orientation Course. Upon departure, received competency certificate in the practice of Nuclear Pharmacy, and a Hospital Pharmacy residency certificate with specialization in Nuclear Pharmacy.
1974 - 1975	Completed requirements for a Master's Degree in Hospital Pharmacy from the University of Michigan. Completed courses in Nuclear Pharmacy and Advanced Nuclear Pharmacy.
1974 - 1975	Attended and graduated as an Honor Graduate from the AMEDD Officers Advanced Course.
	a to the time Versite? Averburg

1969 - 1973 Chief, Pharmacy Service, U.S. Army Hospital, Augsburg, Cormany. Supervised all pharmacy services for a 150 bed hospital and six health clinics. Additional responsibility for one year as AMEDD Detachment Commander for 150 enlisted personnel.

ş

1966 - 1969 Staff pharmacist and Chief, Pharmacy Service, DeWitt Army Hospital, Ft. Belvoir, VA. Directed inpatient and outpatient pharmacy operations for a 200 bed hospital.

NEC 20 1988

1965 - 1966

.....

5

Completed Pharmacy Internship requirements at The George Washington University Hospital. Passed the District of Columbia Board of Pharmacy examination and received license as a registered pharmacist. Worked as staff pharmacist at The George Washington University HOspital until entry on active duty. AMEDD Officers Basic Course completed November 1966.

and of Pharm. Putical Sherial

Certification in Nuclear Marmary

The Board of Pharmaceutical Specialities attests that

Richard Elmo Stotler

by the Specialty Council on Nuclear Pharmacy, is CER TIFIED having fulfilled all requirements, and having been recommended

in the specialty of Nuclear Pharmacy.

Chairman Manuen 7

American Pharmaceutical Association


n. ... August 25, 1982

Secretary Di March 1988

B 134 LETTERMAN ARMY MEDICAL CENTER, PRESIDIO OF SAN FRANCISCO, CALIFORNIA Jepartm. GENERAL. Start Press 30 AUGUST 1976 has successfully completed the SPECIALIZATION IN NUCLEAR PHARMACY BRIGADTER This is to certify that MAJOR RICHARD E. STOTLER, MSC HOSPITAL PHARMACY RESIDENCY WITH Medical GEORGH 1976 10 day of AUGUST SCPTEMBER 1975 N. ---given at Wis 30TH from DEC 2 0 1988

GEORGE L. DUNSON COURSE DIRECTOR (0 2 goot MAJOR, MSC 日本のないない DEPARTMENT OF THE ARMY HU. F. CPO:1974-0-663-413/1009 has successfully completed THE POSTGRADUATE SHORT COURSE his is to certify that NUCLEAR PHARMACY ORIENTATION MAJOR RICHARD E. STOTLER PRESIDIO OF SAN FRANCISCO, CALIFORNIA 12 - 23 APRIL 1976 California Pharmaceutical Association Continuing Education Siven at LETTERMAN ARMY MEDICAL CENTER DA FORM 87, 1 JUL 74 REPLACES DA FORM 87, 1 8EP 54, WHICH IS OBSOLETE. Accredited 15 Hours, Accepted 65 Hours 2 DEC

0 1998



DEC 2 0 1988

the Regents of the University of Michigan have conferred on Hereby it is cortified that upon the recommendation of the portaining tothis degree Aural day of August, 1975. in recognition of the satisfactory fulfilment of the requirements Rh. Flowing .. Morace 7. Ruckham School of Orabuate Studies Ou all who may read these letters Greetings Master of Science in Mharmacy Kichard Telmo Stotler Red. Kennely therdegreeint

NRC FORM 313M SUPPLEMENT A (9-81) AUTHORI	TF	RAINING ANI ER OR RADI				ATORY COMMISSION	
1. NAME OF AUTHORIZED USER OR RADIATIO STOTLER, Richard E.		N SAFETY OFFICER			2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE		
		3. CERTIFICATION			N/A .		
SPECIALTY BOARD	CATEGORY B			MONTH AND YEAR CERTIFIED			
Nuclear Pharmacy Board o Pharmaceutical Specialit American Pharmaceutical Association		Augus			t 1982		
4. TRAINING	RECEIV	ED IN BASIC F	ADIOISOTOP	E HANDLING T	ECHNIQUES		
			dana kalang panakang sarahan na sarahan dan dan	n de mante e paparate e con englis presedente en anno e an	TYPE AND L	ENGTH OF TRAINING	
FIELD OF TRAINING	LOCATION AND DATE (S) OF TRAINING B		LECTURE LABORATO COURSE (Hours)	RY LABORATORY S EXPERIENCE			
a. RADIATION PHYSICS AND INSTRUMENTATION		Univ. of 1		3 Apr 76) Sep 74-Sep ency (Sep 7 Aug 76	5-	120	
b. RADIATION PROTECTION			н	24 30	120		
c. MATHEMATICS PERTAINING THE USE AND MEASUREMEN OF RADIOACTIVITY			31	7 20	80		
d. RADIATION BIOLOGY		**	**	11 60	240		
e. RADIOPHARMACEUTICAL CHEMISTRY	11	11	"	16 60	240		
5. EXPERIENCE	uivalent Expe	rience)					
ISOTOPE MAXIMUM AMOUNT	WHER	E EXPERIENCE WAS GAINED DURATION OF		EXPERIENCE	TYPE OF USE		
		terman Army Medical 5 mont enter, PSF, CA		5 months		Radiopharmacy Resident	
Full Range of Medical Radioisotopes			ler AMC, Honolulu, HI Oct 76-		1 80	Nuclear Pharmac	
		r Reed AMC, Aug 80 - hington, D.C.		Aug 80 -	Jul 85	Nuclear Pharmac	
RC FORM 313M Supplement A -81)			Page 5	L		C 2 0 1988	

STOTLER, RICHARD E.			District Register	of Columbia		
LTC/05 URAMC	Nuclear Medicine	Bldg #2 Room 1G20		AUTHORIZATION		
	3. CERTIFICATIO	N		ng kanang mang kanang kanan		
SPECIALTY BOARD	CATEGO	and the second state of the se	MONTH AND	YEAR CERTIFIE		
NUCLEAR PHARMACY BOARD OF PHARMACEUTICAL SPECIALITIES AMERICAN PHARMACEUTICAL ASSO	c.		AUGUS	c T 1982		
. FORMAL EDUCATION HIGHEST	ACADEMIC DEGREE ATTAINE	0				
Higher Educational Institutions Attended	Type of Program Pure Dotos of Attendan	ed and ca	Dugree, Diplome e Received one			
	Pharmacy		A.A. Jun 64	1		
Medical College of Va.	Pharmacy	ADD VALUE AND ADD ADD ADD ADD ADD ADD ADD ADD ADD	B.S. Jun 65			
Univ. of Michigan	Hospital Pharmac	y 1	M.S. June 75			
	All the particul subjects an except subdivision of the second set of the base top and	•				
FIELD OF TRAINING	LOCATION AND DATE(S) (Include course title B	if known)	TYPE AND LEN LECTURE/ LABORATORY COURSES (Howe) C	CTH OF TRAININ SUPERVISED LABORATORY EXPERIENCE (Houre) D		
RADIATION PHYSICS AND INSTRUMENTATION 2.	Nuc.Pharmacy Orient 80 hrs total 12-23 Hospital Pharmacy R Specialization in 800 hrs in Nuclear	lesidency with	+14	+6		
	Nuclear Pharmacy 4 S Advanced Nuclear Pha (University of Mic	Semaster hrs armacy 4 Seme	+7 ster hrs	75		
 MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY 	"		+7	•		
& RADIATION BIOLOGY			+11			
• RADIOPHARMACEUTICAL CHEMISTRY			+20	+15		
MC FORM 1643 (PREVIOUS EDITIONS AR	E OBSOLETE)		A DEC	(OVER) 2 0 1988		

1'

ISOTOPE MAXIMUM AMOUNT		WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	ENCE TYPE OF USE		
99Mo 8 Ci 99mTc 5 Ci 1311 300 mCi 1231 1 mCi		Nuclear Medicine Service Letterman AMC S.F. Ca.	800 hrs (5months)	Pharmacy Resident		
67Ga 201T1	100 uCi 100 mCi 15 mCi	- 25-844 - 25-10				
59Fe 57Co 58Co	1 mCi 10 uCi 16 uCi	Nuclear Medicine Service Tripler AMC Honolulu, HI.	Oct 76 - July 80	Nuclear		
111In 33Xe 32P 51Cr	5 mCi. 200 mCi 20 mCi 2 mCi					
.69Yb	2 mCi					
	**	Nuclear Medicine Service Walter Reed AMC Washington, D.C.	Aug 80 - present	Nuclear Pharmacist		
				· 1,4"		
				1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1		
	7. EXPE	RIENCE WITH RADIATION PRODUCING DEV				
	7. EXPE	RIENCE WITH RADIATION PRODUCING DEV WHERE EXPERIENCE WAS GAINED		TYPE OF USE		
			ICES (X-ray, Irradiasora, etc.)			
			ICES (X-ray, Irradiasora, etc.)			
n/A	DEVICE		ICES (X-ray, Irradiasora, etc.)			
n/A	DEVICE		ICES (X-ray, Irradiasora, etc.)			
n/A	DEVICE	WHERE EXPERIENCE WAS GAINED	ICES (X-ray, Irradiatora, etc.) DURATION OF EXPERIENCE	TYPE OF USE		
N/A	DEVICE	WHERE EXPERIENCE WAS GAINED	UCES (X-ray, Irradiators, etc.) DURATION OF EXPERIENCE			

8. CERTIFICATION:

I cartify that the information provided hereen is true and complete to the best of my knowledge.

29 Jan 1982 (Date Signed)

· · .

historie ? Lotte

(Signature of Applicant)

PAGE 2, WRAME FORM 1848 (PREVIOUS EDITIONS ARE OBSOLETE)

DEC 2 0 1988

For use of this form,	mans A.R. AO-400; the	proposition and proposition	is the Office of	The Surpeon General.

THIS FORM IS AFFECTED BY THE PRIVACY ACT OF 1974

1. AUTHORITY: Title 5 U.S.C., Section 301; Title 44 U.B.C., Section 3101; and Title 10 U.S.C., Section 1071.

2. PRINCIPAL PURPOSES(S): To define the extent and limits of the practioners clinical privileges as a function of his/her

training and experience. 3. ROUTINE USES: Determine and amoun capability of practioner's clinical practice.

C.

4. MANDATORY OR VOLUNTARY DISCLOSURE: Disclosure of the information is voluntary. Failure to provide information may result in the limitation or termination of your clinical privileges.

the state of the state of the

		IDENTIFICATION	1		1				
AME (Lost	first, middlel			SSN	-t.				
STO	TLER, RICHARD ELM	DATE OF ASSIGNMENT (Doy, MON	1						
RADE	ASSIGNMENT LOCATION								
LTC	MSC	17 August 1980		Nuclea	ar Me	dici	ne S	ervic	e
Ber in for	Contraction of the second s	PROFESSIONAL EDUCA	TION						
tern and an address of the state of a state of the state	PROFESSION	ALSCHOOL	YEARS A	TTENDED		EOF	And the second	SAEE CO	
	NAME	LOCATION	FROM	TO	DEG	REE	DAY	MONTH	
Corres 1	Wash. University	Washington, D.C.	1960	1964	Α.	A.		Jun	64
	College of Va.	Richmond, Va	1964	1965	Β.	S.	6	Jun	65
	ity of Michigan	Ann Arbor, Michigan	1974	1975	M.	S.	23	Aug	75
mivers	ity of memigan	Ann Arbory montepole	u ad us Taxing having		1				1
dout printeriory - you can be	an an tradition of the descent of the first of the second and the provided of the second of the second of the s	POSTGRADUATE TRAIL	NING	ak an margaret				August and a second	
	HOSPITAL OR	INSTITUTION	TYPEPP	OGRAM		TION	D	ATE COM	PLD
	NAME	LOCATION	tresident	ry, elc.)	DUMA	ITION .	DAY	MONTH	AJY
mahan	of Health Sc.	Ft Sam Houston Tx	off. A	dv Crs		mos.		Jun	74
Letterm		P. S.F. Ca	Reside		Service management of service service	non-second splitting states and	6 31	Aug	178
Letterm	Disad development and designed and provide and disaded and a second		o Pharm	Orien	ŧ 2	Wks		Apr	76
	1		1						
	an alter bes descent transf. Barry on whet desters participation provides and the second of provide			Provent and a second	1				
CALANDORE CONTRACT OF A PROFESSION		PREVIOUS HOSPITAL ASSIG	INMENTS .	a new construction of the process of the second	1	the de not an el abrene e			
nondranazi, rasmananana			CLINICAL		IN	CLUSIN	EDA	TES	
	AME OF HOSPITAL	LOCATION	SERVICE	/	FROM			TO	
			ASGD	DAYA	AONTH YEAR		DAY MONTH		YEA
	Army Hospital	Ft Belvior, Va	Pharm		Nov	66		Sep	1 65
		Augsburg, Germany	Pharm		Sep	69		Sep	73
the contrast production of the local products of the product of the local product of the loca	eld Hospital	and a state of the original state of the sta	Pharm		Oct	73		Jan	74
Brooke .	The second s	Ft Sam Houston, Tx	Pharm		Sep	75	alater poter at	Sep	76
Letterm	And the second	P. S.F. Ca Honolulu, Hawaii	Nuc Me	al	Oct	76		Jul	80
Tripler		Washington, D.c.	Nuc Me		Aug	80		prese	
walter	Reed AMC	CERTIFICATION/PROFESSIONAL SOC			- Carton	harrow the trent of	teratory and arrange and	hallan subservation (200	
1	and the second	BOARD EXAMINATION TAKEN		and and a state of the state of the state of	and departmental for it record		Contraction of the local	- and i distance : An	allallocation included
BOARDELI	GIBLE FROM (Date)	DATE 5 Aug 1965	2 TO	TAL I	D PAR	TIAL			
	Give name of Board(a) KC	gistered Pharmacist by ((ES) (Spec(fy)) cine; American Society (CLINICAL PRIVILEGES APP)	of Hosp.	nan unahantik punjament		An and Andreas	an departer of other lines	and the substance	Le problem der cante
	en en el la farrar una sector fait sector fait este a consigne a service a service a de atomican array ann		. · · ·	Carlos and the second second second		,			1
NUCLE	AR PHARMACIST .		· ·			• •			
	E DE APPLICANES -	1				DATE 27	Marc	ch 198	
SIGNATUR	Vargent De tout	1				6-1	T Time in a		
SIGNATUR	istaria Cont	L.	-	-					enales, second

DEC 2 0 1988

1. 4

For use of this f	1	1		1.	1	1			P TRANSPORT	AMANCE		
SPRIVILESES (Lui Bolow)	PERFORMS (Primiters)	ASSISTS (Privilege)	RESTRICTIONS	RESTRICTIONS Exclusions (See Remarks)	REQUIRES OUAL. SUPRY	DESIGNATED AC QUAL. SUPPUL	ACCEPTABLE	ONDERLINE	MACCEPTABLE	DISCIPLIMARY ACTION TAKEN	PRIVILEDE SELOOM EXERCISED	REOUINES
Practice of Nuclear Pharm acy to include procurement receipt, preparation (to include compounding of radiolabeled kits), dispen	'×		x			1	X			0.4		
Hisposition and pharmacol- ogy of radioactive drugs.						-t					*	
Preparation and adminis- tration of radiopharmaceu- ticals for oral administra-	_	-	X	*****	× * * * * *	****	XXXXXX	loge	Re	D.	in .	50
123 I Sodium Iodide, 223 I Sodium Iodide, & 57Co & 58Co Vit B-12. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx								5	1	- 1 - 1 		
Preparation and direct assistance to a physician in the administration of		X	CXXXXX	XXXXX		××××	X	Kalacaca	*****		2014) 05 26 26	6 OD 766 OD
32P Sodium Phosphate Inj. I.V.) and 32 P Chromic hosphate Susp (I.P.)	XXXX	****										
							XXXXX		×××××	******		1 25 26 26 20 2004
						- 1						
				-								-
									1.			I
NAME								1		1		
RICHARD ELMO STOTLER LTO SPECIALTY NUCLEAR PHARMACY	C, MS	с		100U	.E		LOTR.	Participan Adres	M. Bou	Her H	શે	
PERIOD MARCH 1981 TO A	UGUST	1984		MED	ICAL TI	REATM	ENT FA	CILITY	AL CE	ensette un existente tet traduero		

Firme 9-1. DA Form 1692-R

DEC 2 0 1988

1

Ind /

AL PRIVILEURS RENEWSO D MODIFIED (Speetly) I HAVE OBSERVED THIS PRACTITIONER ON A REGULAR BASIS AND HE DOES DOES NOT APPEAR TO BE MENTALLY AND PHYSICALLY COMPETENT. 5' REVIEWED BY DEPTAYE DATE DATE DEPT OF RAD TOLOGY A SEP % SIGNATURE Jack SICH Trank 0000 SHERRY DE BRAHMAN 601 MC APPROVED HOSPITANCOMMANPE DATE demi SEP 21 1000 REMARKS CHE CREDIT: NO OF . DATES OF COURSE COURSE TITLE CME HOURS ; (You may attach an additional page if necessary for CME information.) LAST CPR CERTIFICATION HONTE SEPT YEAR 1983 MY LAST PHYSICAL FIAM WAS PERPORMED IN THE MONTH OF APRIL YEAR 1983 I AM LICENSED IN THE STATE(S) OF (1) D.C. , (2) ,(3) Pharmacy License EDUCATION/TRAINING UPDATE BOARD ELIGIBLE FROM (Dele) BOARD EXAMINATION TAKEN DATE C TOTAL CI PARTIAL BOARD CERTIFIED BOARD OF PHARMACEUTICAL SPECIALITIES ICXYES (Une name of Board (+)) D NO AMERICAN PHARMACEUTICAL ASSOCIATION CERTIFICATION IN NUCLEAR PHARMACY 25 AUG 1982 RECERTIFICATION (BOOMS and Date) UTILIZED IN PRIMARY SPECIALTY YEARS AND DATES OF SPECIALTY TRAINING (Specify only training since initial application) Yox YES CH NO MEMBERSHIP IN SPECIALTY SOCIETY(IES) (Specify) -SOCIETY OF NUCLEAR MEDICINE TOTAL HOURS OF CONTINUING EDU- TOTAL HOURS OF SUSSPECIALTY BOARD THIS PERIOD (Specify) DEC 2 0 1988 the second states and the second second · Internet a V. L. P. Fatelling P. A PROFESSION AND ADDRESS OF A

ENTRY DESTRICT OF COLUMBIA Audit 150941 OFLA-12C NOVEN 1 DEPARTMENT OF CONSUMER AND REGULATORY AFFAIRS OCCUPATIONAL AND PROFESSIONAL LICENSING ADMINISTRATION BOARD OF PHARMACY 5. This is to certify that ELB. Not velid unless stemped By the D.C. Tressurer LICENSE -PHARMACIST STOTLER RICHARD 2278 CENTER ROAD 1 NOVATO, CAL 94947 CO Ser. LICENSE# 1999 1.21 is duly licensed in the District of Columbia 03/01/87 for the period 02/28/89Ranawai No. Parial ?. mura Acting Director, Department of D Consumer and Regulatory Affairs 87-P9526

5

;

CURRICULUM VITAE

NAME: CARL E. BERGSAGEL, MAJ, MSC

ADDRESS: Work: Letterman Army Medical Center ATTN: HSHH-PM-HP Presidio of San Francisco, CA 94129-6700

TELEPHONE: Work: (415) 561-2794 AUTOVON 586-2794

EDUCATION:

University of North Carolina at Chapel Hill, N.C., Master of Science in Public Health (MSPH) with major in Radiological Hygiene, 1985.

East Tennessee State University, Johnson City, TN, Bachelor of Science in Environmental Health (BSEH) (Cum Laude), 1975.

PROFESSIONAL/MILITARY EXPERIENCE:

September 1988-present	Assigned to Letterman Army Medical Center, Presidio of San Francisco, California, as Chief, Health Physics Section, Preventive Medicine Service.
June 1985-August 1988	Assigned to US Army 10th Medical Laboratory, Landstuhl, West Germany, as Health Physicist in Radiological Hygiene Branch.
January 1982-May 1985	Assigned to William Beaumont Army Medical Center, El Paso, Texas, as Chief, Health Physics Section, Preventive Medicine Service. Radiation Protection Officer for USNRC Broad Scope Medical License No. 42-05255-07 and USNRC Radiation Teletherapy License No. 42-05255-08.

CURRICULUM VITAE (continued)

CARL E. BERGSAGEL

July 1980-December 1981 Assigned to US Army Medical Department Student Detachment, AHS, Fort Sam Houston, Texas, with duty at The University of North Carolina at Chapel Hill, Chapel Hill, N.C. for graduate study in Radiological Hygiene.

January 1980-June 1980 Assigned to the Academy of Health Sciences, Fort Sam Houston, Texas. Completed the US Army Medical Department Officer Advanced Course.

November 1975-December 1979 Assigned to the US Army Medical Department Activity, Fort Stewart, Georgia, as Chief, Environmental Health Section, Preventive Medicine Service.

OTHER TRAINING/SHORT COURSES:

July 1987	Nuclear Hazards Training Course, Interservice Nuclear Weapons School, Kirtland Air Force Base, New Mexico (1 week).
October 1985	Medical Effects of Nuclear Weapons Course, Armed Forces Radiobiology Research Institute, and Medical Management of Chemical Casualties Course, US Army Medical Research Institute of Chemical Defense, Mannheim, West Germany (1 week).
April 1985	Radioactive Waste Packaging, Transportation and Disposal Course, Chem-Nuclear Systems, Inc., Columbia, South Carolina (1 week).
April 1984	Laser-Microwave Hazards Workshop, US Army Environmental Hygiene Agency, Aberdeen Proving Ground, Maryland (1 week).
January 1984 .	Health Physics in Radiation Accidents Course, REAC/TS, Oak Ridge Associated Universities, Oak Ridge, Tennessee

CURRICULUM VITAE (continued)

CARL E. BERGSAGEL

- May 1982 Medical X-ray Survey Techniques Course, Academy of Health Sciences, Fort Sam Houston, Texas (2 weeks). April 1982 Radiation Protection Officer
 - Workshop, US Army Environmental Hygiene Agency, Aberdeen Proving Ground, Maryland (1 week).
- February 1979 Health Aspects of Design Review Course, Academy of Health Sciences, Fort Sam Houston, Texas (2 weeks).
- January 1978 Community and Environmental Health Program Management Course (6A-F6), Academy of Health Sciences, Fort Sam Houston, Texas (2 weeks).
- January 1977 Environmental Pollution Control Course, Academy of Health Sciences, Fort Sam Houston, Texas (2 weeks).
- December 1976 Industria' Hygiene Workshop, US Army Environmental Hygiene Agency, Aberdeen Proving Ground, Maryland (2 weeks).

May 1976 US Army Medical Service Corps Officer Basic Course, Academy of Health Sciences, Fort Sam Houston, Texas (4 weeks).

September-November 1975 Community Health and Environmental Science Course (6A-F5), Academy of Health Sciences, Fort Sam Houston, Texas (9 weeks).

PROFESSIONAL AFFILIATION:

American Association of Physicists in Medicine

Health Physics Society

*

The University of Narth Earning having completed the studies and fulfilled the requirements of the Asculty for has accordingly been admitted to that degree, with all the rights, honors, Amitthe K. Cathen, mi The Aujuersity of North Caroline at Chapel Ril Given at Chapel Aill, in the State of North Carolina, this twelfth day of May in the year of Our Pord nineteen hundred and eighty-five In witness whereof, the Seal of the University and the signatures of duly authorized officers are affixed to this diploma. light of Trusters WW Brown of the Crobuste School Blue Murine Stitt of Marth M and of this University the one hundred and ninety-sixth. Master of Science in Jublic Health and privileges thereunio appertaining. lie Professional Graduate Degree of To all to whom these presents shall come Carl Edmin Bergwarel nt Warrel will De it known that Greeting Hild of Care its of North Marolina Work for hand

DEC 2 0 1988

Michael O. Ma Nin

and Community College System of Tennessee when the recommendation 1. L Uner with all the rights, privileges and honors therewate appertaining. The Aate Board of Regents has issued this diploma on the Ray Blander day of August in the y ar of our Lord nineteen hundred seventy-fice. Marchelor of Science in Annironmental Acalth Carl Advin Nerysayel (And of the Faculty has conferred on Johnson City, Tennessee the degree of By & Michen Clarman, Alate Revert of Spright

LEC 2 0 1898

NRC FORM (9-81)	A 313M SUPPLEN		T	RAINING AND EXPERIN	ENCE		LATO	Approved by O 3150-0041 Expires 9-30-86	
1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER Carl E. Bergsagel, MAJ, MS							2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE		
				3. CERTIFICATION					
	SPECIALTY BOA	RD		CATEGOR	Y	MONTH A	ND YE	AR CERTIFIED	
	4. TR	AINING	RECEIV	ED IN BASIC RADIOISOTO	PE HANDLING T	ECHNIQUES	;		
						TYPE AND	LENGT	TH OF TRAINING	
FIELD OF TRAINING				LOCATION AND DATE (SI OF TRAINING	LECTURE/ LABORATORY COURSES (Hours)		SUPERVISED LABORATORY EXPERIENCE (Hours) D	
 RADIATION PHYSICS AND INSTRUMENTATION 				University of North at Chapel Hill, NC August 1980-Decembe	45 hrs.		45 hrs.		
b. RADIATION PROTECTION				University of North at Chapel Hill, NC January 1981-Decemb	90 hr	s.			
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY				University of North at Chapel Hill, NC August 1980-Decembe	45 hr	в.			
d. RADIATION BIOLOGY				University of North at Chapel Hill, NC January 1981-May 19	45 hr	Б.			
e. RADIOPHARMACEUTICAL CHEMISTRY				University of North at Chapel Hill, NC September 1981-Nove	5 hr	5.			
	5. EXPER	IENCE	WITH RA	ADIATION. (Actual use of Ra	dioisotopes or Eq	uivalent Expe	rience,)	
ISOTOPE	MAXIMUM AMO	UNT	WHERE	EXPERIENCE WAS GAINED	DURATION OF	EXPERIENCE	T	YPE OF USE	
Co-60	8,000 Ci	(1)		C, El Paso, TX	3 years		Cal	ibration	
Cs-137				C, El Paso, TX	3 years			s. & Calib.	
1-125				C, El Paso, TX	3 years			surement	
I-131 Ir-192	150 mC1 50 mCi	(2) (1)		C, El Paso, TX C, El Paso, TX	3 years			surement surement	
Tc-99m		(2)		C, El Paso, IX	3 years 3 years			surement s. & Calib.	
Not	e: (1) = Se		Source						
	(2) = Un	seale	d (lig	sid) Source					

0

(9-81)

(

ŗ

19 May 1988

11

ŧ

DATE: 24 Jun 88

LAMC Reg 40-34

FOR OFFICE	USE ONLY	
Review: 21		ht
RCC Approva		

0

SUMMARY OF RADIOLOGICAL QUALIFICATIONS

Dept: Health Physics		*		
Phone: 561-2794/3994	terre aller and a product of a state			
Formal Radiological S Course Title	Safety Tra Date	aining Location	Duration	Subjects Covered
Hea th Physics Training Health Physic Training Nuclear Hazards Training MMED Officer Basic Physics in Mil. Med Hed Effects of Nuc Weapons ad Packaging Course Physics in Mil Med Radiological Instrume	Jun84-Sep8 Sep84-Apr8 Nov 85 Seb-May86 Oct 86 May 87 Xe aug 87 Set 87 ent Experi	84 Ft. Sam Hou 85 Ft. Gordon Kirkland AFB Ft. Sam Hous AEHA Frox Tng Cente Leesburg, VA AEHA	ston 4 mo 7 mo 1 wk ton 1wk 1 wk	Subjects Covered All aspects of Radiation Prot All aspects of Rad Protec Emergency response Instruments/Plume Calculation Rad Protec issues Bio effects Packaging/trans/disposal Rad Protec issues
Instrument Type	Radion	uclides Measu	ired	and a second of a second s
Area monitors GM monitors Scintillation Detecto Ion Chambers Lab counters	Numero " rs " "	us		, ,
Kadiological Safety C Course Title	ourses In Date	istructed Location	Level Aud	ience (undergrad/grad)
Muclear Pharmacy Orin Safe use and Handling Safe use and Handling Rad Safety Courses	May 88 May 87	LAMC	Pharmisci MD thru t MD thru t MD thru t	sts ech ech

Other Nuclear Material Licenses Authorized Under

Type	License	Level of Auth.	Location
Broad		Technician	Ft. Gordon, GA
Broad Broad		Alt RPO	LAMC, PSF, CA
produ	scope	RPO	LAMC, PSF, CA

CURRICULUM VITAE

NAME: Louie L. Tonry, Lieutenant, U. S. Army, Medical Service Corp.

BUSINESS ADDRESS: Letterman Army Medical Center, ATTN: HSHH-PM-HP (Health Physics), Presidio of San Francisco, CA 94129-6700. (415) 561-2794

PRESENT POSITION: Radiation Protection Officer, Letterman Army Medical Center, Presidio of San Francisco, CA 94129-6700

EDUCATION: Bachelors Degree in Chemistry/Mathematics, Boston University, Boston, MA.

MILITARY SCHOOLS:

June 84 - Sep 84 Health Physics Technologist Training Course (Didactic Phase) Ft. Sam Houston, Tx

Sep 84 - Mar 85 Health Physics Technologist Training Course (OJT Phase) Eisenhower Army Medical Center Augusta, GA

Mar 85 - Feb 86 Staff Health Physics Technician Eisenhower Army Medical Center Augusta, GA Feb 86 - May 86 AMMED Officer Basic Ft. Sam Houston, TX

May 86 - Aug 87 Alt. Rad. Protection Officer Letterman Army Medical Center Presidio of San Francisco, CA

Aug 87 - Present Radiation Protection Officer Letterman Army Medical Center Presidio of San Francisco, CA

TRAINING COURSES:

Jun Jun Jun Sep Nov Feb Oct	84444566 8888888888888888888888888888888	 Sep Sep Apr	84 84 85		Patient Administration Course Medical X-Ray Survey. Techniques Course Microwave Survey Techniques Course Health Physics Training Course (Didactic Phase) Health Physics Training Course (OJT Phase) Nuclear Hazards Training Course AMMED Officer Basic Course Physics in Military Medicine Conference
May					Medical Effects of Nuclear Medicine Course
Aug	87			-	Radioactive Waste Packaging Course
Oct	87				Physics in Military Medicine Conference
Jul	38			**	Health Physics Society Annual Conference
Oct	88		-		Physics in Military Medicine Conference

Curriculum Vitae - Louie L. Tonry

EXPERIENCE:

Date: June 1984 - Sep 84

Description of Duties: Attended the four-month Army Health Physics training course at Ft. Sam Houston, TX. This course covered all aspects of Health Physics including such topics as radiation counters and instrumentation, smear survey techniques, physics, chemistry with emphasis on radioactivity, mathematics, biological effects of radiation, X-Ray survey techniques, microwave survey techniques, environmental contamination evaluation and surveys, and procedures associated with nuclear medicine operations. It also covered such diverse subjects as industrial hygiene, ventilation evalutaions, and downwind calculations for accidental release of radioactive materials. Many hours were spent on the review and interpretations of Title 10 and Title 49, Code of Federal Regulations and associated Regulatory Guides, record and report writing, and the methodology and support of a Nuclear Regulatory license.

Date: Sep 84 - Mar 85

Description of Duties: Assigned to Eisenhower Army Medical Center on a seven month on-the-job training program. Eisenhower AMC has a broad scope NRC license and a Ph.D. medical physicist as the Radiation Protection Officer. During this training period, I worked in all aspects of Health Physics associated with the support of a broad scope license. The training was conducted by an experienced instructor who has a masters degree in physics and was review and augmented by sessions given by the RPO on regulations and the operational aspects of maintaining a broad scope license. I spent many hours with the RPO questioning, exploring, and learning the requirements of the NRC and Department of the Army radioactive material license. Upon completion of this training I was awarded a certificate for being the distinguished honor graduate for the entire course.

Date: Apr 85 - Feb 86

Description of Duties: Served as a Health Physics technician at Eisenhower Army Medical Center. Performed all duties involving health physics including smear surveys, training, fume hood surveys, fetal dose calculations, calibration of equipment, record and report maintenance and submission, and processing of radioactive waste. I was the acting Radiation Protection Officer on occasion in the absence of the chief of Health Physics. During this period of time, I was awarded a commission in the United States Army as a Nuclear Medical Science Officer and assigned to Letterman Army Medical Center.

Curriculum Vitae - Louie L. Tonry

Date: May 26 - Aug 87

Description of Duties: Assigned as a Nuclear Medicine Science Officer to the Health Physics Office at Letterman Army Medical Center. I was appointed by the Radiation Control Committee as the Alternate Radiation Protection Officer. Performed all tasks associated with the day-to-day maintenance of this broad scope license. This facility, as well as being a broad scope license holder, has a large Nuclear Medicine Service, Radiation Therapy Service, and an on-going Clinical Investigation Program. It maintains the license for Letterman Army Institute of Research, a large research facility, and supports five smaller outlying clinics. Letterman Army Medical Center has a large Department of Radiology, which has both Cat scan and angiography, and a cardiology department that performs cardiac catheterization on a daily basis. Was the acting Radiation Protection Officer on many occasions when the chief of Health Physics was unavailable. Monitored and controlled radiation safety procedures during numerous nuclear medicine and brachytherapy procedures including initial room preparation, patient body burden evaluation, release of patient, room decontamination, and therapy completion. Performed audits of radioactive use areas and coordinated with all users of radioactive materials to ensure that isotopes were used safely and that the ALARA concept was understood and being followed. Worked closely with the department chiefs and the chairman of the Radiation Control Committee to modify certain procedures to improve the overall Radiation Safety Program.

Date: Aug 87 - to Present

Description of Duties: Assigned as the Radiation Protection Officer for Letterman Army Medical Center. Performed all the duties required to ensure compliance with applicable Federal, State and local regulations. This required daily communications with radioisotope users. Was responsible, as the Chief, Health Physics Branch, with the administrative tasks associated with supervising personnel, ordering supplies and equipment, and controlling budget expenditures. Directed and supervised the staff, giving instruction and training as required. Maintained all exposures to ionizing radiation ALARA through concerted efforts by not only the Radiation Protection staff but all the users also.

PROFESSIONAL ASSOCIATIONS:

a. Health Physics Society

- b. American Association of Physicists in Medicine
- c. American Chemical Society

1

÷

ce of Completi Chem-Nuclear Systems, Inc. Manager, DoD Operations Roger W. Johnson Radioactive Waste Guidance Course for satisfactory completion of the U.S. Army - U.S. Air Force AWARDED T Chem-Nuclear Systems Day Of presented to 20 west cent Uprtit CHEM NUCLEAR SYSTEMS INC. Given This 20 DEC 1988

An R. Siller RESIDENT



regiment bas

1988

DEC 2-0

IN TESTIMONY WHEREOF THIS DIPLOMA IS CONFERRED AT BOSTON, WITH ALL THE HONORS, RIGHTS, PRIVILEGES AND OBLIGATIONS MASSACHUSETTS, THIS EIGHTEENTH DAY OF MAY, 1980 PERTAINING TO THAT DEGREE.

with a Mirnor in Mathematics

BACHELOR OF ARTS


THE DEGREE OF

Coure Landis Conry

THE TRUSTEES UPON THE RECOMMENDATION OF THE FACULTY OF THE

COLLEGE OF LIBERAL ARTS

HEREBY CONFER UPON





C.A.

CERTFORE OF TRANKING DEPARTMENT OF THE ARMY This is to certify that

SPECIALIST FOUR LOUIE L. TONRY

has successfully completed

MEDICAL X-RAY SURVEY TECHNIQUES COURSE

Given at <u>ACADEMY OF HEALTH SCIENCES</u> United States Army For Sam Houston, Texas 78234 18 September 1984

2 0 1988

JOHN M. SOWELL, M.D. COL, MC Course Director \$ U.S. 8 PO- 1923-491-546/5685

22 November 1985 punnut DATE AND IS HEREWITH AWARDED THIS HAS SUCCESSFULLY COMPLETED THE NUCLEAR HAZARDS TRAINING-COLESE (G302P9124-000) KIRTLAND AIR FORCE EASE, YEW NEXICO 87117 PDS CODE: KSX DURATION: 4 DAYS (32 HRS) Air Force CERTIFIES THAT. SGT LOUIE L. TONRY Inited states ate Interservice Muclear Meapons School JAHES A. HERCER, Lt Col, USAF 4 STATES OF CALX IN D 60 4 d b

DEC 2 0 1988

Armed Forces Radiobiology Research Institute

Defense Nuclear Agency

certificate of Completion

This is to certify that

LOUIE L. TONRY

has completed _27 hours of



4 May 1987

MEDICAL EFFECTS OF NUCLEAR WEAPONS



conducted by the Armed Forces Radiobiology Research Institute, Bethesda, Maryland.

As an organization accredited for continuing medical education, the Naval Health Sciences Education and Training Command designates this continuing medical activity as meeting the criteria for 27 credit hours in Category I of the Physician's Recognition Award of the American Medical Association. DEC 2 0 1988

FORM NRC- (8-78)	AUTHORI	TR ZED USE	AINING AND	EXPERIE		AR REGUL	ATORY COMMIS			
	AUTHORIZED USER OR I	RADIATIO	IN SAFETY OFFICER			2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE				
			3. CERTIF	ICATION		and an				
	SPECIALTY BOARD			CATEGOR	MONTH AND YEAR CERTIFIED					
N/A		N/A			A/N					
	4. TRAINING	S RECEIV	ED IN BASIC R	ADIOISOTO	PE HANDLING TE	CHNIQUES				
						TYPE AND L	ENGTH OF TRAIN			
FIELD OF TRAINING			LOCATION AND DATE (S) OF TRAINING			LECTURE LABORATO COURSE (Hours) C	S , EXPERIEN			
	ATION PHYSICS AND RUMENTATION		Eisenhower	v. 1977-1 uston Jur AMC Sep	1980 184-Sep 84 84-Feb 86	554	240			
b. RAD	IATION PROTECTION		Physics in	cer Basic Military	ourse 1985 Course 1986 Medicine 86 Weapons 1987	272	500			
THE	THEMATICS PERTAINING USE AND MEASUREMEN RADIOACTIVITY		Letterman	AMC 1986-	Present	480	200			
d. RAD	ATION BIOLOGY		"	ч		. 93	* 65			
	DIOPHARMACEUTICAL MISTRY				"	220	120			
	5. EXPERIENCE	E WITH R	ADIATION. (Ac	tual use of R	adioisotopes or Equ	ivalent Exper	rience)			
ISOTOPE	MAXIMUM AMOUNT	WHERE	EXPERIENCE W	AS GAINED	DURATION OF E	XPERIENCE	TYPE OF USE			
Group IV- 10 CFR 35		CA	ower AMC, F	t. Gordor	1984-19	986	Health Phys Tech			
Xe-133 Atomic No	40 mCi. 25 mCi ea	0A 11	**	¥1 89	**					
3-83 Gd-153	2 C3.									
Gd-153 Atomic No	5 C1	Letter	man AMC, PS	F, CA	1986-P1	resent	Radiation P Officer			
3-83	.5 Ci				1		67 61			

5

· · · · · ·

....

NRC (3-83	Form 374	U.S. NUCLEAR REGI	ULATORY COMMISSIO	PAG	E OF PAGES
Carla		MATERIA	LS LICENSE		Amendment No. 39
Code here sour deliv licen subje	uant to the Atomic Energy Act of 19 e of Federal Regulations, Chapter I, tofore made by the licensee, a licens ce, and special nuclear material desig er or transfer such material to perso se shall be deemed to contain the ect to all applicable rules, regulation itions specified below.	Parts 30, 31, 32, 33, 34 e is hereby issued authori gnated below; to use suc ons authorized to receive conditions specified in S	4, 35, 40 and 70, and izing the licensee to re h material for the purp it in accordance with section 183 of the At clear Regulatory Com	in reliance on ceive, acquire, p pose(s) and at the the regulation omic Energy A	statements and representations possess, and transfer byproduct, he place(s) designated below; to s of the applicable Part(s). This ct of 1954, as amended, and is
	Licensee Department of the Army Letterman Army Medical ATTN: HSHH-WHP	Center	In accordan dated Septe 3. License number	mber 16, 1 04-01496-	
A DECIS	Presidio of San Francis	co, California	4. Expiration date	February	28, 1989
TTECH I	94129		5. Docket or Reference No.	030-01220	
	Any byproduct material with Atomic Nos. 3 - 83 inclusive	A. Any	d/or physical	may und A.	imum amount that licensee possess at any one time er this license 500 millicuries each except as noted in Subitems 8.8 8.M.
B. C.	Iodine 125	B. Any C. Any		Male .	below -1 curie 1 curie
D.	Xenon 133	D. Any Ch	the CUM	D.	4 curies
Ε.	Hydrogen 3	E. Any	.005-	DE.	1.5 curies
F.	Molybdenum 99	F. Any	1. Y. Y.	F.	5 curies
G.	Technetium 99m	G. Any	in in	G.	5 curies
Н.	Cesium 137	H. Any		н.	2.5 curies
Ι.	Strontium 90	I. Any		Ι.	500 millicuries
J.	Strontium 90	J. Sealed sou	irces	J.	100 millicuries
К.	Iodine 129	K. Any		К.	100 millicuries
L,	Any byproduct material identifed in 10 CFR 35.	L. Sealed sou 500 diagnostic		L.	8 curies
M.	Any byproduct material identified in 10 CFR 35		entified in	Μ.	3 curies total for all sources authorized in Subitem 6.M.
					DEC 2 0 1989

NRC Form 374A (5-84) MATERIALS LICENSE SUPPLEMENTARY SHEET				License number 04-01496-01 Docket or Reference number						
		DUTLEMENTAN		Amendment No. 39						
6.	BYPRODU SPECIAL	UCT, SOURCE, AND/OR NUCLEAR MATERIAL	7. CHEMICAL AND/OR PHY FORM	SICAL 8. MAXIMUM AMOUNT THAT LICENS MAY POSSESS AT ANY ONE TIM UNDER THIS LICENSE						
۱.	Urani	ium	N. Plated metal	N. 136.4 kilograms						
).	Urani	ium	0. Any	0. 200 grams						
Ρ.	Urani (Depl	ium leted in U-235)	P. Plated metal	P. 70 kilograms						
9.	Autho	prized use	a single second s							
۹.	through	n L. Medical resear defined in Sec	ch, diagnosis, and ther tion 30.4(q) of 10 CFR	apy. Research and development as Part 30.						
1.	Medic	cal use described in	10 CFR 35.500.	131 .						
۱.	For u	use as shielding mat	erial in an accelerator							
),	Filli	ing for use in a gla	ss column for gas separ	ation.						
·.	Poses molyb	ssion and use of shi	pping containers as shi -99m generators.	elding for						
			- CONDITIONS							
10.			be used only at Letterm	an Army Medical Center and of San Francisco, California.						
1.	Α.		hall be used by, or und ted by the Radiation Co							
		byproduct material	for medical use, resear the appropriate traini	may permit any physician to use ch, and development. The ng and experience criteria in 10						
		The use of licensed defined in 10 CFR 3		ns shall be by a physician as						
		The Radiation Prote license is Lt. Loui		ctivities authorized by this						
				DEC 2 0 1						

CURRICULUM VITAE

E

;

<1. 4 5 TP

Name: Donald Kenneth Green

Education:

Henry Ford Community College	1970-72						
Pan American University	1972-73						
Southwest Texas State University	1973-75						
State University of New York 12 semester hours short of BS in Physics	1977-79						
Prime Power Production Specialist Course Health Physics Specialty given by the Facility Engine Support Agency, USA.							
Graduated 3rd in class.	1978-79						
Internal Dosimetry Workshop	1981						
RSO Basic Training Course	1982						
Roosevelt University	1985-86						

Certification: None

Licenses:

53-00458-04	TAMC
53-00458-05	TAMC
19-08330-02	USUHS/AFRRI
19-19669-01	USUHS

Donald Kenneth Green

Experience:

Chief, Radiological Safety Division, Environmental Health and Occupational Safety, Uniformed Services.University of the Health Sciences. Was responsible for the radiological safety program for the DOD's only medical school. Received a great deal of experience in radiological research (nonhuman), in vivo and in vitro on micro and macro biological systems. Letter of Commendation (attached) details administrative experience. 1979-82

NCOIC, Radiation Protection Office, Tripler Army Medical Center 1982-87

Experience with Ionizing Radiation:

See NRC Form 313M

Professional Societies:

11 : 11

Baltimore Washington Chapter of the Health Physics Society 1981-82

Hawaii Chapter of the Health Physics Society (held offices of Secretary, Treasurer, President Elect and President) 1983-87

DEC 2 0 1988

-	OR	OF	510	FI	SE	ONLY
	011	011	1	here has	1 miles	VIN6. 1

Review:

RCC Approval:

Name: Green Donald Kenneth Dept: Radioisotopes Services Branch Phone: 3318

ATE:

SUMMARY OF RADIOLOGICAL QUALIFICATIONS

Formal Radiological Safety Training Course Title Date Location Duration Subjects Covered Prime Power Production 78-79 Ft Belvoirva 52 weeks Physics, Mathematics, Health Course-Health Physics. Physics, N.P. Oct. '82 Bethesda Md. 2 weeks **RSO Basic Training** Ensineerins, Radiation Course. Biology, Instrument, Basic H.P. Internal Dosmetry 1981 Harrisburg PA 3 days Internal Dosimetry Workshop Radiological Instrument Experience Instrument Type Radionuclides Measured Gas Flow Prop Counter Am-241 SC H-3, C-14, P-32, S-35, Ca-45, Sr-90 Gamma Well Counter All On Licenses 19-08330-02, 19-19669-01, 53-00458-04, 53-00458-05, 04-01496-01. Radiological Safety Course Instructed Course Title Date Location Level Audience (undergrad/grad) Decontamination of radiation 79-82 USUHS/AFRRI Physicians/Senior Nurses Casualties. (Medical Effects of Nuclear 79-82 Bethesda Grad Nurses , Weapons Cause) (Continuing Nursing Education). Inbriefing/Annual Training. 79-88 All Licenses Trainee-Physician Above Other Nuclear Material Licenses Authorized Under Type License Level of Auth. Location Broadscope Research Principal User/Chief USUHS/AFRRI19-08330-02, Radiological Safety 19-19669-01.

Principal User/NCOTC TAMC 53-00458-04.

53-00458-05.

LAMC/LAIR 04-01496-01

Radiation Protection

Principal User/RPO

Office

Broadscope Medical

w

proadscope Medical/Research

RADIONUCLIDE EXPERIENCE

Indicate type of experience by completing the appropriate table entries below. See supplementary instructions.

Experiemental System	System Used		Location/ Date Supervisor	Level of Involvement** Frequency*	Describe Application		
Whole Animal (type)	S-137	4,200 Ci	USUHS Aug '79-Nov '82 Self	U 2	Whole Animal Irradiation		
Organ System							
Cell or bact. ulture					· · ·		
Cell free sys. (enzyme assay, etc.)							
Wet Chemistry (substrate syn or labeling)	1-125	10,000	USUHS 79-82 Self	U 2	lodination of many Biochemicals		
Other (specify)	1-83	varied	USUHS/TAMC 79-87	S 2	Health Physics Applications		

D=Daily 2=more than once a week W=Weekly M=Monthly I=Infrequently S=Single
 Tater following symbol(s) to show type of involvement in the indicated type of experiment performed:

U=Dnect User P=Principal Investigator S=Supervisor O=Observer T=Student

FORM NRC (8-78)	AUTHOR	TF	AINING AND EXPERIE ER OR RADIATION SAF			EGU	LATC	RY C	OM:	MISSION		
	AUTHORIZED USER OR	RADIATIO	N SAFETY OFFICER	SAFETY OFFICER			2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE N/A					
**************************************			3. CERTIFICATION									
SPECIALTY BOARD			CATEGORY	(MON	TH AI	ND YE	ARCE	RT	IFIED		
N/A			N/A			N/A						
North Contract of Street of Branch	4. TRAININ	G RECEIV	ED IN BASIC RADIOISOTOP	E HANDLING TE	CHNIC	QUES						
NUMBER OF STREET, STRE					TYPE	AND	ENGI	HOF	TR	AINING		
FIELD OF TRAINING			LOCATION AND DATE (S)	OF TRAINING	LECTURE/ LABORATORY COURSES (Hours) C			SUPERVISED LABORATORY EXPERIENCE (Hours) D				
	DIATION PHYSICS AND		 Southwest Texas Iniversity 1973-197 Facility Engine Agency. Fortibe 	froir, WA	{}}	328	hrs	{ē}	34	vears		
b. RAE	NATION PROTECTION		Aug 78 - Aug 79 (3) BSO Basic Train in The Control and Boniphizing Oct 50, by Appli Physics in Appli		(2) (3)					years years		
THE	THEMATICS PERTAINING E USE AND MEASUREMEN RADIOACTIVITY		 (4) Internal Dosime (5) Uniformed Servi Bethesda, Md A 	try Workshop g, PA		80 4	hrs hrs hrs		34.	years years		
d. RAI	DIATION BIDLOGY		(6) Tripler Arpy Me	dical Center MAY 87		260 4	hrs			years years		
	DIOPHARMACEUTICAL	7						(5) (6)		years years		
	5. EXPERIENC	E WITH RA	ADIATION. (Actual use of Rad	diaisatopes ar Eau	ivalent	Expe	rience	,)		ar sensori allang utudi taka		
ISOTOPE	MAXIMUM AMOUNT	WHERE	EXPERIENCE WAS GAINED	DURATION OF E	XPERIE	NCE	-	TYPE	OF	USE		
Atomics Lumpers	(itemse)		ed Services Universi Health Sciences	ty 3 Years	HJ-R		Heae	Health Physics Use and Medical (Non-Human) Research				
Сь-137	4,200 C1		ed Services Univ	3 Years			Gam	ma.I anim	R	adiati s ior esearc		
Atomics 1-03 Co-60	50 mCi 9,000 Ci		Army Medical Center Army Medical Center			:	1			ysics ysics		

144

.

.

f.

;

(B-78)

.



DEFENSE NUCLEAR AGENCY ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE BETHESDA, MARYLAND 20014

1 August 1982

To Whom It May Concern:

SUBJECT: Letter of Commendation for SP6 Donald K. Green

I have been informed that Specialist D. K. Green will soon be departing the Uniformed Services University of the Health Sciences for duty elsewhere. I, therefore, would like to take this opportunity to express my gratitude for his exemplary performance as Chief, Radiological Safety Division, EHOS, USUHS.

Since the use of radioactive materials at the USUHS is governed by the NRC Byproduct License issued to the Armed Forces Radiobiology Research Institute (AFRRI), Defense Nuclear Agency, in my capacity as Head, Radiation Safety Department AFRRI, I have had obvious reasons for remaining abreast of his many accomplishments at USUHS. These accomplishments have been overwhelming, both in quantity and in quality.

His personal rapport with technical and professional personnel has been directly responsible for the maintaining of a safe working environment at the USUHS. This outstanding rapport coupled with his technical competence, his superior grasp of the principles of operational health physics, and his honest dedication to the ALARA Principle (As Low As Reasonably Achievable) has earned for him (and consequently for all of us) an immeasurable respect from civilian and military personnel alike at every level and in every scientific discipline.

I am continually impressed that during a period of great expansion, he was able to prepare the Byproduct License Application for the University. To have been able to maintain control of so rapidly expanding a program, in light of a critical manpower shortage, is in itself a monument to his managerial abilities. To have found the time (primarily evenings and weekends) to prepare an NRC Byproduct License Application is truly commendable.

Preparing an NRC Byproduct License Application is a staggering task for any professional health physicist. To have prepared so outstanding a document so quickly and efficiently while performing his normal duties is evidence of his exceptional dedication to duty. I have known few individuals who could have met that challange so well.

I cannot overstate my confidence is ins abilities as an operational health physicist. In all my years in the public service, I have met few health

physicists with as complete a grasp of the operational aspects of the science, and have rarely seen an individual, at any level, with such total dedication to duty and detail.

The position of Chief, Radiological Safety Division, at any university, is one usually occupied by an individual many levels higher than Specialist Green's current grade. When I bring to mind his many outstanding accomplishments as a health physicist and then recall that he is a health physics technician, not a health physicist, I am again overwhelmed.

I feel compelled to list some of his duties and a few of his accomplishments here for the benefit of others who may not be familiar with them:

- A. Duties
 - Specialist Green has been directly responsible for the operational health physics of the USUHS Radiation Safety Program. Briefly, he has been responsible for:
 - a. Reviewing the safety aspects of all grant proposals in the USUHS
 - Preparing hazard analysis of radionuclide experiment authorization requests
 - c. Advising PhD level scientists of precautions and procedures required to minimize potential exposure to ionizing radiation
 - d. Training all incoming personnel with respect to:
 - 1) Biological effects of ionizing radiation
 - 2) NRC rules and regulations
 - 3) NRC License requirements
 - 4) Safe handling techniques for radioactive materials
 - e. Shield design for certain experiments
 - f. Procurement and accountability of all radioactive materials entering the USUHS

2. Specialist Green has been responsible for overseeing:

- a. Environmental sample collection and analysis
- b. Radiological surveys of restricted areas
- c. Contamination control
- d. Radioactive waste collection, processing, packaging, and trasnsportation
- e. The dosimetry program
- f. The bioassay program
- g. Iodination procedure monitoring

and the second of the

- h. Records management
- B. Accomplishments
 - From the time that Specialist Green arrived at the USUHS to the present, the University has undergone a tremendous expansion. There has been:

a. A 120% increase in the number of radioactive materials in use

DEC 2'0 1988

at USUHS

(...

- a 90% increase in the number of procedures requiring stringent monitoring and surveying,
- c. a 300% increase in the number of active Radionuclide Experiment Authorizations,
- d. a 250% increase in the number of personnel requiring dosimetry, e. nearly a 500% increase in the volume of radioactive waste, and
- f. a 700% increase in the number of restricted areas

At the same time, there has been no increase in the technical support staff.

- Specialist Green completely computerized radioactive waste and source accountability. To a computer expert this may seem a minor task, but Specialist Green had never used a computer prior to attempting this rather complex job.
- 3. His modernization of the university's radioactive waste treatment procedures and facilities resulted in a tremendous savings in manpower and capital. Although the volume of radioactive waste has increased by nearly 500%, the time required to process it and prepare it for transportation has increased a mere 50%.
- 4. Although his lack of official professional status prevented his being appointed to the AFRRI/USUHS Radiation and X-Ray Safety Committee, his numerous invaluable contributions to that committee have been greatly appreciated. An example of this was his reorganization of the USUHS's Radionuclide Experiment Authorization Management System. This reorganization resulted in a much streamlined system which has led to greater control. The AFRRI is in the process of following his lead since it has proven to be a very efficient system.
- Specialist Green has been continually sought to instruct portions of the "Medical Effects of Nuclear Weapons" Course given to physicians, as well as the "Operational Readiness Training Course" given to Navy Nurse Corps Officers.
- 6. Specialist Green's most outstanding accomplishment, to date, has been his preparation of the University's own NRC Byproduct License Application. The "creation" of a radiation safety program requires not only a great deal of labor and dedication, but a superior comprehension of the art and science of health physics. The license required by the USUHS is a Type A Broadscope Byproduct License. This type of license is the most complex of all Byproduct Licenses.
- 7. The type of accomplishments achieved by Specialist Green are examples of performance expected of a top-level professional commissioned officer health physicist. Specialist Green lacks only 12 credit hours towards his undergraduate degree in physics. Because of his personal and professional dedication, he was unable to complete his

degree requirements during evenings and weekends. Instead, he chose to use his personal time to meet the strenuous professional demands of the radiological safety position at USUHS. I strongly recommend that he be allowed to complete his degree and admitted to the commissioned officer corps as soon as possible. He will be a great asset to the Commissioned Radiation Safety Officer Corps in the Army, which is a critical manpower slortage area.

In closing, I would like to express my deepest gratitude for the outstanding manner in which Specialist Green has completed each and every endeavor that he has undertaken here. His total dedication and patently obvious abilities has set him far above his peers.

He is leaving behind him a well thought out, well defined, outstanding radiation safety program, of his own creation, from which the USUHS will benefit greatly for many years to come.

He will be fondly remembered and sorely missed.

areal K: Chawley

Naresh K. Chawla, PhD Head, Radiation Safety Department Armed Forces Radiobiology Research Institute Defense Nuclear Agency

cf:

25 -

J.P. Sanford, M.D., President, USUHS MILPERS, USUHS K. Kinnamon, Associate Dean for Operations, USUHS

ITEM 8

Training for Individuals Working in or Frequenting Restricted Areas

1. Training Program.

- a. Training of Radiation Workers Invoived in the Human Use of Radioisotopes.
 - 1) Personnel will receive instructions:
 - a) Before assuming duties with radioactive materials
 - b) During annual refresher training
 - c) Whenever there is a significant change in assigned duties
 - d) Whenever there is a significant change in procedures, regulations, or terms of the License
 - 2) Instructiona for individuals will include:
 - a) Applicable regulations and License conditions
 - Areas where radioactive materials are used and stored that fall within the scope of the individual's duties
 - Potential hazards associated with radioactive material in each area where the employee will work
 - d) Appropriate radiation safety procedures
 - e) LAMC radiation safety work rules
 - f) Each individual's obligation to report unsafe conditions and suspected procedural, regulatory, or License condition violations to the Radiation Protection Officer
 - g) Appropriate responses to emergency or unsafe conditions
 - h) Worker's right to be informed of occupational radiation exposure and bioassay results
 - The location of pertinent regulations, License and License conditions that are available for employee's review
 - j) Audience specific problems that have occurred in the recent past
 - 3) This training will be conducted by Health Physics staff, and will be in the form of a lecture with an appropriate question and answer period.

ITEM 8

Training for Individuals Working in or Frequenting Restricted Areas

- b. Training of Ancillary Personnel Who May Be Occupationally Exposed to Ionizing Radiation and/or Radioactive Materials Involved in the Human Use of Radioisotopes. Personnel will receive instructions before assuming duties that will bring them into contact with radioactive materials, during annual refresher training, whenever there is a significant change in assigned duties, and whenever there is a significant change in procedures, regulations, or terms of the License.
 - Nursing staff caring for radiopharmaceutical therapy or implant patients will be instructed in the following subject areas. This training will be conducted by Health Physics staff, and will be in the form of a lecture with an appropriate question and answer period. The following topics will be covered:
 - a) Applicable regulations and License conditions
 - Areas where radioactive materials are used and stored that fall within the scope of the individual's duties
 - Potential hazards associated with radioactive material in each area where the employees will work
 - d) Appropriate radiation safety procedures
 - e) LAMC radiation safety work rules
 - f) Each individual's obligation to report unsafe conditions and suspected procedural, regulatory, or License condition violations to the Radiation Protection Officer
 - g) Appropriate responses to emergency or unsafe conditions
 - Worker's right to be informed of occupational radiation exposure and bioassay results
 - The location of pertinent regulations, License and License conditions that are available for employee's review
 - Audience specific problems that have occurred in the recent past. For example, problems associated with the specific type of patient that the individuals will be encountering.
 - 2) Fire and security personnel will receive training. This training will consist of either a lecture provided by Health Physics staff or a video taped lecture. The following topics will be covered:
 - Areas where radioactive materials are used and stored that fall within the scopeof the individual's duties

ţ

8-2

Training for Individuals Working in or Frequenting Restricted Areas

- Potential hazards associated with radioactive material in each area where the employees may work
- c) Appropriate radiation safety procedures
- Each individual's obligation to report unsafe conditions and suspected procedural, regulatory, or License condition violations to the Radiation Protection Officer
- e) Appropriate responses to emergency or unsafe conditions
- f) Worker's right to be informed of occupational radiation exposure and bioassay results
- g) Audience specific problems that have occurred in the recent past
- 3) Housekeeping personnel whose duties will be in restricted areas will receive training. This training will consist of either a lecture provided by the Health Physics staff or a video taped lecture. The following topics will be covered:
 - Areas where radioactive materials are used and stored that fall within the scope of the individual's duties
 - b) Potential hazards associated with radioactive material in each area where the employees may work
 - c) Appropriate radiation safety procedures
 - Each individual's obligation to report unsafe conditions and suspected procedural, regulatory, or License condition violations to the Radiation Protection Officer
 - e) Appropriate responses to emergency or unsafe conditions
 - f) Worker's right to be informed of occupational radiation exposure and bioassay results
 - g) Audience specific problems that have occurred in the recent past
- 2. Other Training Program.
 - a. Training of Individuals Involved in the Non-Human Use of Radioactive Materials
 - 1) Personnel will receive instructions:
 - a) Before assuming duties with radioactive materials
 - b) During annual refresher training

USNRC BML APPLICATION

8-3

DEC 2 0 1988

Training for Individuals Working in or Frequenting Restricted Areas

- c) Whenever there is a significant change in assigned duties
- d) Whenever there is a significant change in procedures, regulations, or terms of the License
- 2) Instructions for individuals will include:
 - a) Applicable regulations and License conditions
 - Areas where radioactive materials are used and stored that fall within the scope of the individual's duties
 - Potential hazards associated with radioactive material in each area where the employees will work
 - d) Appropriate radiation safety procedures
 - e) LAMC/LAIR radiation safety work rules
 - f) Each individual's obligation to report unsafe conditions and suspected procedural, regulatory, or License condition violations to the Radiation Protection Officer
 - g) Appropriate responses to emergency or unsafe conditions
 - Worker's right to be informed of occupational radiation exposure and bioassay results
 - The location of pertinent regulations, License and License conditions that are available for employee's review
 - j) Audience specific problems that have occurred in the recent past. For example, causes of radioactive contamination problems in the laboratory setting.
- 3) This training will be conducted by Health Physics staff, and will be in the form of a lecture with an appropriate question and answer period.
- b. Training of Ancillary Personnel Who May Be Occupationally Exposed to Ionizing Radiation and/or Radioactive Materials Involved in the Non-Human Use of Radioisotopes will be the same as for human-use ancillary personnel.

Facilities and Equipment

1. Annotated Drawings.

- a. Radioactive material may be used and/or stored in areas approved by the RPO with the concurrence of the Radiation Control Committee within the confines of facilities which comprise Letterman Army Medical Center and Letterman Army Institute of Research. Due consideration will be given to the adequacy of the types and quantities of radioactive material to be used prior to approval. Radioactive material use areas will not be released for unrestricted use until approval of the RPO or Atternate RPO is obtained. Records of close-out surveys will be maintained for inspection.
- b. Diagrams of Human Use Areas.
 - Diagram No. 1 a site map of the Presidio of San Francisco with buildings marked which presently contain radioactive material use operations.
 - Diagram No. 2 floor plans of the 1st, 2nd, and 3rd floors of Letterman Army Medical Center, Bldg 1100, with specific use areas indicated.
 - Diagram No. 3 detailed diagram of the Radiation Therapy Clinic. Note that teletherapy is performed using a linear accelerator and an orthovoltage unit.
 - 4) Diagram No. 4 detailed diagram of the Nuclear Medicine Clinic, including the Nuclear Pharmacy.
 - 5) Diagram No. 5 detailed diagram of the room used for Xenon studies.
 - 6) Diagram No. 6 detailed diagram of the RIA laboratory.
- 2. Survey Instrument Calibration.
 - a. Primary calibration will be performed at least annually by the Metrology Division, U.S. Army Calibration and Repair Center, Sacramento Army Depot, Sacramento, CA 95813. The calibration procedures are on file with the NRC under license #4-4279-1.
 - b. Primary calibration may also be performed on site by the applicant using a ¹³⁷ Cs calibration range, which is itself calibrated and verified periodically by a licensed contractor. When calibrations are performed on site, we will establish and implement the model procedure for calibrating survey instruments that was published in Appendix B to Regulatory Guide 10.8, Revision 2.
- 3. Dose Calibrator Calibration.
 - a. Frequency of tests.
 - Constancy at least once each day prior to the assay of patient dosages. This test should be within ± 5%.
 - Linearity at installation and at least guarterly thereafter. This test should be within ± 5%.
 - Accuracy at installation and at least annually thereafter. This test should be within ± 5%.
 - 4) Geometry dependence will be done at installation.

Facilities and Equipment

- b. A mathematical correction shall be made to any geometry or linearity error that exceeds 10% if the dosage is greater than 10 microcuries, and the dose calibrator shall be repaired or replaced if the accuracy or constancy error exceeds 10%. This test will be redone after repair, adjustment, or relocation of the dose calibrator, if appropriate.
- c. The dose calibrator will be inspected on a quarterly basis to determine that the liner of the measurement chamber is in place and that the instrument is zeroed according to the manufacturers instructions.
- d. Dose calibrator calibration providure.
 - <u>Constancy</u>. At least one relatively long-lived reference source such as ¹³⁷ Cs or ⁵⁷ Co will be assayed using a reproducible geometry before each day's use of the dose calibrator. The procedure to be used is described below.
 - a) Assay each reference source using the applicable instrument setting.
 - b) Measure background level at the same instrument setting or check that the automatic background subtraction is operating properly when blanks are inserted in the calibrator.
 - Calculate net activity of each source by subtracting out background radiation and record the results on the daily constancy log sheet.
 - Using one of the sources, repeat the above procedure for the most commonly used setting.
 - e) Compare the reading with the calculated value. If the reading is outside the ± 5% range, immediately recheck steps a through d. If after reassay, the standard still reads outside the ± 5% range, notify the Chief, Nuclear Pharmacy Service, Nuclear Medicine Physician of the Day, or the Chief, Nuclear Medicine Service before using the calibrator for measuring doses.
 - Linearity. The following methods will be used to evaluate linearity of the dose calibrators. Either the Decay Method or the Shield Method will be used.

Shield Method

- a) The shield method shall be done in accordance with the manufacturer's instructions.
- b) The procedures provided by the manufacturer, and currently being used, are attached as Item 9, Annex 1, this application.

Decay Method

- a) Assay the ^{99m} Tc syringe or vial in the dose calibrator, and subtract background to obtain the net activity in millicuries. Record the date, time to the nearest minute, and net activity on a Dose Calibrator Linearity Test Form. This first assay should be done in the morning at a regular time, for example, 8 a.m.
- b) Repeat the assay at about noon, and again at about 4 p.m. Continue on subsequent days until the assayed activity is less than 10 microcuries. For dose calibrators on which you select a range with a switch, select the range you would normally use.

USNRC BML APPLICATION

Facilities and Equipment

- Convert the time and date information you recorded to hours elapsed since the first assay.
- d) On a sheet of semilog graph paper, label the logarithmic vertical axis in millicuries and label the linear horizontal axis in hours elapsed. At the top of the graph, note the date and the manufacturer, model number, and serial number of the dose calibrator. Then plot the data.
- e) Draw a "best fit" straight line through the data points. For the point farthest from the line, calculate its deviation from the value on the line.

(A-observed - A-line) = deviation (A-line)

- f) If the worst deviation is more than ± 0.05, the dose calibrator should be repaired or adjusted. If this cannot be done, it will be necessary to make a correction table or graph that will allow conversion from activity indicated by the dose calibrator to true activity.
- Accuracy. Using at least two NBS traceable sources, instrument accuracy will be checked at least annually using the procedure below.
 - a) Using two of the following reference standards (⁵⁷Co, ¹³⁷Cs, ⁶⁰Co), assay the standard in the dose calibrator at the applicable setting, and subtract the background level to obtain the new activity
 - b) Repeat step a for a total of three determinations for each standard, and average the results.
 - c) The average activity determined in step b should agree with the certified activity of the reference source to within ±5% after the decay correction.
 - Record the average activity readings for each standard on the Accuracy Check Flow Chart.
 - e) Calibration checks that do not fall within the ±5% range indicate that a problem may exist with the instrument that may require repair or adjustment. Report as value outside the range to the Chief, Nuclear Pharmacy, the Nuclear Medicine Physician of the day or the Chief, Nuclear Medicine.
 - f) This test will be performed on installation and at least annually thereafter. The date when the next accuracy test is to be performed will be posted on or near the dose calibrator.
- 4) Geometry. The extent of geometrical variation will be ascertained using a common radionuclide, and correction factors will be computed if variations are greater than ± 5%. The procedure to make this determination is detailed below.
 - a) To measure the geometrical variation in a glass vial, due to increasing volume of liquid, a 20 or 30 ml vial containing approximately 2 mCi of ^{99m} 7c in a volume of approximately 1 ml will be used.

- . . 0

Facilities and Equipment

- b) Increase the volume of liquid in the vial in the following sequence from 1 ml to 2, 4, 8, 10, 20, and 25 mls by adding the appropriate volume of water. After each addition, gently shake the vial to mix the contents and assay the vial at the appropriate setting, and subtract the background reading to obtain the net activity. Record the readings on the Instrument Geometrical Variation Flow Sheet for Glass Vials.
- c; Select one volume as the standard (such as the volume of the reference standard used in performing the test for instrument accuracy), and calculate the ratio of measured activities for each volume to the reference volume activity. This ratio represents the volume correction factor (CF).
- d) If the correction factor is lower that 0.95 or higher than 1.05, then plot the correction factors against the volume on linear graph paper. Use this graph to select the proper volume correction factors for routine assay of the radionuclide.
- e) To measure the geometrical variation of the volume of liquid in different size syringes, approximately 2 mCi of Tc-99m in a volume of approximately 1 ml will be used (except as noted for the 1 ml syringe).
- f) Increase the volume of liquid in each syringe as outlined below by adding the appropriate amount of water. After each addition, gently invert and mix the contents and assay the syringe at the appropriate setting, and subtract the background level to obtain the net activity. Record the readings on the Instrument Geometrical Variation Flow Chart for Syringes.

Syringe Size	Initial Volume ml	Incremental Volume ml
1	0.5	0.5
3	1.0	1.0
5	1.0	1.0
10	1.0	2.0*
20	1.0	5.0**

* For the first increase bring the total volume to 2.0 ml

** For the first increase bring the total volume to 5.0 ml

- g) The initial volume reading will be used as the reference standard for each syringe size. Calculate the ratio of measured activities for each volume to the reference activity. This represents the correction factor (CF).
- h) If any correction factor is lower than 0.95 or higher than 1.05, plot the correction factors against the volume on linear graph paper. Use this graph to select the proper volume correction factors for routine assay of radionuclides.


Facilities and Equipment


4. Personnel Monitoring Program.


a. External Exposure monitoring program:


- All individuals occupationally exposed to ionizing radiation who receive, or are likely to receive, accumulated dose equivalents in excess of 10% (5% if under 18 years of age) of the quarterly occupational exposure standards specified in 10 CFR 20.101 (a), shall be issued appropriate film or TLD monitors that will be processed by a contract service on a monthly basis.
- 2) All individuals who are occupationally exposed to ionizing radiation on an occasional basis, such as nursing staff caring for radiopharmaceutical therapy or implant patients, will be issued a whole body monitor for use during the period(s) of exposure.
- 3) Other individuals who are exposed to radiation on an occasional basis, such as security personnel, administrative personnel who deliver packages, secretarial personnel who work in the Nuclear Medicine Clinic, but do not work with patients, and nursing staff who occasionally care for patients who have received diagnostic doses, will not normally be issued dosimetry.
- 4) The RPO will promptly review all exposure reports to look for workers, or groups of workers, whose exposure is unexpectedly high or low. This procedure does not apply to back-up monitor records, for example pocket ionization chambers, when the monitor of record is a film or TLD dosimeter.
- b. Internal exposure monitoring program:
 - Individuals who work with, or in the vicinity of, unsealed ³ H, ¹²⁵ I, or ¹³¹ I will be monitored by bioassay when directed by the RPO. Requirements for bioassay will be based on criteria published in Regulatory Guide 8.20, Revision 1, dated September 1979, and Regulatory Guide 8.32, dated July 1988.
 - The RPO will promptly review all bioassay results to look for workers whose internal duse or uptake is unexpectedly high.
- 5. Imaging Equipment. Mobile Nuclear Medicine services are not provided.
- 6. Oth Equipment and Facilities.
 - a. Diagrams of Health Physics Office, Non-human Use, and Research areas.
 - 1) Diagram No. 7 detailed diagram of the Health Physics Office, Building 1007.
 - Diagram No. 8 floor plan of Department of Clinical Investigation, Letterman Army Medical Center, Building 1801. Radioactive materials are used only in approved rooms, in the area of the 6th floor designated on the diagram.
 - Diagram No. 9 through No. 13 floor plans for Letterman Army Institute of Research, Building 1110. Radioactive materials are used in approved rooms throughout this facility.
 - 4) Diagram No. 14 detailed diagram of the rooms which make up the Radioisotope Branch of Letterman Army Institute of Research. These rooms comprise the central area where radioactive materials are received, stored, distributed to users, and where the radioactive waste is stored for decay and shipment.

DEC 2 0 1988










DEC 2 0 1988

- and the second

DIAGRAM No. 5 LETTERMAN ARMY MEDICAL CENTER XENON IMAGING ROOM NUCLEAR MEDICINE SERVICE Bldg. 1100




:6

\$

DEC 2 0 1988

DIAGRAM No. 6 LETTERMAN ARMY MEDICAL CENTER RIA LABURATORY Bldg. 1100




出供

DIAGRAM No. 7 HEALTH PHYSICS SERVICE Bldg. 1007

17

;




Low-Level Radioactive Waste Storage--Awaiting Decay and/or Pickup For Disposal. A.


B. Safe Used For Storage of Radiation Sources.

C. Hood Vented to the Outside.

D. Sink Used For Disposal to Sanitary Sewer System.


E. Windows Are Barred For Security of Radioactive Material.





DEC 2 0 1988

E



+++++

.....


LR-B

di

F

DEC 2 0 1988

DIAGRAM No. 10 LETTERMAN ARMY INSTITUTE OF RESEARCH Bldg. 1110, First Floor








DIAGRAM No. 12 LETTERMAN ARMY INSTITUTE OF RESEARCH Bldg. 1110, 2nd Floor - LR Section/3rd Floor - RS Section




18

DIAGRAM No. 13 LETTERMAN ARMY INSTITUTE OF RESEARCH Bldg. 1110, 3rd Floor-LR Section/4th Floor-RS Section



* * *

Ca



Iow Level Id' Radioactive Waste Holding Area

P

F

;

150

•

(RSG)

GROUP

SERVICES

OPE

OSOT

RADI

- - 14

RS 3509

IETTERMAN ARMY INSTITUTE OF RESEARCH Bldg. 1110, Rooms LR2226, LR2227, LR2228, and RS3509

DIAGRAM No. 14

DEC 2 0 1988

Facilities and Equipment

ANNEX 1

Procedures for Dose Calibrator Linearity Test Using the Shield Method

(B)

;

INSTRUCTION MANUAL for CALICHECK

Calicheck

P.O. Box 25589 Cleveland, Ohio 44125-0589

1-15

1.

Calicheck

If you have questions regarding the kit, the directions for its use, or the data generated, call (216) 467-8478 for assistance.

DEC 2

This apparatus and method for it's use is covered by United States Letters Patent No. 4,333,010 itsued on June 1, 1982. FATENTEE expressly withholds all license to use this apparatus to practice methods covered by this patent for cellibrating equipment not pwined by purchase:

· · · · ·

· @.

(··

;

.

TABLE of CONTENTS

...

B

;

SECTION I Product Description	
SECTION II General Information	
SECTION III Calicheck Calibration Procedure	
SECTION IV Activity Linearity Procedure	
SECTION V License Amendment Request	
SECTION VI Calicheck Parts Order Form	


SECTION I

.

Product Description

Calicheck is a kit designed to perform the activity linearity test on a dose calibrator quickly and accurately. The kit consists of seven tubes, six of which are lead-lined to attenuate gamma radiation from radioactive sources, and a seventh, unlined tube. Each lead-lined tube varies in the thickness of lead so as to simulate various stages of radioactive decay. These tubes are sequentially placed over a source of radioactivity in the dose calibrator and, within minutes, seven successive measurements are acquired representing values that would have been obtained at approximately 0, 6, 12, 20, 30, 40 and 50 hours after the initial assay of Tc 99m. The need for determining linearity by fract ionating eluants, or decaying the elution for several days while data is being collected, is eliminated -- and at greatly reduced radiation exposures to personnel.

Each tube is coded with a colored band for identification.



.

SECTIC" III

General Information

Several important points must be understood prior to using Calicheck. The points are as follows:

- Calicheck performs thorough quality control on all kits. However, it is suggested that the kit be checked to ensure that the kit has not been damaged in shipment.
- The components of the kit and/or the dose calibrator can be damaged if misused. It is especially important that damage does not occur to the ends of the tubes. N
- 3. Should tubes become damaged or lost, replacement parts can be ordered with the form found on page 15 of this instruction manual.
- Calicheck confirms activity linearity. It will not make your dose calibrator linear. 4
- be at a minimum equivalent to Appendix C of Regulatory Guide The dose calibrator must exhibit activity linearity prior to utilizing the Calicheck kit. This must be accomplished by performing an activity linearity test using standard techniques such as described in your license application. For NRC license holders, this test should 10.8. August. 1987. If nonlinearity is demonstrated, the instrument should be repaired. ŝ
- interchanged without first confirming celibration factors. Each tube in the Calicheck kit must be calibrated and each time a tube is replaced in the kit, the new tube must be calibrated. A procedure is Calicheck must be specifically calibrated for each doce calibrator in models), are known to exist. Similarly, kits should not be the facility since variations between manufacturers (and sometimes, enclosed that describes the calibration technique. .9
- Readings obtained from Calicheck are not to be used for assay purposes. r
- The radionuclide used for testing must be Tc-99m, and it must be Mo-99 in the sample should the less than .15 uCi Mo-99/mCi Tc-99m. If a central radiophaimacy is used as the source of relatively free of Mo-99 contamination. The concentration of Tc-99m, ask the radiopharmacist for his assay results. eò DEC 2

0 1988

- Do not use the tubes as shielding devices. The black center tube offers absolutely no radiation protection since it is plastic with no lead in its side wall. The other tubes do contain varying amounts of lead, but should never be regarded as a protective shield. 0
- upright position when not in use. The black center tube should be in an The entire kit should be stored in the mailing container inserted upside down to avoid damage to the tubes. 10.
- the blanks, transfer entire letter to hospital stationary, have the application signed and forwarded to your licensing agency. Include activity linearity evaluations be filed with them in the form of a license amendment application. Enclosed (see page 14 of this instruction marual) is a model letter requesting authorization to amendment fees, where applicable. Upon receipt of the amend-Typically, regulatory agencies, such as the Nuclear Regulatory Commission or state licensing agencies, require that methods for use Calicheck, to be sent to the regulatory agency. Simply fill in ment, Calicheck can be put to use. ***

CAUTION: Calicheck should only be used by qualified personnel. Tubes should be carefully placed into the dose calibrator to avoid damage to the tube and/or chamber itself.

SECTIOL. 'I

5

Calibration of Calicheck

States of the second se

OBJECTIVE: " + +

To generate calibration factors for each tube in the Calicheck Kit, thereby expressing the amount of attenuation by each tube.

PREPARATION:

All radiation sources in the vicinity of the dose calibrator should be shielded to avoid erroneous readings. Further, the instrument may be sensitive to dosed patients in the vicinity. Move the patients to another location before you start. Both the "Kit Calibration" and the "Activity Linearity, Procedure" must be performed in an environmentally stable background.

Syringe hangers and vial holder assemblies supplied with Capintec, Nuclear Associates, and some Picker dose calibrators must be removed. Molded chamber liners as supplied by RadX and some Picker dose calibrators must be lifted out. Calicheck will not fit the Mediac dose calibrators because the chamber diameter is too small. The calibration source that is used should be the largest activity measured in the dose calibrator. This would normally be the Monday morning elution in the case of the generator, or the largest dose obtained from your radiopharmacy.

be used and it should be no longer than 1.1/2" in length. When the Splack tube is inserted into the dose calibrator, it should be done carefully with the open end in the upward position. The black tube must remain in the dose calibrator throughout all steps in the calibration cycle. Once the source is placed in the dose calibrator, the source must be kept in exactly the same position throughout the In order to use Calicheck, a source of Tc-99m must be placed into the use extension tongs to transfer the source. If the source is in a bottom loading elution shield, remove the base cover, put the open end of the black tube to the bottom of the lead shield and allow the source to slide down into the black tube by tilting the tube at an angle. The center tube accommodates vial sizes up to 20 ml. and syringes up to 10 ml. Proper technique dictates that when using a syringe, a clean needle central black tube. If the source is in a top loading lead elution shield, test to insure consistent geometry. 2 0 1986

If the unit has a manual range adjust, adjust the range as necessary to acquire three significant figures for each reading.

When the activities displayed are at the uCi level (e.g., when the purple and possibly blue tubes are in place), dose calibrator displays may "float" or vary on successive measurements. Be sure to record an average figure on your data sheets. Record all values on the data sheets in mCi units. Once the procedure is started, do not stop. All readings should be recorded within a matter of minutes. Otherwise, the short half life of Tc-99m will introduce unacceptable error.

Calibration Procedure : (To be performed only once.)*

- 1. Remove any syringe hanger or chamber liner, if necessary, from dose calibrator.
- 2. Set dose calibrator to measure Tc-99m.
- 3. Adjust zero, background, etc., if applicable. Check zero on each
- range. If background is not "zero" on all ranges, zero on one range and record values on all other ranges, to add or subtract from final results when those ranges are used.
- Place calibration source into black tube and insert black tube into dose calibrator CAREFULLY with the open end in the upward position. Read displayed activity.
- Record reading in appropriate positions on Data Sheet #1 "Kit Calibration". (8 entries. See example on page 8.)

Carefully ensure that, in the following steps, each tube is firmly seated against the lead at the base of the black tube.

- 6. Place red tures in the dose calibrator over the black tube. Record reading as the appropriate denominator on Data Sheet #1, Kit Calibration Corm.
- 7. Replace red tube with orange tube. Record.
- 8. Replace orange tube with yellow tube. Record.
- * Or following repair of dose calibrator or Calicheck.

DATA SHEET #1: (To be completed only ONCE)*

St. . . .

9. Replace yellow tube with green tube. Record. 110. Replace green tube with blue tube. Record.

"11. Replace blue tur ith purple tube. Record.

12. Remove the Calicheck assembly and place source in a shielded container. Place Calicheck in storage container provided. 111

----NOTE: For each measure ment, use the tube loui the colored band "up" 39\$ (v. 1.91.3

DATA TREATMENT OF DATA SHEET #1:

Divide the numerator by the denominator in Column B to determine the Calibration Factor, and record in Column C. Retain these values for future reference. These factors will be used for all calip met./i.e., same dose calibrator, same kir, same radionuclide, same ^{rep.} source configuration). Recalculation will be required following future activity linearity tests provided all conditions of the test are ... indire. 54310 1 PAC:

2. Compare results to chart of "Typical Calibration Factors" on page of 9. Differing values may be due to variations in geometry, in the his response of the dose calibrator and/or in the kit manufacturing process itself. act al un なんだい 11.11 5

appropriate place in Column C of Data Sheet #2. (See example on 3.12 Transfer determined Calibration Factors from Data Sheet #1 to page 13.) To confirm the accuracy of the determined factors, complete Data Sheet #2. If no error has been made, all values in Column D (product of B x C) should be the same. If values differ, repeat the determination. 14:44 34.1.1 DEC S.S.F

Kit Calibration

TURFS	DISPLAYED	CALIBRATIGN FACTORS
A		3
Black Only Black Only	mCi	= 1.00
Black Only Black & Red	# mCi	8
Black Only Black & C: 198	# uCi	11
Black Only Black & Yellow	= mCi	B
Black Only Black & Green	= aci	8
Black Only Black & Blue	= mCi	'n
Black Only Black & Purple	mCi	R
SOURCE CONFIGUERATION Syringe	r	*Or following repair of dose calibrator or Calicheck Kit. In all instances these factors can only be determined following proof of activity linearity by

standard techniques. KEEP THIS FORM FOR FUTURE REFERENCE!

Vial

1. 6.11

Ó

Examp'

ţ

To determine the calibration factors for a Brand X dose calibrator, a source of Tc-99m was prepared. The source read 34.2 mCi in the black tube and generated the following data.

SVEL ANDS			CALI	CALIBRATION
a P: TUBES		READINGS	FI	FACTOR
Witter A		B		3
Black Only Black Only		34.2 mCi 34.2 mCi	"	1.00
Black Only Black & Red	ĸ	34.2 mCi 19.9 mCi		1.72
Black Only Black & Orange	8	34.2 mCi 10.6 mCi	8	3.23
Black Only Black & Yellow	R	34.2 mCi 3.59 mCi	и	9.53
Black Only Black & Green		34.2 mCi 1.16 mCi	8	29.5
Black Only Black & Blue		34.2 mCi .354 mCi*		96.6
Black Only Black & Purple	ı	34.2 mCi .112 mCi		305

 "Read as 354 uCi and converted to .354 mCi. Similarly 112 uCi has been converted to .112 mCi and 92 uCi would be converted to .092 mCi. .8

Typical Calibration Factors

.

i	and in case of the local division of the loc	And a supervised of the superv	And the owner of the owner owne	And a	Concession of the local division of the loca	and the second s
	VIAL	SYRINGE	VIAL	SYRINGE	VIAL	SYRINGE
Black	1.00	1 1.00	1.00	1 1.00	1.00	1 1.00
Red	1.83	1.74	2.27	2.16	1.73	1.90
Orange	3.59	3.32	4.58	4.24	3.31	3.49
Yellow	10.9	9.74	14.4	1 12.9	9.71	9.96
Green	34.9	30.4	48.6	42.3	31.1	30.7
Blue	121	103	164	1 140	105	104
Purple	399	334	565	473	342	1 326
		_				_

These factors were determined using Tc-99m in a 10 ml vial and a 3 ml syringe. They represent an average of several determinations using the same kit in different dose calibrators of the same type as welf as different kits in the same dose calibrator. These factors are not to be used as a substitute for determined calibration factors. They are listed here for comparison purposes only.

and the second second	
1000	And Person in Concession, Name
	100.00
	A STATE OF
10.000	171723784
	100000000
	100000
	100
1000	
100	
1000	
-	
-	
And in case of the local division of the loc	
Ser. A	
1000	
Annual Colored	
-	
Strain Advert	
Sec.	
Sector of	
- Second Second	

5

Retivity Linearity Procedure

· 18.1 s us 1. 1. tr. the main and an Styres

1. \$;--OBJECTIVE: N. 12 1.

To determine if a dose calibrator can respond linearly to a variety of levels of radioactivity via the Calicheck Technique.

PREFARATION:

Same as described under "Calibration of Calicheck". See page 4. Use the same source configuration as used in that celibration procedure.

PROCEDURE:

- Remove any syringe hanger or chamber liner, if necessary, from dose celibrator.
- Set Bose calibrator to measure Tc-85m. ri
- Adjust zero, background, etc., if applicable. Check zero on each and record values on all other ranges to add or subtract from final range. If background is not "zero" on all ranges, zero on one range results when those ranges are used. r'
- Place source to be used for the activity linearity procedure into the black, tube and insert tube into the dose calibrator CAREFULLY with the open end in the upward position. n E d
 - Record "displayed activity" on "Black Only" on Data Sheet #2 "Dose Calibrator Activity Linearity Check", [see page 13].

Carefully, ensure that, in the following steps, each tube is firmly seated against the lead at the base of the black tube.

- 6. Place red tube in the dose calibrator over the black tube. Record "displayed activity" on "Black & Red" blank on Data Sheet #2. ż
- 7. Replace red tube with orange tube. Record on "Black & Orange" blank.
- ŝ Replace orange tube with yellow tube. Record on "Black ŝ
- 9. Replace yellow tube with green tube. Record on "Black & Green" 010

あったの

1898

- 10. Replace green tube with blue tube. Record on "Black & Blue" blank.
- 11. Replace blue tube with purple tube. Record on "Black & Purple" blank.
- Remove Calicheck assembly and place source in shielded container.

DATA TREATMENT OF DATA SHEET #2: (To be completed each calendar quarter or at a frequency required by your license conditions.)

- Enter appropriate Calibration Factors from Data Sheet #1 for your dose calibrator in Column C.
- Multiply the value in Column B by the corresponding value in Column C to determine product of each entry for Column D. Record values. (Ideally, these values will all be the same. r'i
- Add all products in Column D and divide by 7 to determine the mean value. Multiply the mean by 1.05 and 0.95 as indicated. These define the upper and lower limits of ±5% variation. e'

continue the determination by withdrawing an aliquot containing 2-3 The test is then repeated (Data Sheet #2 only), using the same source configuration as that used in determining the calibration factor on Data If all values in column D fall between these two limits, your dose calibrator has acceptable activity linearity. The test is complete, unless additional readings are required to check the microcurie range. If so, mCi more activity than the displayed activity in the last measurement. Sheet #1.

if any values in Column D fall outside the limits, repeat the study to rule out possible variations in the initial data. Consistent results that are outside the limits indicate that the instrument is exhibiting nemlinearity. Corrective action is indicated. -

#2 fto be completed each quarter? DATA SHE 1.2

.

4

Ð

Dose Calibrator Activity Linearity Check

Example

A Mo/Tc generator is eluted and yields 342 mCi. The entire elution is placed in the dose calibrator inside the black tube. Subsequent readings generated the following data.

Dose Calibrator Activity Linearity Check

(must be same as on Data Sheet # :)

Source Configuration

Technologist

Date

Dose Calibrator

Model 1 St.

All readings must be taken at lowest range setting available

and converted to mCi units.

CALIBRATION PRODUCT OF

DISPLAYED

ACTIVITY

TUBE COLOR - INC. I INC. Defenseling alter an a man

Black Gnly:

0

1

2

ASS

111

BXC

FACTOR

1.00

×

mCi

×

i)

·

. 1:22+

Black & Red:

×

DE

DE

Black & Yellow: Black & Orange:

Black & Green:

with their star

Black & Blue:

×

iDu

×

mCi

DE

Black & Purple:

12

All readings were taken at lowest range setting available and converted to mCi units.

۵	PRODUCT OF B X C	= 342	: 346	342	325	- 301	= 342	- 363	= 2361
υ	CALIBRATION FACTOR	× 1.00 -					× 96.6		= WNS
8	DISPLAYED ACTIVITY	342 mCi	201 mCi)			-		1.19 mCi	
A	TUPE COLOR	Black Only:	Black & Red:	Black & Orange:	Black & Yellow:	Black & Green:	Black & Blue:	Black & Purple:	

LUWER LIMIT. = UPPER LIMIT* 337 = MEAN = 2361354 320 ŧ X 1.05 = X 0.95 MEAN MEAN

.

The readings for the green and purple tubes are outside the limits. The procedure should be repeated to confirm the data. Repair may be indicated. Failure to account for a re-zeroing problem between ranges (see Procedure Step #3) or an unstable background may also have produced this apparent non-linearity.

• Instead of a variation in the Column D data of ±5%, vour radioactive material license may allow a difference of ±10% in the test results. If so, multipliers of 1,10 and 0.90 can Le used to determine the upper and lower limits.

Compare Column D data to upper and lower limits to confirm linearity.

LOW ER LIMIT. UPPER LIMIT.

> 1 11

> > X 0.95 =

MEAN

DEC

..., MEAN X 1.05 =

SUM

SUM

MEAN =

25

SECTION V

License Amendment Request

To be placed on licensee's stationery

	ZIP	ON:
	STATE	E CONTACTE S APPLICATI PHONE:
NRC of State License Number FACILITY ADDRESS		PERSON TO BE CONTACTED REGARDING THIS APPLICATION:
NRC of State Lic FACILITY ADDRESS	CITY	- 5 0 0

Gentlemen:

ĉ.

Please amend our license as follows:

As an alternative to our present procedure, the dose calibrator can be from C a Li check. The manufacturer's instructions for use as revised on March 2, 1982, will be followed. Test results will be recorded and retained for inspection. Corrective action as stated in our license checked for activity linearity with the use of a device called Calicheck application will be followed if unacceptable linearity is demonstrated.

Sincerely,

1127122

DEC 5 Administrator

「「「「」」」「「「」」」」」」」」 ないないとう · Prices are subject to change without it ないのであってい ないなないない PRICE an alexa Star Carto の上な部 TOTAL ENCLOSED All the state of the state 1 1 1 1 1 1 1 1 1 QUANTITY 小田市 1111 1. 6 P. 14 TOTAL 「ななない」 -----Name? ** Address . SHIP TOM Order F " PRICE* (ea.) liched \$60.00 そう。ために花崎的市場を開始的な \$60.00 「日本」の「「「「「「「」」」」 \$ 6.00 The second vient: 51. t. Ports ead Wrapped Tubes Center Tube See and Storage Container 「「「ないない」 Yellow. Callched いたのあのこ Orange PO BON Seture With S Green Red Th Purple Blue 「「大学 教行がな Black TEM

Radiation Safety Program

1. The Radiation Contro! Committee/Radiation Protection Officer.

- a. The Radiation Control Committee (RCC) shall:
 - Ensure that licensed material will be used safely. This includes review as necessary of training programs, equipment, facility, supplies, and procedures.
 - Ensure that licensed material is used in compliance with NRC regulations and the institutional license.
 - Ensure that the use of licensed material is consistent with the ALARA philosophy and program.
 - 4) Establish a table of investigational levels for individual occupational radiation exposures.
 - 5) Identify program problems and solutions.
 - Be familiar with all pertinent NRC regulations, the license application, the license, and amendments.
 - 7) Review the training and experience of the proposed authorized users and the Radiation Protection Officer (RPO), to determine that their qualifications are sufficient to enable the individuals to perform their duties safely and are in accordance with the regulations and the license.
 - 8) Review, on the basis of safety, and approve or deny, (consistent with the limitations of the regulations, the license, and the ALARA philosophy), all requests for authorization to use radioactive material within the institution.
 - Prescribe special conditions that will be required during a proposed method of use of radioactive material such as requirements for bioassays, physical examinations of users, and special monitoring procedures.
 - Review quarterly the RPO's summary report of the occupational radiation exposure records of all personnel, giving attention to individuals or groups of workers whose occupational exposure appears excessive.
 - Establish a program to ensure that all persons whose duties may require them to work in or frequent areas where radioactive materials are used are appropriately instructed as required in para 19.12 of 10 CFR Part 19.
 - 12) Review at least annually the RPO's summary report of the entire radiation safety program to determine that all activities are being conducted safely, in accordance with NRC regulations, the conditions of the license, and consistent with the ALARA philosophy. The review must include an examination of records, reports from the RPO, results of NRC inspections, written safety procedures, and the adequacy of the management control system.
 - Recommend remedial action to correct any deficiencies identified in the radiation safety program.

Radiation Safety Program

- Maintain written minutes of all Committee meetings, including members in attendance and members absent, discussions, actions, recommendations, decisions, and numerical results of all votes taken.
- 15) Ensure that the byproduct material license is amended, if required, prior to any changes in facilities, equipment, policies, procedures, and personnel.
- 16) Administrative Information:
 - a) The Committee shall meet as often as necessary to conduct its business but not less than once in each calendar quarter.
 - b) Membership will include one authorized user for each type of use authorized by the license, the RPO, a representative of the nursing service, and the Deputy Commander for Clinical Services, who represents management. Management may appoint alternate members to participate in meetings in the case of the absence of principal members.
 - c) To establish a quorum, one-hall of the Committee's membership, including the RPO and the management representative, must be present.
 - d) The Radiation Control Committee has delegated authority to the RPO to implement and enforce the LAMC/LAIR ALARA commitment. The Radiation Control Committee will support the RPO in those instances where it is necessary for the RPO to assert this authority. If the RPO is overruled by the Radiation Control Committee the minutes will record the basis for its action.
- b. The Radiation Protection Officer: See paragraph 2c, this item.
- 2. ALARA Program. (excerpt from the posted ALARA Commitment)
 - a. The Command:
 - 1) This Command is committed to the program described in this paper for keeping radiation exposures (individual and collective) as low as reasonably achievable, ALARA. In accordance with this commitment, this Command has established an administrative organization for radiation safety, and has developed the necessary written policies, procedures, and instructions to foster the ALARA concept. The organization includes a Radiation Control Committee (RCC) and a Health Physics Officer/Radiation Protection Officer (RPO). This Command is committed to ensuring implementation of sound radiation safety practices.
 - 2) A formal audit of the radiation protection program is conducted annually. A written record of this inspection, its recommendations, and required corrective action are maintained at the Health Physics Office. Additionally, personnel exposure records will be reviewed guarterly to ensure procedures are being conducted in the spirit of ALARA.
 - Modification of operating and maintenance procedures, and to equipment and facilities will be made when they will significantly reduce exposures at reasonable costs.

Radiation Safety Program

- 4) In addition to maintaining doses to individuals as far below the limits as is reasonably achievable, the sum of the doses received by all exposed individuals will also be maintained at the lowest practicable level.
- b. Radiation Control Committee (RCC):
 - 1) Review of Proposed Users and Uses.
 - a) In accordance with LAMC Regulation 40-34, the RCC will thoroughly review the qualifications of each principal authorized user, authorized user, or technologist with respect to the radioactive material types, quantities, and uses for which applied, to assure that the user will be able to take appropriate measures to maintain exposure ALARA.
 - b) When considering a new use of byproduct material, the RCC will review the efforts of the authorized user to maintain exposures ALARA. The user should have systematized procedures to ensure ALARA, and will have incorporated the use of special equipment such as syringe shields, gloves, absorbent paper, etc., in his proposed use.
 - c) The RCC will ensure that the user justifies his procedures and that all doses will be maintained ALARA.
 - 2) Delegation of Authority.
 - a) The RCC has delegated authority to the Health Physics Officer/Radiation Protection Officer to implement and enforce the LAMC/LAIR ALARA commitment.
 - b) The RCC will support the RPO in those instances where it is necessary for the RPO to assert this authority. Where the RPO has been overruled, the RCC will record the basis for its action.
 - 3) Review of ALARA Program.
 - a) The RCC encourages all users to review current procedures and develop new procedures as appropriate for ways to implement the ALARA concept.
 - b) The RCC will perform a quarterly review of occupational radiation exposures with particular attention to instances where investigational levels in Table 1 are exceeded. The principal purpose of this review is to assess trends in occupational exposure as an index of the ALARA program quality and to decide if action is warranted when investigational levels are exceeded.
 - c) The RCC will evaluate the overall efforts for maintaining exposures ALARA annually. This review will include the efforts of the RPO, authorized users and workers, as well as those of management.
- c. Health Physics Officer/Radiation Protection Officer:
 - 1) Annual and Quarterly Review.
 - a) The RPO will perform an annual review of the effectiveness of his own radiation protection program in maintaining doses ALARA. Reviews of specific procedures may be conducted on a more frequent basis.

USNRC BML APPLICATION

DEC 2 0 1988

Radiation Safety Program

- b) The RPO will review exposures of authorized users and occupational workers quarterly to determine that their exposures are in keeping with the provisions of this commitment.
- c) The RPO will perform quarterly reviews of the records of radiation surveys in unrestricted and estricted areas to determine that dose rates and amounts of contamination ar ALARA.
- 2) Education Responsibilities for an ALARA Program.
 - a) The RPO will schedule briefings and educational sessions to inform workers of the ALARA program efforts.
 - b) The RPO will assure that authorized users, occupational workers, and ancillary personnel who may be exposed to radiation are instructed in the ALARA philosophy and informed that the Commander, the RCC, and the RPO are committed to implementing the ALARA concept.
- Cooperative Efforts for Development of ALARA Procedures.
 - a) Radiation workers will be given opportunities to participate in the formulation of the procedures that they will be required to follow.
 - b) The RPO will maintain contact with all users and workers in order to develop ALARA procedures for working with radioactive materials.
 - c) The RPO will receive and evaluate the suggestions of individual workers for improving health physics practices and encourage the use of those procedures.
- Reporting and Reviewing Instances of Deviation from Good ALARA Practices.
 - a) The RPO will investigate all known instances of deviation from good ALARA practices, if possible, he w.'l determine the causes. When the cause is known, the RPO will require changes in the program to maintain exposures ALARA.
 - b) The RPO will report all significant instances of deviation from ALARA concepts to the RCC for review.
- d. Authorized Users:
 - 1) New Procedures Involving Potential Radiation Exposures.
 - a) Authorized users will consult with and receive the approval of the RPO and RCC during the planning stage of a new protocol before using radioactive materials.
 - b) The authorized user will evaluate all procedures before using radioactive materials to ensure that exposures will be kept ALARA. This may be enhanced through the application of trial runs.
 - 2) Responsibility of the Authorized User to Supervised Personnel.

Radiation Safety Program

- a) The authorized user will explain the ALARA concept and his commitment to maintain exposures ALARA to all supervised personnel.
- b) The authorized user will ensure that those under his supervision who are subject to occupational radiation exposure are trained and educated in good health physics practices and in maintaining excessions ALARA.
- e. Occupational Worker:
 - The worker will be instructed in the ALARA concept and its relationship to his working procedures and working conditions.
 - The worker will know what resources are available if he feels that ALARA is not being promote on the job.
- Establishment of Action Levels in Order to Achieve Reductions in Individual Occupational Exposures:
 - This Command hereby establishes Investigational Levels for occupational external radiation exposure which when exceeded will initiate investigation by the RPO and/or the RCC. The Investigational Levels that we have adopted are listed in Table 1 below. These levels apply to the exposure of individual workers.

Table 1 Investigational Levels - (mrem per calendar quarter)		
	LEVEL I	LEVEL II
1.Whole body; head and trunk; active blood-forming organs; lens of eyes; or gonads	125*	375*
2.Hands and forearms; feet and ankles	1875	5625
*Cardiac Cath Lab personnel - Head and neck; lens of eyes	625	937.5

- 2) The RPO will review and record on DD Form 1141, Record of Occupational Exposure to Ionizing Radiation, or an equivalent form, results of personnel monitoring, not less than once in any calendar quarter as is required by 10 CFR 20.401. The following actions will be taken at the Investigational Levels as stated in Table 1:
 - a) Quarterly exposure of individuals to less than Investigational Level I:

Except when deemed appropriate by the RPO, no further action will be taken in those cases where an individual's exposure is less than Table 1, Level I values.

Radiation Safety Program

 b) Personnel exposures equal to or greater than Investigational Level I, but less than Investigational Level II:

The RPO will review the exposure of each individual whose quarterly exposures equal or exceed Investigational Level I. He will report the results of his reviews at the first RCC meeting following the quarter when the exposure was recorded. If the exposure does not equal or exceed Investigational Level II, no action is required unless deemed appropriate by the RCC. The RCC will, however, consider each such exposure in comparison with those 1 others performing similar tasks as an index of ALARA program quality and will record the review in the RCC minutes.

c) Exposure equal to or greater than Investigational Level II:

The RPO will investigate in a timely manner the cause(s) of all personnel exposures equaling or exceeding Investigational Level II and, if warranted, take action. A report of the investigation, actions taken, if any, and a copy of the individual's DD Form 1141 or its equivalent will be presented at the first RCC meeting following completion of the investigation. The details of these reports will be recorded in the RCC minutes. The RCC minutes will be sent to the management of this institution for review.

 Re-establishment of an individual occupational worker's Investigational Level II above that listed in Table 1:

In cases where an individual's or a group of workers' exposures need to exceed Investigational Level II, a new, higher Investigational Level II may be established on the basis that it is consistent with good ALARA practices for that individual or group. Justification for a new Investigational Level II will be documented. The Radiation Control Committee will review the justification for, and will approve, all revisions of Investigational Levels II. In such cases, when the exposure equals or exceeds the newly established Investigational Level II, those actions listed in paragraph c above will be followed.

g. Signature of Certifying Officials:

This commitment to the ALARA program is signed by the Commanders of Letterman Army Medical Center and Letterman Army Institute of Research periodically. This document is kept on file in the Health Physics Office. I hereby certify that this institution is committed to the ALARA program set forth above.

3. Leak Test.

- a. Make a list of all sources to be tested. This should include at least the isotope, the activity on a specified date, and the physical form.
- b. If you will be testing sources stronger than a few millicuries, set out a survey meter, preferably with a speaker, so you can monitor your exposure rate.

Radiation Safety Program

- c. Prepare a wipe sample for each source. A cotton swab, injection prep pad, filter paper, or tissue paper is suitable. Samples should be taken as follows:
 - For small sealed sources, it may be easier to wipe the entire accessible surface area. Pay
 particular attention to seams and joints. However, do not wipe the port of beta applicators.
 - For larger sealed sources and devices (survey meter calibrator, bone mineral analyzer source), take the wipe near the radiation port and on the activating mechanism.
- d. The samples will be analyzed as follows:
 - An instrument that is sufficiently sensitive to detect 0.005 microcurie will be used. For beta sources either a gas flow proportional counter, or a liquid scintillation counter will be used. For gamma sources, a scintillation crystal with a ratemeter or scaler will be used.
 - 2) To estimate the detection efficiency of the analyzer used to assay the wipe samples, a certified check source of the same isotope as the sealed source or a certified check source with a different isotope but that has a similar spectrum will be used. If calculations demonstrate that the instrument is not sufficiently sensitive to detect 0.005 microcurie, a different instrument must be used.
 - Assay the wipe sample. It must be in the same geometry relative to the detector as was the certified check source.
 - Record the wipe sample counts per minute. Then calculate and record the estimated activity in microcuries on the wipe sample.
 - 5) If the wipe sample activity is 0.005 microcurie or greater, notify the RPO. The source must be withdrawn from use to be repaired or discarded. If it is a source distributed under an NRC or Agreement State license, the NRC must be notified. (See paragraph 21.21(b) of 10 CFR Part 21 and paragraph 35.59(e)(2) of 10 CFR Part 35.)
 - 6) Sign and date the list of sources, data, and calculations.

4. Safe Use of Radiopharmaceuticals.

- Individuals shall use disposable gloves and protective clothing at all times while handling unsealed radioactive material.
- Individuals handling unsealed radioactive materials shall monitor themselves for radioactive contamination prior to leaving the Nuclear Medicine clinic.
- c. Syringe shields shall be used whenever practicable.
- d. Neither eating, drinking, smoking or applying cosmetics nor the storage of such items is permitted in any area where radioactive materials are used or stored.
- e. Dosimetric devices shall be worn as prescribed by the Radiation Protection Officer.
- Disposal of radioactive material or items suspected of being contaminated with radioactive material is to be accomplished utilizing the designated waste receptacles only.
- g. Never pipette by mouth.

Radiation Safety Program

- Area surveys, both meter and wipe, shall be accomplished in accordance with Item 10, paragraph 12, this application.
- i. Radioactive materials should be kept in shielded containers whenever practicable.
- j. Transportation of radioactive materials shall be accomplished by utilizing a cart or similar device whenever practicable. When the use of such devices is not practicable, care shall be taken to ensure that exposure to the extremities is regimatined as low as reasonably achievable.
- k. Confine radioactive solutions in shielded containers that are clearly labeled. Radiopharmaceutical vials should be labeled with the isotope, the name of the compound and either the LAMC Lot Number or the date and time of receipt or preparation. A record should be maintained containing the following information:
 - 1) total prepared activity
 - 2) specific activity (mCi/cc) at a specified time
 - 3) total volume prepared
 - 4) total volume remaining
 - 5) the measured activity of each patient dosage
- Syringes and unit dosages shall be labeled with the radiopharmaceutical name or abbreviation, type of study, or the patient's name.
- m. Each patient dosage shall be assayed in the dose calibrator to ensure that it does not vary more than 10 percent from the prescribed dosage. Dosages varying more than 10 percent than the prescribed dosage shall not be used, except for prescribed dosages of less than 10 microcuries.
- n. The following shall be checked prior to administering a dosage to a patient:
 - 1) patient's name and identification number
 - 2) prescribed radionuclide
 - 3) prescribed radiopharmaceutical

5. Spill Procedures.

- a. Should a minor spill of radioactive liquids or solids occur, the following actions shall be taken:
 - 1) Notify other persons in the area that the spill has occurred
 - 2) Contain the spill utilizing absorbent material
 - 3) Decontaminate the area keeping the following procedures in mind:
 - a) Wear disposable gloves and protective clothing.
 - b) Use absorbent materials and small quantities of cleansing liquids as appropriate.

Radiation Safety Program

- c) Ensure that the contamination is not spread.
- d' Ensure that all materials used are placed in the appropriate radioactive waste receptacle.
- e) Survey the area with a survey meter ensuring: that the meter does not become contaminated, that the area immediately around the spill is also surveyed, and that hands, clothing, and shoes of personnel involved in the spill, or in close proximity to the spill, are carefully surveyed.
- f) Report the incident to the Radiation Protection Officer as soon as possible.
- g) Radiation Protection staff will do a follow-up survey of the area to ensure adequate decontamination/containment of the spill. This will be documented as a "special" survey.
- b. Should a major spill of radioactive liquids or solids occur, the following actions shall be taken:
 - 1) Notify all persons in the area, not involved in the spill, to vacate the area.
 - Prevent the spread of contamination through use of absorbent materials, and limiting the movement of personnel involved in the spill.
 - If possible without further contamination or significant exposure, shield the spill.
 - 4) Secure the area.
 - 5) Notify the Radiation Protection Officer immediately.
 - 6) Decontaminate personnel by removing contaminated clothing items, and washing contaminated skin with lukewarm water and a mild soap. Should this prove to be unsuccessful, induce sweating by covering the area with plastic then rewash the area as above. Further attempts to decontaminate, such as the use of progressively stronger cleaning agents, shall be accomplished only by qualified medical personnel, under the direction of Radiation Protection staff.
 - Radiation Protection staff will supervise the clean-up of the spill. Steps taken shall be recorded along with survey results. These shall be reported to the Radiation Control Committee.

6. Ordering and Receiving Radioactive Materials.

- a. Ordering:
 - Purchase Requests for radioactive materials shall be approved by the RPO or Jesignee prior to submission for purchase.
 - The Radiation Protection Officer, or designee, prior to approving a purchase request, shall ensure that requested radioactive materials are:
 - a) permitted within the scope of the USNRC License or the Department of the Army Radioactive Material Authorization as appropriate
 - b) authorized by the Radiation Control Committee for use by the requestor

Radiation Safety Program

- Radiation Protection staff will maintain records of each request containing at least the following information:
 - a) authorized user
 - b) isotope
 - c) activity
 - d) chemical form
 - e) supplier/manufacturer
- b. Receipt of radioactive materials during normal duty hours shall be by:
 - 1) Health Physics Office
 - 2) Radioisotopes Services Branch (RSB), LAIR
 - 3) Nuclear Medicine Service
- c. Upon receipt of radioactive material, the following procedure shall be followed:
 - Inspect the package for signs of damage/leakage. Should a package appear to be leaking/damaged, the Radiation Protection Officer shall be notified immediately. Further inprocessing of these packages will be accomplished by Radiation Protection staff only.
 - Ensure that the radioactive material received has been purchased in accordance with paragraph A above.
 - The package will then be opened and inprocessed in accordance with Paragraph 7, below.
- d. Receipt of radioactive materials after normal duty hours shall be accomplished as follows:
 - 1) LAMC
 - a) Materials will be received by the Administrative Officer of the Day, or by the Non-Commissioned Officer of the Day.
 - b) Packages will be inspected for indications of leakage. Should it appear that a package is leaking, the Radiation Protection Officer shall be notified immediately, and his instructions followed.
 - c) Packages will be transported on a cart or similar device to the shielded "holding" container in the Department of Radiology.
 - 2) LAIR
 - a) Materials will be received by the LAIR Staff Duty Officer or Charge of Quarters.
 - b) Packages will be inspected for indications of leakage. Should it appear that a package is leaking, the Radiation Protection Officer shall be notified immediately, and his instructions

Radiation Safety Program

leaking, the Radiation Protection Officer shall be notified immediately, and his instructions followed.

c) The package will be transported to RSB and stored in the appropriate container (e.g. refrigerato', freezer, or ultra-cold freezer) in accordance with the package instructions.

7. Opening Packages.

- a. Special requirements must be followed for packages containing quantities of radioactive material in excess of the Type A quantity limits specified in paragraph 20.205(b) of 10 CFR Part 20 (e.g. more than 20 curies of ⁹⁹ Mo, ^{99m} Tc, uncompressed ¹³³ Xe, or more than 3 curies of ¹³³ Xe, ¹³¹ I, ¹³⁷ Cs, ¹⁹² Ir, or ¹²⁵ I). Such packages must be monitored for external radiation levels and surface contamination within 3 hours after receipt if received during working hours or within 18 hours if received after working hours, in accordance with the requirements of paragraphs 20.205 (a) through (c). The NRC Regional Office must be notified if removable contamination exceeds 0.01 microcurie (22,000 dpm)/100 cm².
- b. For packages received under the specific license, the following procedures for opening each package will be followed:
 - 1) Put on gloves to prevent hand contamination.
 - Visually inspect the package for any sign of damage (e.g. wet or crushed). If damage is noted, stop the procedure and notify the Radiation Protection Officer.
 - 3) Measure the exposure rate from the package at 1 meter and at the package surface. If it is higher than expected, stop and notify the RPO. (The "transport index" noted on packages with "Yellow II" or "Yellow III" labels is the approximate dose rate, in milliroentgens per hour, at 1 meter form the package surface (see 10 CFR 71.4). The surface dose rate for such packages should not exceed 200 milliroentgens per hour. The dose rate from packages with "White I" labels should be less than 0.5 milliroentgens per hour at the package surface (see 49 CFR 172.403)).
 - Open the package with the following precautionary steps:
 - a) Remove the packing slip.
 - b) Open the outer package following the supplier's instructions, if provided.
 - c) Open the inner package and verify that the contents agree with the packing slip.
 - d) If anything is other than expected, stop and notify the RPO.

Radiation Safety Program

- 5) If there is any reason to suspect contamination, wipe the external surface of the final source container and remove the wipe sample to a low-background area. Assay the wipe sample to determine if there is any removable radioactivity. (Use the type of instrument specified in the SOP, for example, a thin-end-window GM survey meter, a Nal(TI) crystal and ratemeter, a liquid scintillation counter, or a proportional flow counter, as indicated. The detection efficiency must be determined to convert wipe sample counts per minute to disintegrations per minute. Note that a dose calibrator is not sufficiently sensitive for this measurement.) Take precautions against the potential spread of contamination.
- 6) Check the user request to ensure that the material received is the material that was ordered.
- Monitor the packing material and the empty packages for contamination with a radiation detection survey meter before discarding:
 - a) If contaminated, treat this material as radioactive waste.
 - b) If not contaminated, remove or obliterate the radiation labels before discarding in in-house trash.
- 8) Make a record of the receipt.
- c. For packages received under the general license in 10 CFR 31.11, the following procedure for opening each package will be followed:
 - 1) Visually inspect the package for any sign of damage (e.g., wet or crushed). If damage is noted, stop the procedure and notify the RPO.
 - 2) Check to ensure that the material received is the material that was ordered.
- 8. Unit Dose Records.
 - a. For each unit dosage received from a supplier, a record will be maintained with the information below:
 - 1) Radionuclide
 - 2) Generic name or its abbreviation or trade name
 - 3) Date of receipt
 - 4) Supplier
 - 5) Lot number or control number, if assigned
 - Activity in millicuries or microcuries as recorded on the unit dosage or packing slip and its associated time
 - 7) Date of administration or disposal



Radiation Safety Program

- 8) If administered, record the following information:
 - a) Prescribed dosage (unless already recorded in clinical procedure manual)
 - b) Measured activity in millicuries or microcuries and date and time of measurement
 - c) Patient name and identification number if one has been assigned
- 9) If discarded, record the date and method of disposal.
- 10) Record the initials of the individual who made the record.
- 9. Multidose Vial Records.
 - a. For each multidose vial received from a supplier or that is prepared at our facility, a record will be maintained with the information below:
 - 1) Radionuclide
 - 2) Generic name or its abbreviation or trade name
 - 3) Date of receipt or preparation
 - Date and time of initial assay and amount in both millicuries and cubic centimeters (cc) or milliliters (ml)
 - 5) Supplier or kit manufacturer
 - 6) If administered, record the following:
 - a) Prescribed dosage (unless already recorded in clinical procedure manual)
 - b) Date and time dosage was drawn and measured
 - c) Calculated volume that is needed for prescribed dosage
 - d) Measured activity in millicuries or microcuries
 - e) Patient name and identification number, if one has been assigned
 - 7) If discarded, record the method of disposal and date.
 - 8) Record the initials of the individual who made the record.

Radiation Safety Program

10. 99 Molybdenum Concentration Records.

- a. The regulations require that each licensee who uses a technetium generator to prepare radiopharmaceuticals must test each elution or extraction for its molybdenum concentration. This measurement is usually made with a dose calibrator. Radiopharmaceuticals will not be administered if it is determined that they contain more than 0.15 microcurie of ⁹⁹ Mo per millicurie of ^{99m} Tc at the time of administration. If an elution or extraction has a higher concentration, there may be a manufacturing defect that should be reported under paragraph 21.21(b) of 10 CFR Part 21.
- b. The procedure for measuring molybdenum concentration is based on the use of a "molybdenum breakthrough pig." The dose calibrator manufacturer has supplied a molybdenum breakthrough pig made of lead. The pig is thick enough to shield all the technetium photons but only a fraction of the molybdenum photons. The manufacturer specifies the ⁹⁹ Mo correction factor to convert from measured ⁹⁹ Mo to total ⁹⁹ Mo.
- c. Each time a generator is eluted, a record with the following information will be maintained:
 - 1) The manufacturer's lot number assigned to the generator
 - 2) Date and time of elution
 - Product of the measured ⁹⁹ Mo activity and the correction factor noted by the molybdenum breakthrough pig manufacturer
 - 4) Measured 99m Tc activity in millicuries
 - 5) Ratio of the total ⁹⁹ Mo microcuries per millicurie of ^{99m} Tc. The action level of 0.07 microcurie of ⁹⁹ Mo per millicurie of ^{99m} Tc will be used. If this level is exceeded, the product will not be used and immediate notification will be made to the C, Nuclear Pharmacy, or the Nuclear Medicine Physician of the day. In conformance with paragraph 21.21(b) of 10 CFR Part 21, the NRC will be notified if a leaking generator is detected. [The 0.07 action level allows for the quicker decay of the Tc through the day of use. It is assumed that the material will be used within 6 hours, at which time the concentration of ⁹⁹ Mo to ^{99m} Tc would have doubled.]
 - 6) Initials of the person who made the record

11. Implant Source Use Records.

- All long-lived sealed sources being used for implant therapy will be stored in a locking storage container.
- b. A list of those individuals who are authorized to handle the sources will be located in a binder with the inventory log sheet near the storage safe.
- c. On the front of the storage container, a map of the contents of each drawer will be posted. This map will include the number of sources per drawer, their position in the drawer, and their activity. Short-lived sources (e.g., ¹⁹² Ir) will be stored in the manufacturers storage container when not in use and will be stored in a locked room when not attended.

Radiation Safety Program

- d. Each time a source is removed, the inventory form will be annotated with the number and activity of the sources removed, the room number of the use or the patient's name, the time and date the sources were removed, and the name or initials of the person removing the sources.
- e. Each time sources are returned to the storage area, they will be counted to ensure that every source originally removed is returned. The inventory form will be annotated with the number and activity of the sources returned, the room number or the name of the patient, the time and date of return and the name or initials of the person returning the sources.
- If there is ever a real or perceived discrepancy between the record and the number of sources in use and in storage, the RPO will be immediately notified.

12. Area Survey Procedures.

- a. Ambient Dose Rate Surveys:
 - 1) Survey Areas:
 - a) In radiopharmaceutical elution, preparation, and administration areas, a survey will be conducted with a radiation detection survey meter at the end of each day of use. When diagnostic administrations are made in patients' rooms and special care is taken to remove all paraphernalia, the rooms need not be surveyed.
 - b) In laboratory areas where less than 200 microcuries of gamma emitting materials are used at a time, surveys will be conducted at least monthly with a radiation detection survey meter.
 - c) In radiopharmaceutical storage and radiopharmaceutical waste storage areas, a survey will be conducted weekly with a radiation detection survey meter or a radiation measurement survey meter.
 - d) In sealed source and brachytherapy storage areas, a survey will be conducted quarterly with a radiation measurement survey meter.
 - The RPO will be notified if any survey instrument fails the daily constancy test or unexpectedly high levels are recorded.
- b. Removable Contamination Surveys:
 - 1) Survey Areas:
 - a) In radiopharmaceutical elution, preparation, and administration areas, a survey will be conducted weekly for removable contamination. If diagnostic administrations are occasionally made in patients' rooms and special care is taken to remove all paraphernalia, those rooms need not be surveyed.
 - b) In laboratory areas where less than 200 microcuries of radioactive material is used at a time, a survey will be conducted at least monthly for removable contamination.
 - c) In radiopharmaceutical storage and radiopharmaceutical waste storage areas, a survey will be conducted weekly for removable contamination.

Radiation Safety Program

- 2) The wipe sample assay procedure should be sufficiently sensitive to detect the presence of 2000 dpm/100 cm² of removable contamination or 200 dpm/100 cm² for isotopes of iodine. A radioactive source with a known amount of activity will be used to convert sample measurements to disintegrations per minute or dpm.
- c. Records:
 - Records of dose rate and contamination survey results will contain the following information:
 - a) The date, area surveyed, and equipment used
 - b) The name or initials of the person who made the survey
 - c) A drawing of the areas surveyed with contamination and dose rate action levels as established by the RPO
 - d) Measured dose rates in mR/hr or contamination levels in dpm/100 cm², as appropriate
 - e) Actions taken in the case of excessive dose rates or contamination and follow-up survey information
 - The RPO will review and initial the record at least quarterly and promptly in those cases in which action levels were exceeded.
 - Radiation contamination levels and dose rate action levels will be established for different areas on a case-by-case basis. The levels for removable contamination will not exceed the limits published in Reg Guide 8.23, Revision 1, Table 2.
- 13. Air Concentration Control.
 - a. Worker Dose from Noble Gas:
 - Spent noble gas will be collected in a shielded trap and the effluent monitored in accordance with the model procedure for checking trap effluent published in Appendix O.3, Regulatory Guide 10.8, Revision 2. Or,
 - Spent nobel gasses will be vented to the atmosphere, and the model procedure in Appendix O.1, Regulatory Guide 10.8, Revision 2, shall be used to calculate worker doses from noble gases.
 - b. Worker Dose from Aerosols: Spent aerosols will be collected in a shielded trap. For reusable aerosol traps, the trap effluent will be monitored with an air contamination monitor which will be checked regularly according to the manufacturer's instructions.
 - c. Public Dose From Airborne Effluent: The model procedure in Appendix O.2, Regulatory Guide 10.8, Revision 2, will be used to calculate airborne effluent.
 - d. Spilled Gas Clearance Time: The model procedure in Appendix O.4, Regulatory Guide 10.8, Revision 2, will be used to calculate spilled gas clearance time.

Radiation Safety Program

14. Radiopharmaceutical Therapy.

- a. The patient's room will be as far as practicable from the nursing station and heavy traffic hallways as is feasible. It will be a private room with private sanitary facilities and will not be carpeted.
- b. The room will be prepared, in the following manner:
 - Leak-proof absorbent paper will be used to cover large surfaces that are likely to be contaminated. Small items will be covered with protective material to prevent contamination and facilitate decontamination upon termination of the therapy.
 - Separate containers will be provided for linen and disposable items. These containers will be lined with a plastic bag.
 - Patient excreta will be disposed of through the sanitary sewer system and will not be collected unless medically indicated.
 - 4) Disposable table service will be used for the duration of the therapy procedure.
 - Housekeeping will not be permitted in the therapy room until it is released for unrestricted use by the Radiation Protection Officer.
- c. The nursing staff assigned to care for the patient will be provided with dosimetric devices. Individuals not provided dosimeters will not be permitted to enter the room or care for the patient.
- d. The nursing staff will be briefed on the radiation safety precautions to be followed during the therapy. An instruction sheet detailing safety precautions will be made available to the staff and time will be allotted for questions during the briefing.
- e. The patient will be briefed by the Radiation Protection Staff regarding the procedure to be conducted and safety procedures to be followed, including contamination control, visitor control, radioactive waste, and other items as applicable.
- Only those persons necessary for radiation safety, medical and/or training purposes will be present during administration.
- g. A visitor's safe line will be taped on the floor to indicate the 2 mR/hr line. Visitors will not be allowed to enter the room any further than the safe line.
- h. Following the administration of the dosage, the exposure rates at the bedside, at one meter from the patient, at several areas within the room, at the door to the room, at the nurses station, and on the walls of the adjacent rooms will be measured with a radiation measurement survey meter. If the dose rates in the adjacent rooms exceed 2 mR/hr, access will be denied to those rooms for the duration of the therapy.
- For patients treated with ¹³¹ I, the thyroid burden will be measured after 24 but before 72 hours on all personnel who helped prepare the dosage or were present during administration of the material to the patient. Other personnel may be measured for thyroid burden if, in the opinion of the Radiation Protection Officer, they might have had significant uptake.
- Contaminated materials will be picked up and transferred to the Health Physics Office for decay-instorage as needed.

Radiation Safety Program

- k. The patient will not be released until either the exposure rate from the patient is less that 5 mR/hr at a meter or the retained activity of radionuclide is less than 30 millicuries.
- I. The room will not be released for unrestricted use until the following actions have been completed:
 - 1) All absorbent paper is removed form the room.
 - 2) Containers of trash and linen is remo ed.
 - A radiation detection survey meter is used to check for contamination and any contaminated areas are cleaned until removable contamination is less than 200 dpm/100 cm².
- m. Once the actions in item 12 above are completed, the room will be released for unrestricted use by the Radiation Protection Officer.

15. Implant Therapy.

- a. The patient's room will be as far away from the nursing station and heavy traffic hallways as is feasible consistent with good medical care. It will be a private room unless the dose at one meter from the implant meets the requirements in paragraph 20.105(b) of 10 CFR Part 20.
- b. The nursing staff responsible for providing patient care will be supplied film badges or other exposure monitoring devices.
- c. The nursing staff will be briefed on radiation safety precautions. An instruction sheet detailing safety precautions will be made available to the staff, and time will be allotted for questions and answers during the briefing.
- d. Brief the patient on radiation safety procedures for confinement to bed, visitor control, and other items as applicable, consistent with good medical care.
- e. Only those persons needed for medical, safety, or training purposes should be present during the implant procedure.
- A visitor's safe line will be taped on the floor to indicate the 2 mR/hr line. Visitors will not be allowed to enter the room any further than the safe line.
- g. Following the implant, the exposure rates at the bedside, at one meter from the patient, at several areas within the room, at the door to the room, at the nurses station, and on the walls of the adjacent rooms will be measured with a radiation measurement survey meter. If the dose rates in the adjacent rooms exceed 2 mR/hr, access will be denied to those rooms for the duration of the therapy.
- h. Do not release any patient from the hospital who has received a temporary implant until both a radiation survey of the patient and all sources have been removed from the patient and are accounted for. This check will be performed immediately after the removal of the sources. A record confirming the source count, and a radiation survey of the implant room will be maintained. For low-activity seeds, less than 1 millicurie, an individual seed will be used to check the survey meter to be sure it will easily detect a seed that has not been removed or has been lost.

Radiation Safety Program

 No patient, who has received a permanent implant, will be released from the hospital until the exposure rate from the patient is less than 5mR/hr at 1 meter. This measurement will be made at a distance of 1 meter from the umbilicus with the patient standing.

16. Other Safety Procedures.

- a. The radioactive materials to be used in non-human research are those identified in Item 5.
- b. The use of radioactive materials for non-human research shall be approved by the Radiation Control Committee. The Radiation Protection Officer, or Alternate Radiation Protection Officer may grant interim approval for a specific radioactive material protocol. Prior to approval, the principal investigator shall submit to the RPO the following information:
 - 1) Principal Authorized User
 - 2) Authorized Users
 - 3) Technologists
 - 4) Trainees
 - 5) Resident Users
 - 6) Nuclide
 - 7) Physical Form
 - 8) Chemical Form
 - 9) Maximum Quantity per Source Viai
 - 10) Maximum On-Hand Quantity
 - 11) Maximum Daily Use Quantity
 - 12) Anticipated Monthly Use Quantity
 - 13) Location of Proposed Use
 - 14) Location of Storage of Radioactive Materials
 - 15) Location of Interim Waste Storage
 - 16) Species of Animal to be Used if Applicable
 - 17) Procedures for the Handling of Animal Wastes and Tissues
 - 18) A description of the Life-Cycle of the Radioisotope addressing the following:
 - a) Is the radioisotope gaseous, or volatile

Radiation Safety Program

- b) Is heating or freezing of the radioactive material part of the procedure, and if so, will there
 be a phase change
- c) Will strong chemical agents be utilized
- d) Is there a possibility of airborne contamination
- e) Does the protocol require that liquid radioactive waste materials be disposed of directly (e.g., through the use of a radioactive material disposal sink) rather than being collected and transferred to the Health Physics Office or Radioisotope Services Branch for disposal
- Due to the nature of the nuclide, are any special shields or remote handling devices indicated
- g) Does the protocol involve the use of hazardous materials (other than radioactive) such as toxic or carcinogenic chemicals, flammables, etc.
- h) Other safety precautions deemed necessary
- A general description of the flow of the experiment. For example, material diluted to ______, injected into animal, urine and fecal samples collected for _____ hours for analysis, animal euthanized and disposed of in accordance with procedures, samples analyzed and disposed of in accordance with procedures
- 19) The Radiation Protection Officer will review the protocol and information and determine:
 - a) are the proposed facilities adequate
 - b) is a fume hood required
 - c) are shields or special handling equipment indicated
 - d) is dosimetry required
 - P) is bioassay required
 - f) is any special training required for personnel involved in the protocol
- The Radiation Protection Officer will document this review and submit it to the RCC at the time of the approval process.
- c. The Radiation Protection Officer for the non-human use of radioisotopes shall be in accordance with Item 7.3.
- d. The Radiation Control Committee shall be in accordance with Item 7.1.
- e. Authorized Users, and Technologists shall be credentialed in accordance with Item 7.1.
- f. Training shall be conducted in accordance with Item 8.2.
- g. Facilities for the non-human use of radioisotopes are described in Item 9.

Radiation Safety Program

- h. The policies and commitments of the RCC are in accordance with item 10.1.
- The commitment for the ALARA program for non-human use of radioisotopes is in accordance with Item 10.2.
- j. Procedures for leak testing sealed sources are in accordance with Item 10.3.
- k. The following general laboratory safety procedures shall apply to non-human radioisotope research facilities.
 - 1) Never pipette by mouth.
 - Disposable gloves and protective clothing appropriate to the type and quantity of radioactive material being used shall be worn whenever radioactive contamination is possible.
 - Radiation workers shall monitor themselves for radioactive contamination prior to leaving the laboratory, with a survey instrument, when appropriate.
 - Neither eating, drinking, smoking or applying cosmetics nor the storage of such items is permitted in any area we are radioactive materials are used or stored.
 - 5) Dosimetric devices shall be worn as prescribed by the Radiation Protection Officer.
 - 6) Disposal of radioactive material or items suspected of being contaminated with radioactive material is to be accomplished utilizing the designated waste receptacles only.
 - 7) Area surveys, both meter and wipe, shall be accomplished in accordance with Paragraph 10.12.
 - 8) Radioactive materials should be kept in shielded containers whenever practicable.
 - The area within the laboratory where radioactive materials are routinely utilized shall be clearly labeled as such.
 - Bench tops where radioactive materials are utilized shall be covered with absorbent material, and labeled as a use area.
 - 11) Storage containers (e.g., refrigerators, etc.) shall be clearly labeled.
 - 12) Items of equipment routinely used for use with radioactive materials shall be labeled, and treated as contaminated, for safety purposes, unless shown otherwise by a wipe survey.
- Spill procedures shall be in accordance with Item 10.5.
- m. Ordering and Receiving radioactive materials shall be in accordance with Item 10.6.
- n. Opening packages of radioactive material shall be accomplished in accordance with Item 10.7.
- o. Area surveys of radioisotope use areas shall be in accordance with Item 10.12.

10-21

Radiation Safety Program

- p. Should gaseous, aerosol, or volatile radioactive materials be used the following procedures will be followed.
 - 1) They shall be used in a fume hood approved by the RPO .
 - 2) Air samples shall be taken as deemed appropriate by the RPO.
 - 3) Bioassay will be performed, where appropriate, in accordance with Item 9.4.
- g. Radioactive waste materials shall be handled/disposed of in accordance with Item 11.

*

Waste Management

1. Waste Disposal.

a. The following procedures will be used when disposing of radioactive waste. There are four commonly used methods of waste disposal: release to the environment through the sanitary sewer system, decay-in-storage (DIS), transfer to a burial site or back to the manufacturer, and release to in-house waste. With the exception of the patient excreta (see 10 CFR 20.303(d)) and generally licensed *in vitro* kit exemptions (see 10 CFR 31.11(f)), records of disposal of licensed material will be maintained in accordance with 10 CFR 30.51(a) and 20.401(c)(3).

1) General Procedures

- a) All radioactivity labels will be defaced or removed from containers and packages prior to disposal to in-house waste. If waste is compacted, all labels that are visible in the compacted mass will be defaced or removed.
- Nonradioactive waste, such as leftover reagents, boxes, and packing material, will be kept to a minimum.

c) Procedures will be monitored occasionally to ensure that radioactive wastels not created unnecessarily. New procedures will be reviewed to ensure that waste is handled in a manner consistent with established procedures.

2) Procedure for Disposal of Liquids and Gasses

Liquids may be disposed of by release to the sanitary sewer. A formal review will be conducted by the radiation protection officer of all requests for "hot sinks" to assure compliance with federal, state, local and license requirements. Due consideration will be given to the regulations regarding the toxic or hazardous properties of these materials.

- a) Regulations for disposal in the sanitary sewer appear in 10 CFR 20.303. Material will be readily soluble or dispersible in the water. Daily and monthly limits based on the total sanitary sewerage release of our facility will be established. (Excreta from patients undergoing medical diagnosis or therapy is exempt from all the above limitations; see 10 CFR 20.303(d).) Records of the date, radionuclide, estimated activity that was released in millicuries or microcuries will be maintained.
- b) Liquid scintillation-counting media containing not more than 0.05 microcurie per gram of H-3 or C-14 may be disposed of without regard to its radioactivity (10 CFR 20.306). A record of the date, radionuclide, estimated activity in millicuries or microcuries, calculated concentration in microcuries per gram, and how the material was disposed of will be maintained.
- 3) Procedure for Disposal by Decay in Storage (DIS)

Short-lived material with physical half-life less than 100 days will be disposed of by DIS. Material will be separated according to half-life.

a) When the container is full, it will be sealed with tape and marked with an identification number that relates back to the DIS logbook. The logbook will include the contents, the generator of the waste, the date put into storage, the date after which 10 half-lives of the longest isotope will have passed, the highest exposure rate on the surface of the box, and the initials of the person sealing the box.

USNRC BML APPLICATION

DEC 2 0 1988

Waste Management

- b) All material will be decayed for a minimum of 10 half-lives except waste containing only microcurie guantities of I-125 which will be held for a minimum of 5 half-lives.
- c) Prior to disposal as in-house waste, each container will be monitored as follows:
 - i) The radiation detection survey meter will be checked for proper operation
 - Monitoring will be conducted in an area where background does not exceed 0.05 millirem per hour
 - iii) All shielding will be removed from around the container
 - iv) All surfaces will be monitored on each individual container
- d) Only those containers that cannot be distinguished from background will be discarded as in-house waste. A record of the date on which the container was monitored, the instrument used, the background reading, the highest package reading, and the initials of the individual preforming the monitoring will be maintained. All visible labels will be removed or defaced.
- e) Containers that can be distinguished from background radiation levels will be returned to the storage area for further decay or transferred for burial.
- 4) Procedure for Transfer for Burial

Except for material suitable for DIS and animal carcasses containing not more than 0.05 microcuries of H-3 or C-14 per gram, solids will be transferred to a burial site. Shipments will be done by a licensed contractor hired by the U.S. Army Munitions and Chemical Command (AMCCOM). Records of the disposal will be the maintained by AMCCOM at Rock Island, IL 61299-6000. A copy of the consignment sheet that the transfer agent completed on shipments will be maintained in the Health Physics Office.

5) Procedure for Release to In-House Waste

Waste from *in vitro* kits that are generally licensed pursuant to paragraph 31.11 is exempt from waste disposal regulations. Radioactive labels should be defaced or removed. There is no need to keep any record of release or make any measurement.

6) Procedure for Returning Generators to the Manufacturer

Used ⁹⁹ Mo/^{99m} Tc generators may be returned to the manufacturer. These shipments will be in compliance with 10 CFR Part 71 and Department of Transportation (DOT) regulations.

- Records will be maintained to demonstrate that the package qualifies as a DOT Specification 7A container if required (see DOT regulations, paragraph 173.415(a) of 49 CFR Part 173).
- b) The package will be prepared in accordance with the manufacturer's instructions.
- c) Dose rate and removable contamination measurements required by paragraph 173.475(i) of 49 CFR Part 173 will be made.

Waste Management

- d) The package will be labeled and the shipping papers will be completed in accordance with the manufacturer's instructions.
- 2. Other Waste Disposal Procedures. All waste will be disposed of in accordance with paragraph 1, this item.